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SYNOPSIS
The application of monoclonal antibody technology is a rapidly expanding 
area of research, encompassing most areas of the biological sciences. The 
potential of the technique to provide standard but uniquely specific analy­
tica l reagents, which can be used singly or in combination is overwhelming by 
its  ever increasing application.
In this work the main aims were to produce specific high a ffin ity  
monoclonal antibodies to the human anterior p itu itary hormone, Thyroid 
Stimulating Hormone (TSH); to characterise the monoclonal antibodies and 
demonstrate their application in relation to human TSH.
Two indirect enzyme-linked immunosorbent assays (ELISA), and a solid
phase separation radioimmunoassay (RIA) system were developed for screening
of the hybridoma cultures.
The. immunogenicity of TSH in the spleen cell donor mice was monitored by 
standard TSH double antibody RIA.
Eight fusion experiments were done before stable positive cultures were
established from the fusion experiments. Eleven positive primary cultures
and 27 positive monoclonal cultures were frozen down and stored at -196°C in 
liquid nitrogen. Some d iffic u lty  was encountered in recovery of some of 
these cultures from the frozen state.
Six monoclonal antibody cultures have been characterized with regard to 
t i t r e  in culture supernatant and ascitic f lu id , antibody content, immuno­
globulin class, sub-class and lig h t chain content. The antibody chain
composition of the preparations was also investigated. Cross reac tiv ity  in 
relation to the other closely related anterior p itu itary  hormones: 
luteinizing hormone (LH), fo ll ic le  stimulating hormone (FSH), and the 
placental hormone human chorionic gonadotrophin (HCG) whole molecule and the 
a and B subunits were investigated. The antigenic determinant specific ity  
of these antibodies was also investigated by competitive binding between 
radiolabelled monoclonals and unlabelled monoclonals.
The monoclonals a ll had high titre s  and high a ff in ity .
Only one of the monoclonal antibodies investigated displayed any 
recognisable cross reactivity to HCG and FSH but this was s t i l l  minimal.
All six monoclonal antibodies were used in an indirect immunocytochemical 
immunoperoxidase procedure and demonstrated to be highly suitable for the 
localization of TSH in tissue. Four preparations of human anterior p itu itary
were examined, in addition to human placenta, kidney, and gut. Possible 
cross reacting animal TSH's were also investigated using baboon, dog, rat and 
ferret p ituitary sections.
The use of the monoclonals together with the immunoperoxidase technique 
offers quite d istinct advantages of improved specific ity , a permanent source 
of specific pure antibody and improved sensitivity (low observed background), 
and permanent stained records.
Finally one of the monoclonals was investigated for use in a two-site 
m icrotitre enzyme -  linked immunosorbent assay (ELISA) with an anti-h-TSH 
polyclonal anti sera. An enzyme-linked immunosorbent assay was developed with 
a detection lim it of 4 mU/1 based on the 95% confidence lim it from zero. The 
assay showed good in tra - and inter-assay precision over the whole range of 
the standard curve, and as such may be suitable for clinical application.
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ABBREVIATIONS
Ab antibody
AF Ascitic flu id
Ag antigen
a/s anti sera
BSA bovine serum albumin
CAM cellulose acetate membrane
cm centimetre
CPM count per minute
DMSO Dimethyl sulfoxide
ELISA Enzyme linked immunosorbent assay
FSH Fo llic le  Stimulating Hormone
g gram
H2 SO4  Sulphuric acid
HAT Hypoxanthine ami nopterin thymidine
HCG Human chorionic gonadotrophin
HC1 hydrochloric acid
HRPO Horse radish peroxidase
h-TSH Human thyroid stimulating hormone
Ig immunoglobulin
LD lim iting dilution
LH Luteinizing hormone
M molar
mA milliamphere
McAb monoclonal antibody
mg milligram
ml m il l i l i t r e
NETRIA North East Thames Regional Immunoassay Unit
NIBSC National Institu te Biological Standards and Control
nm nanometres
NMS normal mouse serum
No number
NSB nonspecific binding
NSI P3 NSI/l-Ag4.1
NSS normal sheep serum
OD optical density
PAS periodic acid schiff
PBS phosphate buffered saline
PEG polyethylene glycol
RIA Radioimmunoassay
rpm revolutions per minute
SD standard deviation
SDS-PAGE Sodium dodecyl sulphate - Polyacrylamide gel electrophores
SEM standard error on mean
SN supernatant
TSH(Barts) S^H supplied by Dr. R. Edwards
V volts
x mean or average
a alpha
3  beta
°C degree centigrade
> greater than
< less than
yCi micro curie
yg microgram
yl m icrolitre
-ve negative
+ve positive
% percentage
*Ag radiolabelled antigen
1 ° primary
2 ° secondary
3° te rtia ry
4° quarternary
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CHAPTER 1
Introduction
INTRODUCTION
Since the f ir s t  pioneering demonstrations by Kohler and Milstein (1975 
and 1976) that the specific antibody secreting function of a single cell 
could be immortalized, the technology has developed rapidly and has been 
exploited in many areas of biological research. In fact, where ever the 
precise identification , characterization, purification and/or quantitation of 
material is required, providing the material is , or can be made immunogenic, 
then the technique is applicable.
The production of one or more specific single specie of antibody (a mono­
clonal antibody) to each antigenic determinant on the immunogen is possible. 
They may be used singly or in subtle but defined combinations which may 
comprise a unique 'fingerprin t1 of the antigen according to the application.
Immunology, the study of the immune system and its  responses encompasses 
and u tilizes  an extensive repertoire of methods and techniques (Hudson and 
Hay 1980, Weir 1979).
Antibodies, which are the tools of immunological methods, are exquisitely 
sensitive and highly specific reagents obtained conventionally from the sera 
of specifically immunized animals. Conventional anti sera represent however, 
the irreproduceable combination of antibody products of many antibody 
secreting cells or clones, containing background as well as specific antibody 
(Benner 1982). In practice even under s tr ic tly  controlled identical condi­
tions each animal produces a unique mixture of immunoglobulins with varying 
specific ities and a ffin itie s . Even very simple antigens introduced in the 
same amounts into genetically identical animals do not e l ic i t  identical 
immunoglobulins in response. Serum immunoglobulin levels vary in addition 
with genetic background, antigenic load and age (Wostmann 1975, Van Snick and 
Masson 1980, Benner and Naaijman 1980 and Radi 1981).
This general lack of reproduceability of the response constitutes one of 
the most serious lim itations of heterogeneous conventional antisera.
Monoclonal antibody production (Kohler and Milstein 1975, 1976) overcomes 
many of the major d iffic u ltie s  imposed by that lim itation and even using 
impure antigen preparations (Secher and Burke 1980) or heterogeneous 
undefined antigens (Foster 1982) such as the combined antigens in whole cell 
preparations (Parham and Bodmer 1978, Hoffman et al 1980, Roehrig 1982, 
Tedder et al 1983, Schlesinger et al 1983) an unlimited supply of highly 
specific monoclonal antibody may be derived. Specific anti sera for such 
antigens would be impossible under conventional anti sera regimes. The 
special and unique properties of the immune system: namely antibody specifi­
c ity , yet diversity engendered in the a b ility  to in it ia te  a response to an
enormous number of and including novel immunogenic stim uli, the ce llu la r  
property of one plasma cell producing only one antibody, and the technology 
to rescue these functions in a permanent cell line have in combination 
produced the versatile monoclonal antibody.procedure. I t  permits in theory 
the production, isolation, and maintenance of specific antibodies to any 
antigen or single antigenic determinant. This in turn has the potential to. 
greatly fa c ilita te  and expand fields of study where sensitive isolation and 
analytical antibody procedures are desirable and applicable and in the past 
been impracticable.
1.2 THE IMMUNE SYSTEM
The immune system constitutes the major defense mechanism which protects 
against potentially deleterious invading foreign material. Material capable 
of evoking an immune response include stimuli from a wide range of sources 
. such as disease promoting pathogenic microorganisms and th e ir byproducts, 
cellu lar intrusions including foreign transplanted tissue, molecular material 
and chemicals from the environment.
Vertebrates have evolved in addition to the non-specific immune mechan­
isms possessed by lower animals (Hilderman and Reddy 1973, Marchalonis 1976) 
an adaptive response. The three major characteristics of memory, specific ity  
and the recognition of non self material affords greater f le x ib il i ty  and a 
more effective response to antigenic challenge (R o itt'1980).
1.2.1 Functional Cells of the Immune System
The immune response is dependent upon populations of cells  with 
properties of antigen recognition and processing a b ilit ie s , in te r-c e llu la r  
communication, antigen stimulated d ifferentiation  and expression of effector 
function. The cells of the immune system begin as unspecialised ancestral 
stem cells with the in trinsic capacity for self renewal, extensive rep lic ­
ation and d ifferentiation  (Metcalf and Moore 1971). Lymphopoiesis in the 
primary lymphoid organs - the Thymus and Bursar of Fabricius in birds or 
Bursar Equivalent probably the foetal liv e r and bone marrow in mammals 
(M ille r 1966, M ille r and Osolia 1967, Greaves et al 1973, Weissman et al
1974) is antigen independent. In these organs maturation yields immuno­
competent small lymphocytes equipped with antigen specific receptors and 
specific organ homing properties.
These small lymphocytes circulate via the lymph and blood network systems 
but are mainly confined to discrete domains in the secondary lymphoid organs: 
the B cells in the primary fo llic le s , and the T cells in the diffuse cortex 
(Howard 1972, Sprent 1973).
These secondary organs provide the necessary environment and accessory 
cells for processing and presentation of antigen, leading to the antigen 
dependent mature immune response. That the small lymphocytes are the 
functional units of, and essential for an appropriate immune response have 
been amply demonstrated (Gowans et al 1962, McGregor and Gowans 1963, Hunt et 
al 1972, Howard and Gowans 1972). Chronic depletion of lymphocytes by 
whatever means abolishes immunological responses while replacement therapy 
restores the response.
On a functional basis two antigen specific small lymphocyte populations 
have been defined (M iller 1962, Claman e t a l  1966, M iller and Mitchell 1968, 
Cooper et al 1966, Kiesielow et al 1975, Beverly 1977). Thymectomy grossly 
depleted cell-mediated reactions mediated by Thymus dependent T cells (Roitt 
1980, Cooper et al 1966, Claman et al 1966), while bursectomy in chickens 
abolished humoral responses mediated by the B cells (Cooper et al 1966). 
Observations of human clin ical conditions are in agreement with the
functional classification of small lymphocytes. Thymic deficiencies such as 
Di George's and Nezelof syndromes, are immuno-deficiency syndromes character­
ised by the absence of T cells and cell-mediated immune function, but with 
near normal B lymphocyte and antibody functions. B cell insufficiency states 
such as Bruton's congenital agammaglobulinaemia occur on the other hand in 
which T cell mediated immune responses are normal but humoral immunoglobulins 
are greatly depleted (Herbert and Wilkinson 1977, Bergsma et al 1975).
Under the lig h t microscope (M ille r 1974), there is no apparent morpho­
logical difference between the T and B small lymphocytes. Apart from the 
functional distinction however, they may be identified by a variety of 
characteristic surface markers (Raff 1971, Loor and Hoelants 1975, Kiesieow 
et al 1975) and reaction sp ec ific ities , for example, sheep red blood cell 
rosette formation with human T cells (Jondal et al 1972). Table 1.1 below 
summarises some of the identifying markers of small lymphocyte populations.
I t  is the differentiated functional responses of antibody production by 
B lymphocytes, or the effector functions of the T lymphocyte subpopulations 
that are the targets for rescue in a continuously growing cell line employing 
hybridoma technology.
TABLE 1.1
T and B lymphocyte marker characteristics (adapted from M ille r 1974)
Identifying property T cel Is B cells References
Antigen ++ (type?) ++ ( ig ) Raff 1971, Marchalonis 
and Cone 1973, V ite lla  
et al 1975
Receptors ( Fc - ++ Basten et al 1972
C3 - ++ Dukor and Hartmann 1973
E rosettes ++ - Jondal et al 1972
Differentiation ( 
cell surface ( 
antigens (
Thy 1 
Ly 1 2 3
++
subsets
divisions
++
- Schlesinger 1972 
Raff 1971
Kiesielow et al 1975
Antigen stimulated 
release
Transfer
factor
lymphokmes
igG
AME
Lawrence and Landy 1969
(++) effector present; ( - )  not present.
1.2.2 The Immune Response
A great deal of work on antibody response has involved experimentation at 
the single cell level. The subject has been extensively reviewed by
Cunningham (1973). Of the 1-5 x lO '7 antibody repertoire estimated to occur 
in an inbred mouse (Klinman and Press 1975, Kreth and Williamson 1973, Kohler 
1976) only between 1000 and 8000 seem capable of recognising any particular 
antigenic determinant (Kreth and Williamson 1973, Kohler 1976). Of these 
between 5 and 1 0  are observed in conventional antisera in response to each 
antigenic determinant (Schreier et al 1980). This indicates the probable 
reason for the highly heterogeneous nature of any conventional anti sera and 
the d iffic u lty  of producing a reproduceable reagent (Shulman and Kohler 
1979).
According to the clonal selection theory proposed by Burnet (1959), a 
heterogeneous cell population exists, but each cell possesses the capacity to 
produce only one antibody specificity. On antigenic challenge the majority 
of cells remain unstimulated. They do not possess receptors which f i t  the
antigen. A small number however do, and these are stimulated. This theory 
was the f ir s t  to emphasise the unit of selection was the whole c e ll. The 
receptor specificity was la ter confirmed by Ada (1970) and Raff (1971) 
demonstrated that these receptors were immunoglobulins on the B lymphocyte 
cell surface.
The stimulated cells were triggered to proliferate and d ifferen tia te  and 
to produce clones of cells derived from single ancestral ce lls . Mitchison 
(1967) suggested the cell surface receptors were exact copies of the secreted 
antibody for B ce lls .
The prediction of one cell producing only one antibody specific ity  has 
been overwhelmingly demonstrated and reviewed by Cunningham (1973). The 
identification of multiple myeloma as a neoplasm of an antibody producing 
c e ll , the product of which occur as paraprotein in patients serum; and that 
such paraproteins are indistinguishable from normally secreted immunoglobulin 
(Weissman 1978, Potter 1978, Cebra et al 1974, Capra et al 1975, Haber et al 
1977.), together with the experimental induction of analogous mouse myeloma 
tumors producing homogeneous immunoglobulin proteins (Potter 1972) have also 
confirmed the essential one cell one antibody specificity prediction which 
forms the basis of monoclonal antibody selection.
Antigenic stimulation of B and T cells in the appropriate environment 
results in the following summarised cycle of events characteristic of the 
humoral and cell-mediated immune responses respectively.
a) Humoral response to soluble antigen stimulus
neutralization  
precipitation lysis  
end product etcAg Accumulates in 2 
lymphoid tissue
Antigen driven clonal 
expansion cell cooperation 
between B and T cells Production 
and release 
of antibodies
Primed memory cell 
population for fast 
2 ° reaction N Effector plasma 
cells
b) Cell mediated immune response to cell surface or particulate antigenic 
determinants — ^—1— —
 Patrolling
sensitized T cells
Clonal expansion 
in 2 ° lymph organs Execution of 
effector function 
cytolysis, suppression etc
Primed memory cell 
population for fast 
2 ° reaction Effector cel 1s of appropri ate 
. Type TH Tc Ts TD etc
2 ° = secondary 
= He!per T cell 
Tc = cytotoxic T cell 
= Suppressor T cell 
Tq = delayed hypersensitivity T cell
Response of the immune system:
a) 1B1 lymphocyte to soluble antigens (Cunningham 1978) and
b) 'T 1 lymphocyte response to cellu lar antigens; (Munro and Bright 1976)
Further discussion w ill be directed towards the B lymphocyte antibody 
responses because i t  is monoclonal antibody production via hybridoma 
technology (Kohler and Milstein 1975 and 1976) with which we are mainly 
concerned, although T cell hybridomas have also been produced (Hammer!ing 
1977 and reviewed by Beezley and Ruddle 1982).
1.2.3 Antibody Specificity and Cross Reactivity
The unique specific ity of antibody antigen reactions was conclusively 
demonstrated by Landsteiner and Van der Scheir (1936). They demonstrated 
that even small changes in the antigen were detectable (figure 1 . 2 ) , by the 
antibodies; but similar determinants were bound by the antibodies to varying 
degrees resultingj'the cross reactiv ity  phenomenon.
FIGURE 1.1
Substitution Positions
ORTHO META PARA
Sulphonate (-SO3 ) 
Arsonate (-ASt^H- ) 
Carboxyl ate (-CC£)
++ .+++
FIGURE 1.2 -
Specificity and cross reactiv ity  of antibodies to m-aminobenzene sulpho­
nate in reaction with various similar haptens. The effect of substitution of 
the different side groups scored according to their inhibitory effects on 
precipitation of original hapten.
+++ = strong, -  = no effect. Adapted from Cummings 1978 and Roitt 1980.
I t  is therefore true to say that i f  an antibody preparation is to be a 
useful immunological reagent then i t  must be specific, binding only the 
antigen i t  was meant to recognise.
The d iffic u ltie s  encountered in obtaining suitably specific antisera for 
the clinical assay of human thyroid stimulating hormone (h-TSH) for example, 
serves to illu s tra te  the importance of antibody specific ity  (OdeTl et.a l 1968 
Odell and Utiger 1973).
Monoclonal antibodies produced by hybridoma technology should however, 
eliminate such problems since the antibodies are selected for their high 
specific ity for only one antigenic determinant. Where cross reactiv ity  is 
observed this w ill undoubtedly be due to the antigenic determinant being 
shared by the cross reacting molecules.
This property of s tr ic t specificity of effector function carries
important implications in vivo for the animal as a whole in addition to the 
precise elimination of foreign material. Wider binding specific ities would 
possibly result in disastrous cross reactions against self components in 
vivo. I t  is this particularly stringent specific ity  specification which is 
employed in vitro in immunological procedures.
.4 Antibody Structure, Class, and Function
Antibodies consist of four polypeptide chains (Porter 1967 and Edelman 
1969, 1970); two identical heavy (H) chains and two identical lig h t (L) 
chains. A covalent disulphide bridge between the H and L chains, and between 
the two H-L chain- units constitutes the main linkage forming the whole 
antibody molecule.'
The antibody molecule is illustrated  in figure 1.3.
Suitable material for structural analysis was found to be homogeneous 
myeloma serum paraprotein (Seligmann and Brovet 1973). Some have been found 
which bind antigen and have been shown to be serologically identical to 
normally synthesized antibodies binding the same antigen (Potter 1978). Such 
myeloma protein and other homogeneous antibodies, for example, those induced 
against antigens such as bacterial polysaccharides (Krause 1970, Haber 1970) 
have been used in amino acid sequence studies (Cebra et al 1974, Capra et al 
1975a, 1975b, Haber et al 1977) with concordant results.
Each heavy and light chain has two d is tinct regions; a variable (V)
region at the amino N-terminus which contains hypervariable 'hot spots' and
comprises the antibody binding domains; and a constant (C) region a t the 
carboxyl C-terminus. This C-region of the H-chains contains the structures 
which confer the antibody biological ac tiv ity  (see Table 1 .3 ). The structure 
and function of antibodies have been extensively discussed by Nisonhoff et al
(1973) and Steward (1981).
Using sera prepared against the L-chain dimer Bence Jones protein and
myeloma proteins (Epp et al 1974, Roitt 1980) two types of L-chains have been
established and designated kappa (k) and lamda (x) L-chains; and five classes 
of heavy chains have been identified. These are immunoglobulin G, A, M, D 
and E together with subclass variations. They a ll exhibit varying physical 
properties and biological effects which are shown in Tables 1.2 , 1.3 and 1.4. 
Some of these biological effects and properties of the immunoglobulins and 
the ir subclasses have serious implications for the detection, selection and 
subsequent application of monoclonal antibodies.
Antigen binding 
site
Variable portions with 
hyper variable regions
COOH
terminus
Hinge
region
440214
108
H chain L chain
CHO
CHO
NH2  terminus
FIGURE 1.3 IgG antibody structure.
The clear areas of the H and L chain are the variable 
regions while the hatched area, are the constant 
regions. The oligosaccharide groups are designated 
[CHO].Papain cleaves the structure at the hinge region 
site (—*) to yield 2 Fab + FC fragments. Pepsin 
cleaves below the S-S bond to yield F(ab')2. (Adapted 
from Lehninger 1976)
TABLE 1.2
The physical properties o f human immunoglobulins
W.H.O. designated 
classes
IgG IgA IgM IgD IgE
No of subclasses 4 2
No of basic units 1 1 or 2  
(dimer)*
5
(Pentomer)*
1 1
Heavy chain class * , 1 , 2 ,3 ,4 ' ctl, 2 u 6 E
Light chain type k or X k or X k or X k or x k or x
Molecular weight 150,000 160,000
dimer
900,000 185,000 2 0 0 , 0 0 0
Valency for antigen 
binding
2 2 or 4 1 0 2 2
Concentration range in 
normal serum (mg/ml)
8-16 1.4-4 0.5-2 0-0.4 17-450
ng/ml
% Total serum Ig 80 13 6 0 - 1 0 . 0 0 2
% Carbohydrate 
content
3 8 1 2 13 1 2
H a lf-life  in serum 
days
23a 5.8 5.1 2 . 8 2.5b
Occurrence Serum 
amniotic 
f l  uid
Serum Serum 
secretion 
saliva and 
tears colostrum
Serum Serum
* IgA dimer and IgM pentomer each contain a J chain 
a Excluding IgG3  (10 days)
b IgE binds basophils and mast cells and has a longer half l i f e  in tissues
TABLE 1.3
B iolog ica l properties of the human immunoglobulin classes
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TABLE 1>4
Comparison o f the properties o f human IgG subclasses
IgGi IgG2 ! 9g3 19^4
IgG in serum, 
% of total
65 23 . 8 4
Spontaneous
aggregation
- +++ -
Ga site reacting 
with rheumatoid 
factor
+++ +++ +++
Combine with 
staphylococcal 
protein A
+++ +++ - +++
Crosses placenta ++ + ++ ++
Complement fixation  
classical
+++ ++ ++++ +
Binding monocytes +++ + +++ +
Binding heterologous 
skin
++ - ++ ++
Blocking Ig to 
binding
. - - +
+ -  gradation in effect 
- = effect not present
References for Tables 1.2 - 1.4. [R oitt 1980, Hudson and Hay 1980, Tomasi 
and Bienenstock 1968, Dorrington and Tanford 1970, Metzger 1970, Kochwa et al 
1971, Bennich and Johansson 1971, Natvig and Kunkel 1973, Waldman et al 1970 
and Spiegelberg 1972, Hubbard 1981].
.5 Generation of Antibody Diversity
To deal with the vast array of environmental antigens, an extensive 
repertoire of specific antibody molecules are required. The precise 
mechanism by which th is is achieved is somewhat s t i l l  in question. Three 
main theories have been, proposed. The germ-line theory (Hood et al 1975) 
advocates that all antibody genes are inherited in the usual way and are thus 
present in all cells of the animal. During lymphocyte d ifferen tia tion , as i t  
occurs in other cells only one complete complementary gene set is selected 
for expression appropriate to the differentiation type. All others are 
suppressed.
The somatic mutation theory on the other hand (Weigert 1970) suggests 
that only a very few V region genes exist at each locus in the germ lin e . 
Mutations are thought to occur in the lymphocyte V genes and prepare the 
cells to react’ adequately to challenge. Mutation is however a random event 
and the theory demands that during differentiation some selective mutational 
event occurs rapidly to make all the possible antibody types (Cotton et al 
1973).
Finally rearrangement of pre-existing gene segments (Weigert et al 1978) 
during d ifferentiation may be responsible for antibody diversity.
Saturation hybridization analysis (Valbuena et al 1978) and amino acid 
sequencing (Weigert et al 1978 and Schilling et al 1980) have supported the 
theory that the variable (V) region genes and constant (C) region genes of an 
immunoglobulin molecule are all present within the gene complement of ce lls . 
But i t  is the somatic recombination of these (Sakano et al 1979, Max et al 
1979, Seidman and Leder 1979) during the differentiation process, together 
with the hypervariable regions within the V regions, which form the basis of 
antibody diversity we observe.
MONOCLONAL ANTIBODY
A monoclonal antibody may be defined in this context as the antigen - 
specific homogeneous immunoglobulin product of a B lymphocyte clone derived 
from one immortalized ancestral plasma c e ll. Monoclonal antibodies are 
therefore the selected product secreted from a hybrid cell line produced by 
fusion of a myeloma cell line with an antibody producing plasma cell (Kohler 
and Mil stein 1975 and 1976).
Naturally occurring or experimentally induced myeloma tumors provide 
unlimited sources of homogeneous monoclonal antibody (Seligmann 1973, Potter 
1972). Such antibodies although they have been shown to be synthesised and
assembled by processes very similar to those occurring in normal antibody 
production (Scharff and Laskor 1970, Kuehl 1977, Williamson 1971) and
research with them has greatly advanced understanding of immunoglobulin 
production (Raschke 1980), th e ir value is limited by the fact that very few 
react with known antigens (Potter et al 1977 and Potter 1978), and the known 
antigen binding myeloma proteins have only been identified by intensive
effort (Cohn 1967).
Early approaches to secure a permanent supply of homogeneous antigen
binding antibodies relied on the transformation of antigen sensitized cells  
in the presence of the antigen using a virus. Baumal et al (1971) employed 
Epstein-Barr (EB) virus and antigen primed peripheral blood ce lls . 
Successful specific antibody secretors were not obtained. Strosberg et al
(1974) used Simian Virus 40 (SV40) with sensitized rabbit cells and obtained 
a cell line producing small amounts of homogeneous antibody against the 
antigen pneumococcal type I I I  polysaccharide; while S tein itz et al (1977, 
1979) employed Epstein-Barr virus with antigen (4-hydroxy-3, 5-dinitrophen- 
acetic acid (NNP)) sensitized human B lymphocytes. Antigen binding 
antibodies were obtained which gradually lost ac tiv ity  with time in culture. 
Zurawski et al (1978, 1981) also employed Epstein-Barr virus to produce
permanent specific anti-tetanus antibody secreting cell lines from antigen 
sensitized cells with sim ilar results. These methods of production while 
having limited success were by no means satisfactory since to date the 
antibody secreting function was ultimately lost. The permanent production of 
active cell lines has to date therefore only been accomplished by the fusion 
techniques. Yelton et al (1981) have produced a comprehensive discussion on 
the development and application of hybridoma procedures.
.1 Cell Fusion
Since the f irs t  observations in vitro.(Barski et al 1960) of spontaneous 
fusion of somatic vertebrate ce lls , cell fusion technology has been widely 
applied in many areas but especially in those concerned with the investiga­
tion of gene expression and control, and the cellu lar and molecular mechan­
isms involved (Harris 1970, Ephrussi 1972, Puck 1972, Davidson and de la Cruz 
1974 and Bernhard 1976).
Those early observations were unexpected because of the very nature of 
metazoan organisation. Somatic cells and th e ir descendants are required, in 
spite of being in close permanent contact in tissues and organs, to maintain 
their individual status and th e ir genetic in tegrity  (Bernhard 1976).
Only a few exceptional cases of spontaneous fusion of eukaryotic cells  
are known to occur in vivo, usually representing a stage in terminal 
differentiation. The most notable examples include the fusion of myoblasts 
to form myotubules during the histogenesis of striated vertebrate muscle, 
fe rtiliz a tio n , osteoclasts and foreign body giant cells formation (Ringertz 
and Savage 1976); although the f ir s t  observations of fusion and hetero- 
karyosis was on fungi and yeast (Fincham and Day 1971).
The earliest fusion experiments (Harris 1965, Harris and Watkins 1965) 
established that:
1 ) heterokaryons can be produced with various differentiated cell types. 
Fusion was not affected by any tissue incompatibility mechanism;
2 ) the processes of suppression of gene expression was reversible; .
3) the cells of the immune system did not mount an immune response 
against the partner, and
4) no nuclear incompatibility was observed.
Myeloma x myeloma fusion studies including those by Milstein et al (1977) 
and Kohler and Milstein (1975) established conclusively that:
1 ) hybrids could be obtained from the fusion between d ifferent myeloma 
cells;
2 ) compatible cell partners (see phylogenetic and ontogenetic restric ­
tion) yield hybrids which exhibited codominant gene expression, producing all 
the immunoglobulin chains of the parent lines, and no new immunoglobulins 
were produced. Furthermore Kohler et al (1976) demonstrated that immuno­
globulin synthesised by one parent was not extinguished by fusion with a non­
producing partner and reactivation of its  immunoglobulin synthesis did not 
occur. The hybrids continued to produce only the immunoglobulin of the
active • parent. Where both parents produced immunoglobulins however the
immunoglobulin products of the hybrids were found to be mixed molecules 
containing chains from both parent cell lines (Margulies et al 1977, Kohler 
and Milstein 1976, Galfre and Milstein 1981);
3) Chromosome loss did occur since the total chromosome numbers in the 
hybrids were less than that of the sum of the parents. This loss sometimes 
was accompanied by the loss of immunoglobulin chains. All these observations 
were v ita lly  important to the establishment and refinement of the monoclonal 
antibody procedure.
Phylogenetic and ontogenetic restrictions to function retention
The production of viable hybrid cells with the desired gene product 
(whole active immunoglobulin molecules) intact is the primary aim of 
monoclonal antibody technology. In the hybrid cells therefore a combination 
of the two parental chromosome endowment must persist so that cell division 
mechanisms remain functional, while retaining the required d ifferentiated  
function.
Unlike normal sexual karyogamy however somatic cell fusion results in 
duplication of two or more diploid chromosome sets in a synokaryon. 
Depending on the parental combination i t  has been established that in the 
hybrids supernumary chromosome in s tab ility  results in the preferential 
elimination of some of one of the parent cell chromosomes in an irregular and 
unpredictable manner (Bernhard 1976). Several, examples of this phenomenon 
have been cited. For example, from human-mouse (Boone and Ruddle 1969, Weiss 
and Green 1967), human-chinese hamster (Jones et al 1972, Sun et al 1974), 
human-rat (Croce et al 1973b) hybrids extensive and preferential elimination 
of human chromosomes were reported. Chromosomal in s tab ility  resulted in loss 
of immunoglobulin production (Kohler 1980) from human peripheral blood 
lymphocyte-mouse myeloma hybrids, and from frog 1ymphocyte-mouse myeloma 
hybrids (Hengartner et al 1978). Rabbit spleenocyte-mouse myeloma fusions 
were also unsuccessful in terms of hybrid production and rabbit immuno­
globulin secretion (Shulman and Kohler 1979, Yarmush et al 1980). On the 
other hand syngeneic fusions (Kohler and Milstein 1976) and allogeneic fusion 
(Kohler et al 1977a) of mouse myeloma and spleen cells; and rat spleen cells  
with mouse myeloma cells (Galfre et al 1977, Howard et al 1980) have a ll 
yielded high hybrid production with stable immunoglobulin secretion. Human- 
mouse hybrids producing human immunoglobulins have however been produced 
(Koprowski et al 1978, Levy et al 1978, Schlom et al 1980). I t  may be 
suggested therefore that even with the limited interspecies success of 
immunoglobulin retention cited above, phylogenetic restrictions do lim it the 
choice of fusion partners. The closer the phylogenetic relationship between 
the fusion partners the easier i t  is to obtain hybrids in which the desired 
function has been rescued.
Not only are there phylogenetic restrictions but, in addition the 
ontogenetic relationship of the fusion partners have an important influence 
on the success or fa ilu re  of functional hybrid production. During cell 
fusion two different cells fuse and the ir nuclei come to exist in a common 
cytoplasmic environment. During subsequent mitosis the two nuclei fuse
giving hybrid progeny cells. Early fusion experiments were designed to 
answer questions concerning the expression and interaction of parental tra its  
in inter or intra species hybrids.
Many tra its , for example, tumorgenicity endowing immortality (Hobart and 
McConnell 1975, Harris 1970) were found to be dominant. On the other hand 
functional expression was shown to depend on the relationship of the cells  
forming the hybrid partnership. For example, fusion of mouse myeloma cells  
with mouse spleen ce lls , while supporting immunoglobulin production did not 
allow T cell marker Thy 1 expression (Kohler et al 1977). Fusion of thymoma 
cells however with spleen cells (Goldsby et al 1977, Hammerling 1977) while 
rescuing Thy 1 T cell marker expression did not support immunoglobulin
production. The extinction of cell markers such as Thy 1 (Hyman and Kelleher
1975) and immunoglobulin production (Periman 1970, Caffino et al 1971) was 
also displayed by the fusion of fibroblasts and spleen ce lls , demonstrating 
the revers ib ility  of gene expression.
Ontogenetically closely related cell lines (one of which was capable of 
growing in permanent culture) are therefore shown to be a specific
requirement for the continued expression of the differentiated function of 
interest (Kohler et al 1977, Shulman and Kohler 1979).
Hybrid cell partners
As indicated above the original work by Kohler and M ilstein (1976)
indicated that in order to secure the rescue of the d ifferentiated function
of a normal cell by hybridization with an immortal fusion partner, then both 
populations of cells should be at the same state of d ifferen tiation  and 
preferably from the same specie.
Antibody secreting hybrids are derived from antigen stimulated 
B lymphocytes and a myeloma cell line (Kohler and Milstein 1975, 1976). The 
primary source of stimulated B lymphocytes has been the secondary lymphoid 
organ, the spleen; where mice or rats were the antigen sensitized donors 
(Kohler and Milstein 1976, Galfre et al 1977), although the popliteal lymph 
nodes, for example, have been used as the source of B lymphocytes after foot 
pad immunization (Buttin et al 1978). Peripheral blood lymphocytes have also 
been used successfully (Levy et al 1978, Koprowski et al 1978).
A considerable number of permanent cell lines exist (Horibato and Harris 
1970, Potter 1972, Melchers et al 1978). The.tumor cell lines from the three 
main species used most frequently, in hybridoma production are lis ted in 
Table 1.5.
TABLE 1.5
Permanent cell lines employed for hybridoma production
Species Myeloma cell line  
name
Secretes/
expresses
References
Human SK0-007 IgE Olsson and Kaplan, 1980
GH 1500.6TG-A12 igG Croce et al 1980
LICR.L0N/HMy2 igG Edwards et al 1982
Mouse P3-X63-Ag8 igGl (k) Kohler and Milstein 1975
P3-NSI/I-Ag4-1 k chain only Kohler and Milstein 1976
P3-X63-Ag8.653 Kearney et al 1979
Sp2/0.Agl4 - Shulman et al 1978
45.6GT1.7 IgG2b (k) Margulies et al 1976
PuBul-On IgG2a (k) Kohler and Milstein 1976
MOPC-315 igA (X2)
FO Fazekas de St Groth and 
Scheidegger 1980
BW 5147 H-2k+,Thyl.X+,Fc Kohler et al 1977b
EL4 Lyz+,Thyl.2+ Pauli and Pauli 1978
Rat 210.RCY3.Agl k chain only Galfre et al 1979
As a result of codominant expression of immunoglobulin product in hybrids 
the problem of mixed immunoglobulin molecules becomes apparent (Kohler and 
Milstein 1975, Kohler et al 1978, Galfre and Milstein 1981). In tra -ce llu la r  
complementation results in immunoglobulin molecules containing specific and 
non-specific chains forming the antigen binding s ite . The result is a 
reduction or loss of antigen binding a b ility .
The problem has been alleviated however by the derivation and use of 
myeloma fusion partners which have lost the a b ility  to express immunoglobulin 
chains (see Table 1 .5 ). P3-NS1/1-Ag4-1 (designated NSI) is the most 
frequently used mouse myeloma cell line (Kohler and Schulman 1978, Kohler
and Milstein 1975), and was used for this work. I t  does not completely 
overcome the problem however since i t  synthesizes a k light chain, but i t  
does not secrete i t .
The human myeloma lines hold great promise for the development of human 
monoclonal antibodies for diagnosis and therapy.
Fusogenic agents
Spontaneous cell fusion as observed by Barski et al 1960 is a very rare 
event, occurring at a frequency of about 1/10^-10^ cells (Yelton et al 1981). 
Specific reagents were therefore required to fa c ilita te  and increase the 
fusion frequency. In early fusion experiments (Harris 1965, Cotton and
Milstein 1973, Kohler and Milstein 1975, 1976, Margulies et al 1976), u ltra  
vio let (U.V.) inactivated Sendai virus was used for this purpose. A 
comprehensive review of virus-induced cell fusion is to be found by Post and 
Pasternak (1978). The frequency of viral-induced cell fusion however was 
found to be only marginally increased above the spontaneous rate (Yelton et 
al 1981). This procedure was therefore unsatisfactory from this point Of 
view. In addition there was the persistent d iffic u lty  of obtaining repro- 
duceable standard batch preparations of virus for long term work (Pentecorvo
1975).
Polyethylene glycol (PEG) was f ir s t  used to agglutinate plant protoplasts 
(Power et al 1978) and was found to effect extensive* cell fusion on dilution  
with no adverse effect on v ia b ility  (Kao and Michayluk 1974). PEG was 
however f ir s t  applied in fusion of mammalian somatic cells by Pontecorvo
(1975), and has since been described as a universal fusogen (Power et al 
1978, Lucy 1978) because of its  action on a wide range of ce lls .
As a consequence commercially available PEG is now the preferred fusion 
agent giving high fusion frequencies with l i t t l e  effect on v ia b ility  and 
permitting standardization of the fusion protocol. The efficiency of PEG 
induced fusion has been shown to be dependent on the molecular weight, 
concentration and treatment time used (Davidson et al 1976, Fazekas de 
St Groth and Scheidegger 1980, Goding 1980, Gefter et al 1977). The 
inclusion in the fusion mixture of dimethyl sulphoxide (DMS0) (Norwood et al
1976), which effects fusion in its  own right (Ahkong 1975), has been shown 
to mainly protect the cells from the effects of too rapid dilution after  
fusion (Fazekas de St Groth and Scheidegger 1980), with l i t t l e  improvement in 
fusion efficiency above that obtained by PEG alone.
The mechanisms of PEG induced fusion are not well understood and the 
possible effects are reviewed by Lucy 1978.
One final fusion promoting system must be mentioned which although in the 
early stages of development shows great promise for future application. This 
is the electric fie ld  induced fusion (Zimmermann et al 1981). This technique 
has been employed for the production of a variety of heterokaryons including 
the fusion of plant protoplast (Zimmerman and Scheurich 1980, Zimmermann et 
al 1981, Vienken et al 1981); sea urchin eggs (Richter et al 1981); and 
mammalian cells (Pilwat et al 1981, Zimmermann et al 1981) and specifically  
for hybridoma production involving the fusion of mouse myeloma cells and 
spleen cells (Vienken and Zimmermann 1982).
This fusion procedure gives high yield of viable heterokaryons which can 
be manually selected and cloned straight after fusion, eliminating the need 
for long term biochemical selection and tedious cloning procedures (Vienken 
and Zimmermann 1982). Further development of the procedure to allow large 
scale hybridoma production w ill no doubt precede its  wider application in 
this fie ld .
.2 Selection of Hybrids
The most important requirement immediately after fusion is a selective 
system to allow the recovery of hybrids from the fusion mixture. Such a 
fusion mixture w ill not only contain the desirable myeloma-spleen cell 
hybrids, but w ill also contain myeloma-myeloma hybrids and spleen cell-spleen  
cell hybrids, in addition to unfused myeloma and spleen cells .
The hybrid spleen cells and unfused spleen cells present no problems. 
These cells are terminally differentiated and therefore die a fter a very 
short time in culture. The unfused myeloma ce lls , and the myeloma-myeloma 
hybrids however persist indefin ite ly under optimum growth.conditions. I t  is 
necessary that these unwanted cell types be eliminated from the fusion 
- products.
This is achieved using the L itt le f ie ld  (1964) selection technique. 
Aminopterin (A), a fo lic  acid analogue is employed to block reactions of the 
enzyme dihydrofolate reductase in the de novo pathway to purine and
pyrimidine synthesis (figure 1 .4 ). The alternative salvage pathway permits
the rescue of normal cells by the enzymes hypoxanthine-guanine-phosphoribosyl 
transferase (HGPRT) (EC 2 .4 .2 .8 ) or Thymidine kinase (TK) (EC 2.7 .15.5) 
u til is —ing supplied hypoxanthine (H) and Thymidine (T) respectively and so 
nucleotide synthesis continues.
The myeloma cells are selected to be HGPRT deficient and therefore die in
HAT selective media containing hypoxanthine lCT^M, aminopterin 10“ M^ and
thymidine 4 x 10~5m.
N O v O  ,
De Nova And Salvage Pathways For Nucleotides7Synthesis
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dCTP dTTPdGTP dATP
FIGURE 1.4 Nucleotides synthetic pathways with sites of action of some 
inhibitors ===___
HX -  hypoxanthine; £  -  guanine; A - adenine; U_ -  uracil; C -  cytidine; 
AG - azaguanine; TG - thioguanine; OK orotic acid; IMP -  inosine 
monophosphate; CMP -  cytosine monophosphate; UMP -  uridine monophosphate; 
GMP - guanosine monophosphate; AMP - adenosine monophosphate; CDP, UDP, GDP, 
ADP -  cytosine diphosphate etc; dCDP etc -  deoxycytosine diphosphate etc; 
dUMP deoxyuridine monophosphate; dTMP - deoxythymidine monophosphate; CTP, 
UTP, GTP, ATP - cytosine triphosphate etc; dCTP, dATP, dGTP, dTTP - 
deoxycytosine triphosphate etc; 1_ -  thymidine; B - bromodeoxyuridine; 
F - fluorodeoxyuridine; Am -  aminopterin; AL - alanosine; HU -  hydroxyurea. 
(Adapted from Paul 1980).
The spleen cells being normal cells possess the intact enzymes in the 
salvage pathway. Hybrid cells of spleen and myeloma cells are therefore 
complemented with respect to the enzyme HGPRT and can synthesize nucleotides 
and therefore survive under HAT selection.
P3 NSI/l-Ag4-l (NSI) myeloma cells are 8-azaguanine resistant and there­
fore are HGPRT deficient ce lls . This cell line was used for this work and 
was a kind g ift  from Dr Cezar Milstein, MRC Laboratories, Cambridge; via The 
Wellcome Foundation Ltd, Dartford, UK.
3 Hybridization
A great many detailed protocols are available for the production of 
monoclonal antibody secreting hybrids; examples of which include Oi and 
Herzenberg (1980), F lin t and Hudson (1980), Hudson and Hay (1980), Schreier
(1980), Galfre and Milstein (1981).
. Two essential features necessary for the successful hybridization of the
cell fusion partners needs to be mentioned. F irs tly , i t  was suggested from 
direct observation (Kohler and Milstein 1976) that there was preferential 
fusion between myeloma cells and specific plaque forming ce lls , because of 
the high frequency of specific hybridomas obtained (Shulman and Kohler 1979). 
Rapidly dividing immunoglobulin secreting B lymphocytes which resulted from 
1ipopolysaccharide (LPS) stimulation, have been shown to fuse more readily  
than unstimulated ce lls , and blast cells fuse better than small lymphocytes 
(Andersson and Melchers 1978).
Together these observations indicate that dividing cells are the prefer­
ential fusion partners. Therefore the success of the hybridoma procedure 
w ill depend upon the av a ila b ility  of rapidly dividing antigen-stimulated
antibody producing ce lls . This of course w ill depend upon the success of the
immunization regime employed with the spleen cell donor.
Secondly the status of the myeloma cells prior to fusion w ill also affect 
the success of the procedure (Galfre and Milstein 1981). In effect the same 
criterion for preferential fusion is expected to persist. The efficiency of 
fusion was greatest when the myeloma cells were maintained in logarithmic 
growth phase for an extensive period before fusion.
Consequently the v ia b ility  of the cells to be used is c r it ic a l.  Greater 
than 90% v ia b ility  of the myeloma cells is imperative (Hudson and Hay 1980).
After fusion which may be performed in suspension (Galfre et al 1977, 
Galfre et al 1979, Hudson and Hay 1980, Galfre and Milstein 1981, Kennett 
1981) or on solid f i l t e r  unit (Buttin et al 1978, Galfre and Milstein 1978) 
or as an adherent monolayer (McKearn 1981), the cultures are maintained by 
replacing most of the growth media with fresh media every two to three days.
Cloning hybrids
Cloning at an early stage is essential to prevent the loss of valuable 
positive clones due to overgrowth by non-producing competing clones that may 
be in the culture (Galfre and Milstein 1981). Cloning may be carried out in 
soft agar (Schreier 1980, Hudson and Hay 1980, Kohler and Milstein 1975, 
Caffino et al 1972, Metcalf 1977, Kennett 1981) which fa c ilita te s  positive 
clone selection directly  (Sharon 1979, Kohler and Milstein 1975, 1976, Cook
and Scharff 1977).
Alternatively the cultures may be cloned by lim iting dilution (Hudson and 
Hay 1980; Goding 1980, McKearn 1981). The cells are diluted so that they may 
be grown in small numbers per well. In these circumstances the growth in 
wells follow the Poisson distribution (Lefkovits and Waldmann 1979) such that
f(o ) = e"*
(where f(o) is the fraction of wells containing no cells; A is the average
number of clones required per w ell).
When A = 1 then f(o) = 0 .3 7 . Therefore where one clone is required per
w ell, then 37% of th e w e lls  should show no clones in order to obtain a
reasonable probability P(1) = 0.6 that any wells with growth w ill contain
only single clones. On this premise single clone cultures may be selected 
visually and positive cultures grown for further investigation. With this  
procedure cloning should be repeated to ensure monoclonality.
Parks et al (1979) and Dangle and Herzenberg (1982) have described 
cloning procedures involving the fluorescence activated cell sorter. This 
type of procedure, which employs fluorescent antigen to mark the specific 
antibody producing cells allow simultaneous selection and cloning.
: The cloning strategy decided upon, however, w ill depend to a large extent 
on the number of positive cultures. Where a large number of positive 
cultures arise these may have to be assessed to find those of most interest 
prior to cloning.
Feeder layers
Many cells grown in culture are density dependent. That is why, for 
example, the myeloma cell line used for this work was maintained at a density 
of between 1 x 10  ^ cells/ml and 8 x 10^ cells/m l. Below or above those 
numbers the cells grew poorly and may die.
Consequently feeder layer cells are usually included for plating out 
fusion mixtures (Galfre and Milstein 1981, Goding 1980). The use of feeder 
cells is therefore also necessary in cloning hybrids where the cells are 
required to begin growth at one cell per well. Feeder cells improve the 
cloning efficiency which is usually low, especially in newly isolated hybrids 
(Caffino et al 1972, Lernhardt et al 1978). The recovery of cells from 
freezing is sometimes greatly improved by the inclusion of feeder cells  
(Edwards 1981).
Various feeder cell types have been used with good results. Some of 
these include thymocytes (Lernhardt et al 1978, Oi and Herzenberg 1980), 
peritoneal macrophages (Fazekas De St Groth and Scheidegger 1980, Hengartner 
et al 1978) or normal unfused spleen cells (Levy et al 1978, Hammerling et a l 
1978), fibroblasts (Kennett et al 1978) or contact inhibited 3T3 cells  
(Caffino et al 1972).
The precise function of feeder cells is by no means certain, but they are 
thought, in addition to providing what may be termed non-specific cell-mass 
effects (Foster 1982), to act as specific hybrid cell carriers during 
dilution, and may additionally provide undefined growth promoting factors. 
The successful use of ce ll-free  conditioned cell supernatants from xenogeneic 
endothelial cells (Astaldi et al 1980) have suggested that the factors 
producing the beneficial effects were most probably soluble.
Another function of the feeder cells may be to reduce possible toxic 
effects of plastic culture vessels (Goding 1980). Macrophages used in this  
capacity have the added advantage that their phagocytic ac tiv ity  may assist 
in keeping contamination in check.
1.3.4 Screening of H.ybridomas
Most workers in monoclonal hybridoma production would now agree that the 
success or fa ilu re  of monoclonal hybridoma production depends to a very large 
extent on the screening procedures employed.
However, whichever procedure is decided upon i t  should f u l f i l l  the 
requirements of speed, re lia b ility , high sensitivity and be adaptable to a 
high through put of samples.
The assay should also be chosen with the subsequent application of the 
antibodies in mind. Individual monoclonal antibodies have been shown to have 
some lim itations in application and as such may not react as expected. The 
assay procedure must therefore be chosen with care from amongst the vast 
selection available. In Chapter 2 a description of some assay procedures 
used in hybridoma screening has been presented together with those developed 
for this work.
Monoclonal antibodies are required for use as standard reagents. I t  is
Ctherefore necessary to chara£erize them as soon as they are established. 
They are usually purified and characterized with respect to immunoglobulin 
chain class and subclass, antigen specificity and cross-reactivity, and 
binding a ffin itie s . Antibody sensitivity to pH or salt concentrations is  
sometimes important (Herrmann and Mescher 1979, Mason and Williams 1980).
.5 Applications of Monoclonal Antibodies
Until the advent of monoclonal antibody technology (Kohler and Milstein  
1975, 1976) the single most prominent ambition of immunologists was to find a 
ready source of homogeneous antigen-specific antibody (Krause 1970).
Monoclonal antibody reagents are now being described at a phenomenal 
rate.. Their homogeneity,specificity and ava ilab ility  has dictated their  
replacement of polyclonal antisera in many areas and make them ideal standard 
reagents for the future in analytical/diagnostic, purification and 
therapeutic procedures (Sevier et al 1981).
In addition to research workers in the f ie ld , many commercial sources 
have predicted by th e ir interest that monoclonal antibodies could revolu­
tionize our perception of immunological procedures. They could for example 
promote new, and until now impracticable immunological procedures. But by 
far some of the most compelling reasons for adopting this technology include 
the demonstrated potential for the isolation and use of monospecific 
antibodies to antigenic determinants from so called 'd irty ' antigenic sources 
like  tumors comprehensively reviewed by Neville et al (1982) Kennett et al
(1981) and Sevier et al (1981); and to other cell surface antigens such as 
the c lin ica lly  important major histocompatible complex (MHC) HLA region 
specific antigens (Bodmer et al 1978, Brodsky et al 1979). Indeed Charion 
and McDevitt (1979) have suggested that the careful selection of a panel of 
specific monoclonal antibodies w ill almost certainly result in a more 
reliable tissue typing procedure than is at present available. This applies 
also to microorganisms and parasites; examples of which include Hepatitis B 
virus (Goodall et al 1981, Tedder et al 1983) Herpes Simplex virus (Pereira 
et al 1982, Showalter et al 1981); Rabies (Wiktor and Koprowski 1978, Flamand 
et al 1980); Epstein-Bar virus (Hoffman et al 1980, Pearson et al 1983) and 
amongst the parasites Malaria (Plasmodium) sporozoite stage (Yoshida et al 
1980) merozoite stage (Freeman et al 1980) and to the gamete stage (Rener et 
al 1980). Monoclonal antibodies to rare and/or weakly immunogenic material 
or even to new and previously unrecognised antigens, for example, 
differentiation antigens (Boyse and Old 1969) have also been identified (King 
et al 1979, Reinherz and Schlossman 1980, Goding and Burns 1981, Tidman et al
1981, DeCock et al 1981, Brooks et al 1980, Stashenko et al 1980, Funderud et 
al 1983).
The fine specificity of monoclonal antibodies together with unlimited, 
but consistent supply places the technology in the vanguard of the search for 
such cell specific antigens and provides the means for identifica tion , 
purification and consequently allows precise biochemical comparisons to be 
made. Their value as analytical and diagnostic tools in th is area are only 
now being realised.
Dramatic and improved purification.procedures recalling the interferon 
story (Secher and Burke 1980) or human renin (Pau et al 1981) have become 
practicable and, in the area of immunotherapy, monoclonal antibody could be 
employed in passive immunization schemes (New Scientist 1981), or as ly tic  
agents destroying particular cells (Baumgartner et al 1982); in immune 
regulation, in a suppressor or activator capacity (Sherburne and Condie 1981, 
Rawls 1981, Ivars et al 1982, Homberg et al 1982); or in the capacity of what 
Ehrlich (1960) called the 'magic b u lle t ', precisely directing ly t ic  or 
chemical agents to target cancer cells (Staines and Lew 1980, G illiland  et al 
1980, Blythman et al 1981, Thorpe et al 1982, Mach et al 1981).
Another important area of application is the immunoassay of soluble 
antigens in body fluids. High a ff in ity  non-crossreacting antibody reagents 
may be produced against, for example, antigens for which pure samples are 
d iff ic u lt  to obtain for the production of conventional antisera, or where 
structural sim ilarities usually result in cross reactivity of the antisera. 
Examples include somatomedin C (Baxter et al 1981) thyroid stimulating 
hormone (Soos and Siddle 1982, Wada et al 1982) luteinizing hormone (Federici 
et al 1982) human chorionic gonadotrophin (Gupta et al 1980, Wada et al 1982) 
gastrin (Suddith et al 1981) substance P (Cuello et al 1979) human a in ter­
feron (Adolf et al 1982) human growth hormone (Irany and Davis 1980, Bundesen 
et al 1980) prostatic acid phosphatase (Wang et al 1981) carcinoembryonic 
antigen (CEA) (Accolla et al 1980, Kupchik et al 1981) alpha-foetaprotein 
(AFP) (Tsung et al 1980, Uotila et al 1980) alkaline phosphatase (Mi 11 an et 
al 1982, Slaughter et al 1981). These examples are by no means exhaustive, 
but serve; to illu s tra te  the variety of c lin ic a lly  important material to 
which monoclonal antibody technology has been applied and thereby demonstrate 
the ve rs a tility  of the technique.
Any or a ll of these previously impossible, or d if f ic u lt  procedures may 
now be at the very least theoretically highly feasible. The impact of the 
technology is highlighted by the many excellent reviews recently published 
containing prodigious accounts of various aspects of the current applications 
of monoclonal antibodies.
Some of these include Kennett, McKearn and Bechtol (1981); Hammerling, 
Hammerling and Kearney (1981); Foster (1982); Edwards (1981); Staines and Lew 
(1980); Schroder (1980); Tse-Wen ChaiTg (1982); Hubbard (1981); Neville et al 
(1982); Rawls et al (1981); McGregor(1981); McMichael and Bastin (1980);
Sevier et al (1981); Melchers et al (1978); and papers are being published at
an unprecedented rate.
Human monoclonal antibodies
The major d iffic u lty  of human therapy with xenogeneic monoclonal
antibodies is that generally such antibodies induce an immune response of
.the ir own and so effectively reduce the potential worth of the therapy. 
Additionally a hypersensitive reaction may occur in response to repeated 
injection of foreign protein. These sorts of problems may be overcome using 
human monoclonal antibodies. The problem of the ava ilab ility  of myeloma cell 
partners may have fin a lly  been solved (Table 1 .5 ). The antigen sensitized 
lymphocyte partners may however, prove more of a problem. This may 
eventually be solved by developing e ffic ien t in vitro  lymphocyte antigen 
sensitization regimes.
Human-human hybridomas have however been produced. Olsson and Kaplan 
(1980) derived anti-2,4-dinitrophenyl (DNP) hybridomas, the hapten sensitized 
lymphocytes were obtained from a human spleen. Croce et al (1980) on the 
other hand used peripheral blood lymphocytes from a patient with subacute 
sclerosing panencephalitis. Hybridomas were derived which secreted human 
IgM antibodies specific to measles virus.
Sikora et al (1982) have also derived human-human hybridomas using 
malignant glioma as the permanent cell line and glioma intratumoral 
lymphocytes to produce hybridomas secreting antibodies which bound glioma 
cells.
Of course human monoclonal antibodies have also been derived by S te in itz  
et al (1977, 1979) by Epstein-Barr virus transformation of antigen sensitized 
lymphocytes and by mouse-human fusions (Kohler 1980, Koprowski et al 1978, 
Levy et al 1978, Schlome et al 1980), but these although successful are 
nevertheless restricted by the technological lim itations outlined in the 
text.
Monoclonal antibodies have proved advantageous in a wide range of 
situations and as more become available w ill probably eventually replace 
conventional anti sera in much of their present application. Their potential 
role as therapeutic agents w ill however remain unrealised until human mono­
clonal antibody generating systems are re liab ly  and e ffic ie n tly  organised.
In the meantime the available antibodies may be applied to standardise 
procedures and as the technology matures with time, and is applied to new 
areas of research, w ill yield data which w ill add to our understanding of 
previously unyielding biological phenomena.
4 THYROID STIMULATING HORMONE
I t  has already been stated that one of the greatest potential values of 
monoclonal antibodies becomes apparent where specific conventional antisera 
is practically impossible to produce such as areas where antisera are 
required to distinguish between very similar molecules. High a ff in ity  non 
cross reacting antisera are required for the immunoassay of c lin ic a lly  
important substances in body flu ids. Among such substances is the hormone 
thyroid stimulating hormone (TSH).
4.1 TSH Structure
TSH is secreted by the anterior p itu itary. I t  is one of a group of four 
glycoprotein hormones consisting of an alpha (a) and beta ( 3 ) subunit 
structure (Pierce and Liao 1970, Pierce 1973, Pierce et al 1971c). The a 
subunit is nearly identical to that of the other p itu itary glycoprotein 
hormones: Luteinizing hormone (LH) (Liao and Pierce 1970, Stockwell-Hartree
et al 1971, Pierce et al 1971a); Fo llic le  Stimulating hormone (FSH) (Papkoff 
and Ekbald 1970); and the related placental glycoprotein Human Chorionic 
Gonadotrophin (HCG) (Canfield et al 1971). Following the separation of the 
subunits of bovine TSH, the subunits retain l i t t l e  biological ac tiv ity  (Liao 
and Pierce 1970); but the a subunits have been shown to be interchangeable 
and combine with the hormone specific 3  chains to reconstitute the specific 
hormone ac tiv ity  (Liao and Pierce 1970, Pierce et al 1971a, Pierce et al 
1971b).
The 3  subunit conveys not only biological but also the immunological 
specificity (Shome et al 1968, Vaitukaitis et al 1973). However five  
sequence homologies have been demonstrated even between the 3  subunits of TSH 
and LH (Pierce et al 1971c). TSH has a molecular weight of about 28000 
(Pierce 1974, Canfield et al 1971) similar to that of the other glyco­
proteins. All this together with the very low TSH content per gland 
(10-15 mg/1000 gland) (McLean 1981) makes complete TSH purification d if f ic u lt  
and LH usually is found as a persistent contaminant of most purified TSH 
preparations (Condiiffe 1973).
Electrophoretic heterogeneity (Carston and Pierce 1960, Goetinck and 
Pierce 1966) observed possibly results from two regions of polymorphism,
one at the amino terminus and the other at the carboxyl terminus of the TSH
3 chain (Pierce et al 1971).
The structural sim ilarities between the hormones and the d iff ic u lty  in 
obtaining pure hormones for immunization for the development of specific 
antisera and for labelling for assay purposes have in the past presented the 
greatest obstacles to the achievement of highly specific assays for TSH.
.2 Immunological Characteristics Of TSH
The development of immunoassays’ for the specific quantitation of the
hormone resulted in the increased importance of the immunological properties
of TSH and the specificity of the antibodies. An understanding of the 
precise nature of the hormone aided in the development of specific assays and 
in the elimination of cross reactiv ity .
Shome et al (1968) demonstrated that human and bovine TSH are immuno- 
_ logically  d is tinct, notwithstanding the s im ilarities in structure and 
biochemical properties of the two hormones. A comparison of TSH from a 
variety of species has been given by (Pierce et al 1974). But perhaps the 
most striking and immunologically opportune observations of studies with, for 
example, TSH and LH, were that the antibodies to whole hormones were directed 
primarily at the 3 chain determinants (Pierce et al 1971a) Which gave strong 
reactions with their homologous hormone anti sera. The a chains on th e ir own 
reacted only weakly with such anti sera however. On the other hand the whole 
hormone reacted with antisera to either the a or the 3 chain (Vaitukaitis and 
Ross 1972). The 3 chain has therefore been used to derive anti sera of 
improved specific ity (Vaitukaitis et al 1973, Jacobs and Lawton 1974) for use 
in clinical assays.
Cross reactivity of conventional anti sera is usually removed by 
adsorption with large amounts of HCG (Odell et al 1967) which mops up cross­
reacting anti-a chain antibodies.
.3 Functions o f TSH
The primary function of thyroid stimulating hormone is the control of the 
thyroid gland's synthesis and secretion of the thyroid hormones -  triiodo  
thyronine (T3) and thyroxine (T4). The major overt processes associated in 
the thyroid glands with TSH stimulation and regulation includes inorganic 
iodide trapping, iodide oxidation and tyrosine iodination, together with 
oxidative coupling of mono- and di-iodotyrosines to form T3 and T4. Also 
included is the colloidal uptake by fo llic u la r  cells and the subsequent 
hydrolysis and release of stored T3 and T4 from thyroglobulin molecules. 
These various aspects have been discussed extensively by Van den Hove -  
Vandenbroucke (1980). Many of these TSH stimulated processes have been 
utilized  in the past in bioassays of TSH (Bakke 1973).
The acute functional effects of TSH stimulation described above are 
accompanied by general thyroid hormone regulated physiological and 
biochemical effects which cover a wide variety of biological phenomena 
involved in general metabolism, growth and developmental control (Bernal and 
De Groot 1980, Dumont and Lamy 1980).
In addition to the acute effects, TSH also causes delayed trophic effects 
where growth and division of thyroid fo llic u la r cells are featured promin- 
antly. Chronically administered TSH results in an increase in numbers and 
size of thyroid fo llic u la r cells with increased vascularization. Conversely 
tonic effects become evident in the absence of TSH resulting in a decline in 
the numbers of these cells which become flattened and vascularization is much 
reduced (Dumont and Lamy 1980).
TSH is therefore an important hormone with wide reaching implications in 
general good health. Its  effects are apparent not only in its  primary 
control of the thyroid gland function its e lf ,  but also in the capacity of the 
gland to function by its  trophic or tonic ac tiv ity .
4 Control Of TSH Secretion
The control of TSH secretion revolves around what is described as the 
hypothalamo-pituitary-thyroid axis (Demeester-Mirkine and Dumont 1980). TSH 
secretion is regulated via a negative feed back effect of the free thyroid 
hormones in the blood in such a way that small changes affect TSH secretion 
over the entire physiological range (Reichlin and Utiger 1967, Connors and 
Hedge 1981).
The thyrotrophs of the anterior pituitary which produce and secrete TSH 
display hypertrophy and hyperplasia in primary hypothyroidism (Bonnyns et al 
1974), with increased serum TSH levels (Odell et al 1965, Utiger 1965, Hall 
et al 1971, Hersham and Pitman 1971). Hyperthyroidism on the other hand 
results in unchanged thyrotroph numbers but with decreased TSH content in the 
cells (Phifer and Spicer 1974) and in serum (Turnbridge and Hall 1976).
The thyroid hormomes also exert a secondary controlling influence on TSH 
inhibiting the secretion of thyrotrophin releasing hormone (TRH). I t  has 
however been conclusively demonstrated that the thyroid hormones are potent 
inhibitors of TSH secretion in response to TRH (Ormston et al 1976), and that 
the inhibitory activ ity  at the pituitary level may be due to the effective  
reduction in TRH binding sites (De Lean et al 1977). Figure 1.5 shows the 
proposed major factors controlling TSH secretion.
TSH secretion is however under the direct positive control of the neuro­
endocrine tripeptide TRH, secreted by the hypothalamus (Ormston et al 1971, 
and reviewed by Labrie et al 1979 and Demeester-Mirkine and Dumont 1980).
Additional factors such as cold in neonate and children (Woolf et al 
1972) has a positive, while stress has a negative, effect (Demeester-Mirkine 
and Dumont 1980) on TSH secretion. Oestrogen stimulates (De Lean et al 1977) 
while neurotensin (Sheppard et al 1983) and somatostatin (S ile r et al 1974) 
inhibits TSH response to TRH. The opposing dopaminergic and adrenergic 
effects have been reviewed by Scanlon et al (1978) and Labrie et al (1979).
TSH is therefore linked in a major self regulating system which under 
normal conditions maintain optimum hormone levels. Under such a regulatory 
system normal basal TSH levels in man fluctuate very l i t t l e  with basal 
concentrations ranging from undetectable to about 4 yU/ml with a mean of 
about 1 yU/ml in adults (Demeester-Mirkine and Dumont 1980) measured by RIA.
Perturbation of the system therefore leads to variation in TSH levels 
which may be quantified in an attempt to delineate and define precisely the 
various interrelationships and assess their significance in the progress of 
thyroid dysfunction.
5 Assays For TSH
Tests which employ TSH assays are usually undertaken in an exploratory 
and/or diagnostic capacity to assess primarily the functional capacity of the 
thyroid. The c lin ica l evaluation of TSH is therefore usually designed to 
quantify TSH secretion either directly in the serum or indirectly by measure­
ment of its  biological effects in the resting state or in response to its  
controlling factors. The tests are therefore designed to identify the point 
of defect within the hypothalamus-pituitary-thyroid axis.
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TSH bioassays
A large variety of TSH assay methods have been described, the majority of 
which include the various in vivo and in vitro bioassays (Bakke 1973,
Tunbridge and Hall 1976). These contain many inherent lim itations. The
usefulness of any assay method is judged by its  sensitiv ity , sp ecific ity ,
precision and economy in application. The various bioassays have been
demonstrated to be limited in many of these respects (Tunbridge and Hall 
1976, Mornex and Orgiazzi 1980).
The bioassays have therefore now been superseded by other assays such as 
radioimmunoassays in general clin ical use, but nevertheless remain essential 
for delineating the biological reactivity of TSH preparations as opposed to 
immunological reactiv ity  measured by radioimmunoassay.
TSH radioimmunoassay
Radioimmunoassay of TSH has replaced the tedious bioassay methods has the 
advantages of good precision and the capacity to handle a large number of 
samples simultaneously.
However RIA carries its  own lim itations, and as described e a rlie r , 
because of the similar structures and sequence homology of TSH subunits and 
the gonadotrophins LH and FSH and HCG, most polyclonal antisera to h-TSH 
cross react with these to a greater or lesser extent (Odell and Utiger 1973).
Most of this cross reactivity is normally eliminated by the addition of a
large amount of HCG to the assay tubes to give the required sp ec ific ity .
Various modifications have been applied to the earliest TSH radioimmuno­
assays (Odell et al 1965, Utiger 1965) in order to improve assay sensitiv ity . 
Some 'of these include attempts to reduce radiolabelling damage (Marchalonis
1969, Butt 1972); the dilution of TSH standard material with TSH free serum, 
and the incubation of standards and test sera with the antisera prior to 
adding the labelled hormone, and better separation with an antiimmunoglobulin 
(Odell et : al 1967). However TSH RIA in clin ical application (Hall et al 
1971, reviewed by Tunbridge and Hall 1976) are s t i l l  limited by th e ir  
sensitiv ity , not being capable of measuring TSH levels in some normal and 
subnormal individuals. Other persisting lim itations of TSH RIA include high 
interassay variation, the extended assay period and the inter-centre  
variation in normal TSH value estimates (Tunbridge et al 1975).
Clearly because in this assay unlabelled TSH competes with radio labelled 
TSH for the limited amount of antibody binding sites, then the quality of the 
assay is dependent to a large extent upon the purity of the TSH preparations 
used. Pure TSH is required for immunization, for radio-labelling and as 
standard preparations (Bangham and Cotes 1971, Hurn and Landon 1971).
Recently reported immunoradiometric assays for TSH have solved many of the 
problems of TSH RIA and have approached (Sutherland et al 1982, John and 
Woodhead 1982) and surpassed the sensitivity (Pekary and Hershman 1984, Cobb 
et al 1984) obtainable by RIA.
Other assays
TSH has also been measured by other methods such as the cytochemical 
assay technique of Bitensky et al (1974). This assay while being very
sensitive is nevertheless limited for general use by its  small capacity,
-expense and assay time.
Enzyme-linked immunosorbent assays (ELISA) (Engvall et al 1971, Van 
Weeman and Sahuurs 1971, 1972, Voller et al 1979) have developed rapidly 
since its  f ir s t  inception and have now become established as an alternative  
immunoassay procedure to RIA. This rapid acceptance has been brought about 
because sensitiv ities can be achieved similar to RIA values and because i t  
overcomes the major disadvantages of working with and disposing of radio- 
active materials. The procedure is very robust and is now fu lly  automated
which fa c ilita te s  a large sample throughput.
ELISA has been described for TSH measurement (Miyai et al 1976, Tshikawa 
et al 1982) and commercial kits are available (Tanswell et al 1979). Recent 
reports of fluorometric TSH assays have also appeared (Kato et al 1980).
Even more exciting for TSH assay is the very recent report (Jones et al 
1984) of a very sensitive immunochemiluminometric assay which can d iffe re n ti­
ate the lower end of the normal basal TSH level from that of the hyperthyroid 
state. This assay employed a monoclonal antibody instead of the usual 
polyclonal antisera. Sensitivities of 0.015 mU/1 were achieved. This 
demonstrates the special fa c ility  of monoclonal antibodies to form the basis 
of highly specific sensitive assay systems.
.6 The Clinical Application Of TSH Assays
The value of TSH assays has been established by their application in the 
clin ical situation in the diagnosis and assessment of thyroid function and 
disorders of the hypothalamus-pituitary-thyroid axis.
TSH levels in the resting state
Considerable inter-centre variation have been reported for the normal TSH 
range (Tunbridge and Hall 1976). I t  is therefore necessary for each centre 
to establish its  own normal range.
As a result of the inaccuracy of the available RIA at very low TSH levels 
only normal and elevated levels are recognised and are therefore c lin ic a lly  
significant (De Visscher and Burger 1980). As a consequence the major 
application of TSH assay is in the evaluation of hypothyroidism where TSH 
levels are usually observed to be elevated.
The significance of this application is overwhelming by its  importance in 
the diagnosis of thyroid insufficiency resulting in the condition of 
cretinism. The congenital neonatal frequency (Klein e t a l  1974, Dussault et 
al 1975, Walfish 1975) is greater by a factor.o f two or three than that of 
phenylketonurea (Scanlon et al 1978) for which mass screening exists and is 
about 1:4000 babies (Sutherland et al 1981, Hulse et al 1980, Dockeray et al 
1980, Delange et al 1981, John and Woodhead 1982). This together with the 
good prognosis of early treatment highlights the significance of early TSH 
screening.
Thyroxine therapy alleviates the symptoms in overt and mild hyperthy­
roidism and the decrease in serum TSH levels may be used to monitor the
progress of therapy. In subclinical or compensated hypothyroidism however
elevated TSH levels are found in conjunction with low or normal thyroid
function but without the expected hypothyroid symptoms. A comprehensive
discussion of hypothyroidism, its  clin ical implications and treatment is 
given by De Visscher and Ingenbleck (1980).
Elevated TSH levels accompanied by the presence of thyroglPbulin
antibodies are also found in autoimmune thyro id itis  (Tunbridge and Hall
1976). Elevated basal TSH levels are also found in the rare hyperthyroid 
condition involving oversecretion of TSH due to p itu itary lesion (Mornex and 
Orgiazzi 1980).
Low or undetectable basal TSH levels are however the usual finding in 
hyperthyroidism. TSH assays are not sensitive enough to separate these 
levels from those of the lower end of the normal range. A rise in TSH levels  
however may be indicative of successful treatment with antithyroid drugs.
TSH levels in response to TRH
TSH response to thyrotrophin releasing hormone (TRH) has its  major 
clin ical application in the diagnosis of disorders of the hypothalamus- 
pituitary-thyroid axis (Ormston et al 1971b).
The suppression of TSH response to TRH is usually observed in hyper­
thyroidism. A normal TSH response therefore excludes th is condition, and is  
of primary importance in diagnosing mild hyperthyroid states with absent 
clin ical symptoms but with the suppressed TSH response to TRH s t i l l  evident
(De Visscher and Burger 1980, Scanlon et al 1978). However i t  must be noted 
that this sort of suppressed TSH response is observed in other thyroid 
related conditions (Scanlon et al 1978). I t  is therefore not a complete 
diagnosis of the hyperthyroid state.
In normal subjects the TSH response in the TRH test (Ormston et al 1971b) 
is elevated with maximum values occurring at about 20 minutes a fter TRH 
administration. The peak levels are observed to be d irectly related to the
basal TSH levels and as such the response is exaggerated in al 1 hypothyroid
conditions.
In a few cases, congenital neonatal hypothyroidism, described above would 
be missed i f  assessed on TSH levels alone. These are the hypothalamic- 
pitu itary hypothyroid cases. TSH response in the TRH test in secondary or 
te rtia ry  hypothyroidism suggests the origin of the defect. The p itu itary is 
indicated where there is absent or minor response to TRH. On the other hand
where the defect is of hypothalamic origin, a frequently delayed but
nevertheless elevated TSH response is observed (De Visscher and Burger 1980).
To summarize, the TSH assays are important when measured in the resting 
state to diagnose and possibly provide screening fa c ilit ie s  for hypothyroid­
ism. TSH levels in response to TRH exclude hyperthyroidism and in particular 
differentiate  the mild state from an anxiety state; and delineate the point 
of defect in secondary or te rtia ry  hypothyroidism while an exaggerated 
response confirms primary hypothyroidism.
THE MAJOR PROJECT OBJECTIVES
1) The d iffic u ltie s  of TSH assays especially in relation to those 
inherent; in the use of polyclonal antisera have been outlined. We therefore 
set out to f ir s t  immunize Balb/c mice with human TSH to produce spleen cell 
donors. These were to be used in fusion with NSI myeloma cells to produce 
anti-h-TSH antibody secreting hybridomas.
2) From these antibody secreting hybridomas we hoped to derive stable 
hybrids secreting specific and high a ffin ity  anti-h-TSH antibodies.
3) Characterization of the hybridomas and specific antibodies was to be 
in terms of cell growth and maintenance characteristics, antibody specific ity  
and cross-reactivity, t i t r e ,  a f f in ity , antibody class and subclass.
4) I t  was intended to demonstrate the antibodies in specific appl ication 
in immunocytochemical identification of thyrotropes in various p itu itary  
preparations; and to attempt to u tilis e  the antibodies in a sensitive TSH 
immunoassay. We chose to attempt to set up a sandwich enzyme-linked 
immunosorbent assay for TSH, because of the advantages of this procedure 
(Lancet editorial 1976, Gosling 1979).
CHAPTER 2
Development Of Assay Methods For The 
Detection Of Monoclonal Antibodies to h-TSH
INTRODUCTION
The range of monoclonal antibodies that can be produced is theoretically  
unlimited. However, in practice each antibody's detection and consequently 
its  possible selection may be severely limited by the quality of the 
screening assay. Essential features of the assay chosen for screening
purposes are:
(1) I t  must be very sensitive, capable of detecting only very small 
amounts of antibody produced in the f ir s t  few days after fusion.
(2) I t  must be reproduceable and re liab le . Since i t  is to be used to
screen very large numbers of hybridoma cultures, then detection rate must be
consistent.
(3) I t  must also be accurate. I f  this criterion is not met a great deal 
of time and e ffo rt could be wasted persuing false positive cultures or even 
more disasterous, valuable positive cultures could be lost as false  
negatives.
(4) F inally , the assay must be rapid to perform, and capable of handling 
a large number of samples. Speed is of the essence since slow growing
hybrids which may be producing particularly important antibodies may be 
overgrown by faster growing non-producing hybrids or by those producing non­
specific antibodies.
The success or fa ilu re  of the technology then is dictated to a large
extent by the screening procedures employed.
Many assays have been used to detect monoclonal antibodies some of which 
have been described in the study of antibody formation at the single cell 
level (Cunningham 1973). However, the assay must be chosen with regard to 
the predicted nature of monoclonal antibodies, 'the nature of the antigen and 
the uses for which the antibodies are intended (Edwards 1981, Galfre and 
.■Milstein' 1981, Catty et al 1981, Foster 1982).
Monoclonal antibodies have been shown in application to exhibit important 
lim itations which would exclude their selection . by assays requiring the 
exploitation of any of these lim iting characteristics. For example, because 
of the very nature of monoclonal antibody preparations, only one antibody 
type exists which binds only one single antigenic determinant on the 
molecule, (unless of course the specific epitope is a repeated u n it). This 
is not conducive to the formation of three dimensional la ttices  leading to 
precipitation. Monoclonal antibodies can only crosslink antigens into 
dimers, hence cannot usually precipitate the target antigens (M ilstein et al 
1980). The in a b ility  of monoclonal antibody to produce immunoprecipitation 
was predicted by the la ttic e  theory (Marrack 1938).
The double immunodiffusion assay of Ouchterlony (1958, 1962 and 1979), 
although fa ir ly  rapid and simple, is therefore not always appropriate for 
screening purposes. This is not to say however that monoclonal antibodies 
cannot be used la ter in these procedures. A mixing of two or more suitable 
monoclonal antibodies have been shown to adequately overcome the problem and 
produce precipitation (Jefferies et al 1980). Immune precipitation of 
antigen has however been used for screening by Brown et al (1980).
A similar situation has been found to exist in cytotoxic assays where 
some monoclonal antibodies may be missed. Monoclonal antibodies individually  
may be poorly cytotoxic or not at a ll;  but, in combination are highly effec­
tive  (Howard et al 1979). This is because complement mediated cytotoxicity  
requires for its  in itia tio n  at least two molecules of IgG antibodies bound to 
juxtaposed antigenic determinants. In addition, complement fixing a b ility  is  
dependent on the immunoglobulin class and subclasses present (see Chapter 1 ). 
Only IgG and IgM are effective; and within the IgG class, the subclasses f ix  
complement with varying effeciencies (Roitt 1980). Modifications of such 
assays may however allow their use (Kennett 1981).
Mason and Williams (1980) studied the binding of monoclonal antibodies to 
their appropriate antigens under various assay conditions and showed also 
that, the conformation of the antigen was important. In the solubilized  
state, antibody which bound strongly in the cellu lar configuration, for 
example, now exhibited rapid dissociation characteristics. Roehriget al
(1982) also demonstrated that the conformational state of the antigen also
influenced the reactiv ity . I f  the antibodies are required, for example, for
work with soluble membrane components, then i t  is appropriate that the 
antigens should be in the solubilized state in the selection procedure in 
order to obtain the best quality antibodies in terms of th e ir binding 
characteristics.
I t  is generally possible however to adapt and modify many of the
available immunological assays for the detection of monoclonal antibodies i f  
the above considerations are taken fu lly  into account when choosing the
screening assay. .
1 Screening Assays
Antibody secreting hybridomas have been detected in two main ways:
1) Indirectly, by the use of spent media from actively growing cultures; and
2) by direct detection in the microenvironment of isolated cells .
In d ire c t detection
The presence of antibody in spent culture media may be detected by 
binding assays in which specific antibody binds directly to the 'indicator' 
labelled antigen, and, under the appropriate assay conditions the behaviour 
of the complex demonstrates the antibody presence.
Such assays include the haemagglutination assay techniques described by 
Coombs (1981), and detailed specifically for use in hybridoma screening by 
Galfre and Milstein (1981) and Catty et al (1981). In these assays the 
antigen is coupled to red blood cells and the presence of antigen specific 
antibody in spent media, is indicated by agglutination.
The haemolytic spot test involving complement mediated lysis was used 
successfully in the pioneering experiments of Kohler and Milstein (1976). 
Another ly tic  assay which has since been used in this context was the ^*Cr 
release assay, where the specific antibody binding was detected by the 
release of the radioisotope following lysis of the labelled target cells  
(McKearn 1981, Schreier et al 1980, Pearson et al 1977, Eisenbarth et al 
1978, Galfre et al 1977).
Various modifications of the radioimmunoassay (RIA) (Yallow and Berson 
1960) comprehensively reviewed by Hunter (1979), have been used for screening 
(Ivanyi and Davis 1980, Park et al 1980, Soos and Siddle 1982, Catty et al 
1981, Baxter et al 1982, Tsung et al 1980).
Spent media samples were also used in indirect binding assays. This 
group of assays represents the largest majority of assays employed, because 
they do not require purified antigen in hybridoma screening. Such assays 
include those which employ a second labelled antiglobulin to indicate the 
presence of antigen binding antibodies. Several labels and binding reagents 
have been combined. Antiglobulins may be * ^ I  radio-labelled according to 
Miles and Hales (1968), and used in the solid phase system devised orig inally  
by Catt and Tregear (1967) and reviewed by Wide (1970). The system has been 
adapted for use with m icrotitre plates and the combined solid phase assay may 
be used for monoclonal antibody detection as described by Goding (1980), 
Catty et al (1981), Galfre and Milstein (1981), Hubbard (1981) and Tsu et al 
(1980), Hudson and Hay (1980).
In this type of assay the antigen, which may be a cell surface component/ 
components, or a soluble protein antigen, is adsorped onto a solid phase 
support. The prospective antibody solution is added to the solid phase 
antigen followed by the indicator antiglobulin (Bechtol 1981). The two 
immediate advantages of such an assay are:
(1) separation of bound label from free is no longer a problem and is 
accomplished merely by several washing steps; and
(2) all types of antibodies directed against the antigen w ill be bound 
and thereby detected. This type of assay therefore allows the detection of 
antibodies with additional specialist functions described above.
The enzyme-labelled antiglobulins reviewed comprehensively by Wisdom
(1976) and Avrameas (1978), were used in enzyme-linked immunosorbent assays 
(ELISA) f irs t  described by Van Weeman and Schuurs (1971) and (1972), Engvall 
et al (1971), Engvall and Perlman (1971, 1972). The procedure has since been
expanded (Bidwell et al 1976, Voller et al 1976, 1979) and has found wide
application (Voller et al 1979, 1981, Voller and Bidwell 1980).
ELISA methods for the detection of monoclonal antibodies have been 
described by Kennett (1981), Catty et al (1981), Noat and Remmington (1981), 
Sundar Raj et al (1982), Ross et al (1981) and Douillard et (1980). The 
antiglobulin may be substituted with Protein A which has been enzyme-labelled 
(Suter 1980) or radio-labelled (Brown et al 1979, Businaro et al 1981 or 
Nowinski et al 1981) to produce an effective assay. ELISA is performed on 
the same format as the solid phase RIA described above. However after excess 
unbound enzyme label is removed, a colourless enzyme substrate is added, 
which when cleaved by the enzyme, form a soluble coloured compound and the 
optical density of the solution is read on a simple spectrophotometer. 
(Hudson and Hay 1980, Catty et al 1981, Douillard et al 1980).
These enzyme-labelled antiglobulins may also be used in immunocyto-
chemical screening (Sternberger 1979), and such an assay is analagous to the 
ELISA system. The main differences include antigen immobilization within the 
tissue or cells instead of being absorbed on to the assay well and the enzyme 
substrate when cleaved form an insoluble colour product at the site  of the 
localized enzyme ac tiv ity  (Ross et al 1981).
Another important antiglobulin label is fluorescein. Coonset al (1941) 
published the f ir s t  account of such labelled antibodies; and the topic is 
extensively reviewed by Johnson et al (1979) and Landon and Kamel (1981). 
This label may be used with the fluorescein-activated cell sorter (FACS) 
which can be adapted for simultaneous screening and cloning of hybridomas 
directly  (Parks et al 1979, Dangl and Herzenberg 1982).
Assays based on the effect of specific antibodies on the biological 
ac tiv ity  of the antigen have also been used. These types of assays also 
obviate the need for pure antigen preparation for an effective and sensitive 
assay. Culture supernatants may be added to a biologically active antigen 
preparation and subsequent inhibition of the biological ac tiv ity  is  
indicative of the presence of specific antibody. The classic example of this  
type of assay used to good effect was in the screening of interferon  
monoclonal antibodies by Secher and Burke (1980).
D irec t detection
In contrast to detection of antibodies in the spent media, antibody 
secreting hybridomas may be identified directly by detecting very small 
amounts of antibody in the immediate v ic in ity  of the ce lls , or actually 
adhering to the cell surface (Galfre and Milstein 1981). As already outlined 
above one way of accomplishing this is with the FACS technique.
The plaque assay technique of Jerne (1965), Jerne et al (1974), has been 
used where the cells were grown in the semi-solid support like  agar or 
agarose (Galfre and Milstein 1981, Kohler and Milstein 1975 and 1976). 
Direct visualization of specific antibody secreting cells was realised by 
complement dependent lysis of antigen coated erythrocytes. The cell may 
therefore be picked and grown up as appropriate.
Replica immunoabsorption methods may also be used to indicate specific 
antibody secretors in situ. These methods involve the absorption of antibody 
into overlaid nitrocellulose f ilte rs  followed by labelled specific indicator 
(Sharon 1979).
All these screening assay methods outlined have their own special merits 
and disadvantages in terms of cost, practicability  and sensitiv ity  in 
specific application. Of the greatest importance to assay choice is a 
consideration of the numbers of cultures which may have to be screened, and 
even more significantly the capacity to detect antibodies to very rare and/or 
weakly immunogenic antigens and even the detection of antibodies to unknown 
antigens. A major lim itation however is that the assay may have to be 
performed using only very small amounts of the antigen often in an impure 
form, eg, Secher and Burke (1980) monoclonal antibodies to interferon; or be 
used to detect antibodies to unknown antigenic material which is a component 
in cell membrane (Magnani et al 1981).
The majority of the assays described are relative ly  inexpensive and the 
reagents i f  not readily available are easily synthesized. Some of the assays 
also require very l i t t l e  in terms of elaborate fa c ilit ie s  and so may be 
performed with ease under most laboratory conditions. D ifficu lty  however may 
be encountered, for example, in the assays requiring radio labelled reagents. 
A specifically designated Grade C laboratory is needed for radioiodinations. 
The counters are also expensive to purchase specifically for this purpose 
unless already available in the laboratory.
Having considered the uses for which the monoclonal antibodies are 
intended, and the available assays which f u l f i l l  the requirements, the next 
immediate task was to develop and optimise the assays for screening.
In the very early stages of this work liquid phase radioimmunoassay
(Hall et al 1971) using radio-labelled human thyroid stimulating hormone 
(h-TSH) was the assay chosen for screening. The primary reason for th is
choice was that an assay system with available; labelled h-TSH was already
in every day use by the Supraregional Assay Service Centre, Dept of C linical
Biochemistry, St Lukes Hospital, Guildford.
Later a solid phase separation RIA (Hunter 1979), and an indirect enzyme- 
linked immunosorbent assay (Voller 1979) (figure 2 .1 ), was developed 
specifically for screening purposes.
FIGURE 2.1
Indirect ELISA for TSH specific monoclonal antibodies
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2.2 MATERIALS AND METHODS
2.2.1 Preparation Of Antimouse Immunoadsorbent For RIA
Many immunoadsorbents have been used since its  f irs t  conception by Catt 
and Tregear 1967. Some of these include the covalent coupling of the
immunoglobulin fraction to sephadex or cellulose (Wide 1969, Hales and 
Woodhead 1980) or insoluble dextran (Wide et al 1967). Two conjugation 
methods are mainly used. That employing cyanogen bromide (Wide et al 1967 
and Wide 1969), the various applications of which are reviewed by Wide 
(1970); or the diazotization method of Gurvich et al (1961). This la tte r  
diazotization method is that which was employed in the preparation of the 
immunoadsorbent (Addison 1971, Hales and Woodhead 1980).
Preparation of aminocellulose
A small amount of aminocellulose was obtained through the courtesy of 
Dr D Teale, Dept, of Clinical Biochemistry, St Lukes Hospital, Guildford.
Further quantities were prepared by the method of Addison (1971).
1.4 g m-nitrobenzyloxymethyl pyridiniurn chloride (British Drug House, Poole, 
Dorset).
0.5 g anhydrous sodium acetate were dissolved in 20 ml 90% ethanol in a 
100 ml beaker. ,
10 g cellulose powder (Whatman CC41, Whatman Ltd, Springfield M ill ,  Kent) 
was added, mixed thoroughly and dried at 80°C on a heating block in the fume 
cupboard.
The dried powder was then heated at 100°C for 2 hours. The n itro ­
cellulose powder was then washed three times with 200 ml benzene and then a ir  - 
dried followed by washing with 3 lit re s  deionised water. All washings were 
done on a sintered funnel with gentle suction applied.
The nitro groups on the nitrocellulose were then reduced to amino groups 
by warming to 60°C for 30 minutes in 150 ml of 20% (w/v) sodium hydrosulphite 
solution.
The amino cellulose (AC) was washed four times with 200 ml deionised 
water, three times with 100 ml of 30% (v/v) acetic acid, and four times with 
200 ml deionised water until all the odour of hydrogen sulphide was removed.
The aminocellulose was dried in a desiccator and stored sealed at 4°C 
until required.
Suspension of aminocellulose
The aminocellulose was reprecipitated from an ammoniacal copper solution.
Cupric hydroxide was obtained by dissolving 5 g copper sulphate
(Cu SO4  5 H2 O) in 500 ml deionised water, and 2 g sodium hydroxide (NaOH) in
75 ml deionised water and the two solutions mixed. The suspension of cupric
hyroxide was washed with 2 lit re s  deionised water on a sintered funnel. The 
precipitate was dissolved in 1 0 0  ml of (specific gravity 0 . 8 8 ) ammonia. 
0.33 g sucrose and 1.0 g aminocellulose was added slowly with constant 
stirring for 30 minutes.
The volume was made up to approximately 400 ml with deionised water and 
about 300 ml of 10% HgSO^  is added until flocculation occurred.
The precipitate was washed by centrifugation five times with deionised 
water and suspended in 1 0 0  ml, ie , 1 0  mg/ml assuming no loss of m aterial.
This preparation was used within 24 hours.
Diazotisation and coupling of immunoglobulin fraction
All procedures were performed at about 4°C on ice, and washes were by 
centrifugation.
200 ml of 2M HC1 was added to the 100 ml suspension of aminocellulose - a 
pink colour developed. 8  ml of 1 % (w/v) sodium n itr ite  was added and the 
pink colour disappeared. The mixture was allowed to stand for 30 minutes 
after which solid urea was added to remove excess nitrous acid which was 
detected with starch iodide paper.
The diazo cellulose was washed three times with 200 ml ice cold deionised
water and once with 200 ml of 0.05M borate buffer pH 8 . 6 . I t  was then 
suspended in 40 ml, ( ie ,  at 25 mg/ml) borate buffer.
The presence of diazo groups was detected by the characteristic bright
orange colour which developed when a small amount of suspension was reacted
with a l i t t l e  saturated 3 -naphthol in borate buffer. The diazotized 
preparation is unstable and must be used immediately.
The ammonium sulphate purified donkey antimouse (Guildhay, University of 
Surrey) immunoglobulin 0.5 g in 35 ml PBS ( = 14.28 mg/ml) or 1.5 g in 35 ml 
PBS (= 42.8 mg/ml) was added immediately to the 40 ml diazocellulose 
suspension and mixed at 4°C for about 72 hours (immunoadsorbent A and 
immunoadsorbent B respectively.
The conjugates were then washed three times with 200 ml 0.05M borate 
buffer followed by resuspension in 40 ml of 1.0M ethanolamine in borate 
buffer and incubated overnight.
The immunoadsorbents were then washed with 200 ml borate buffer followed
by 200 ml 0.2M acetic acid and then three times with 200 ml borate buffer.
Finally the antibody-cellulose conjugates were resuspended in 50 ml TSH 
assay diluent buffer which was 0.01M phosphate buffered saline pH 7.4 
containing 0.2% (w/v) BSA (Miles Laboratories Ltd, Stoke Poges). The 
conjugate was stored at 4°C. Assuming 100% recovery the suspensions contain 
20 mg/ml cellulose conjugate.
Purification of donkey antimouse antiserum
165.0 ml donkey antimouse antiserum was partia lly  purified by ammonium 
sulphate precipitation (Nowatny 1979).
To donkey antimouse antiserum (D60IE 30.70.81) (kindly donated by 
Guildhay, University of Surrey, Guildford) was slowly added, 99.0 ml 
saturated ammonium sulphate to a final concentration of 37.5% (v /v ),
adjusting the. final pH to 7.4 with NaOH. The mixture was stirred for
30 minutes at room temperature, after which the precipitate was collected by 
centrifugation for 15 minutes on the MSE bench centrifuge.
The precipitate was kept concentrated by redissolving in 45 ml of 0.15M 
phosphate buffered saline (PBS) pH 7.4. The immunoglobulins were reprecipi­
tated by adding slowly 22.5 ml to a final concentration of 33.3% (v/v) 
ammonium sulphate. This was stirred for 30 minutes and then centrifuged as 
above. The supernatant was decanted and the precipitate redissolved to 45 ml 
in PBS.
The immunoglobulin preparation was dialysed against six changes of PBS at 
4°C over 48 hours. The preparation was centrifuged, and the supernatant 
collected and stored at 4°C. The protein content of the solution was 
determined from adsorbance values read at 280 nm (0D 280) on a Cecil CE292 
spectrophotometer.
2.2.2 Assessment of Immunoadsorbent
The two essential RIA reagents required for the assessment of the 
immunoadsorbent were: radio-labelled hormone and specific antibodies. The
assay procedure was a modification of Soos and Siddle (1982).
Labelled human Thyroid Stimulating Hormones
1 ? C
I labelled human thyroid stimulating hormone (h-TSH) was kindly 
supplied on a monthly basis by Dr D TeaTe, Dept. Clinical Biochemistry, 
St Lukes Hospital, Guildford.
The iodinated h-TSH was obtained as freeze dried samples which were 
reconstituted with 1.0 ml d is tilled  water. This was then diluted according 
to the instructions 1:40 and used lOOyl per assay tube. The average specific 
activ ity  of the batches was 80 yCi/yg.
Anti sera
Specific mouse anti-TSH antisera was obtained from mice immunised with 
h-TSH as detailed in Section 3 .2 .1 . Both non-immune serum and TSH anti serum 
was obtained by bleeding the mice by retro-orbital puncture. The blood 
collected was le f t  over night at 4°C then separated by centrifugation for 
15 minutes at 3000 rpm in the Beckman J6  centrifuge after which the serum was 
decanted from the clot. The serum was then stored in 200 yl aliquotes at 
-20°C until required.
Solid phase RIA
RIA assay diluent consisted of 0.01M phosphate buffered saline pH 7.4 
made up as follows:- 3.025 g Na2 HP0 4 . 1 2 H2 0 , 0.3 g NaH2 P0 4 . 2 H2 0  and 9gNaCl
were dissolved in 500 ml d is tille d  water. The pH was checked and the volume
made up to 1.0 l i t r e  0.2% BSA (w/v) was added immediately before use.
Method •'
The immunoadsorbent was assessed in a h-TSH assay and a methotrexate 
assay.
For the TSH assay, duplicate LP3 tubes (Luckham Ltd, Burgess H i l l ,  
Sussex) were set up each containing 100 yl pooled mouse anti-TSH diluted  
1:8000 in assay diluent or serum from only one animal diluted 1:5000. 
Negative control tubes contained normal mouse serum diluted 1:8000 or 1:5000. 
In nonspecific binding - (NSB) tubes, sera was replaced by 100 yl of assay 
diluent. Duplicate NSB tubes were set up for each.immunoadsorbent d ilu tion . 
Next 100 yl labelled h-TSH was added, the tubes were vortexed and incubated 
for 2 hours or 24 hours at room temperature.
At the end of the incubation period 200 yl of the solid phase second 
antibody diluted with assay diluent was added per tube which were vortexed.
The immunoadsorbent was investigated at various dilutions 1:10, 1:5, 1:2 
and undiluted. During the dispensing of the immunoadsorbent care was taken 
to ensure i t  was stirred continuously to ensure even distribution of the 
suspension. The tubes were incubated for a further 2 hours at room
temperature after this time, 1 . 0  ml assay diluent was added to dilute the 
contents and the tubes were spun down for 15 minutes at 3000 rpm on a Beckman 
06 centrifuge. The supernatant was then aspirated. The pellets were counted 
(LKB Rack Gamma counter) for 100 seconds.
For the methotrexate assay , 100 yl mouse anti sera d il uted 1:40 ,000  was
added to each tube followed by 100yl -methotrexate. Following incuba­
tion of 4 hours at room temperature 100 yl of the diluted immunoadsorbent
was added. The tubes were vortexed thoroughly then incubated for 2 hours at
room temperature, followed by dilution of the contents with assay diluent 
(Assay diluent consisted of 0.05M Phosphate buffer pH 7 .4  containing 0.1% 
(w/v) gelatin plus 0.5% (w/v) sodium chloride). They were then spun down at 
3000 rpm on the Beckman J6  centrifuge for 15 minutes; a fter which the
supernatants were decanted and the pellets counted. The methotrexate assay 
was kindly performed in the Clinical Biochemistry Lab, University of Surrey.
TABLE 2.1 
Lowry et al (1951) Assay Protocol
[BSA] 100 yg 80 - 60 40 20 10 5 0 Test
ml BSA solution 1.0 0 .8 0.6 0 .4 0.2 0.1 0.05 0 .0 0 .0
ml 0.25 yNaOH . 0.0 0.2 0 .4 0 .6 0 .8 . ° - 9 0.95 1 .0 0 .0
Test Sample 0.0 0 .0 0.0 0 .0 0 .0 0.0 0 .00 0 .0 1 .0
Reagent ‘Cm!
10 minutes incubation 5 .0 5 .0 5.0 5 .0 5 .0 5.0 5.00 5 .0 5 .0
Reagent 1E'ml 
30 minutes incubation 0.5 0.5 0.5 0.5 0.5 0.5 0 .50 0 .5 0 .5
The absorbance at 720 nm was read on the Cecil CE 292 spectrophotometer.
Protein content of immunoadsorbent
The amount of protein bound to the aminocellulose was determined by the 
Lowry et al 1951 method.
BSA FrV (Miles Laboratories Ltd, Stoke Poges) was used as the standard
protein. 1.0 mg was dissolved in 10 ml 0.25M NaOH.
The test solutions were diluted 1:25 with d is tille d  water, then an equal
volume of 0.5M NaOH was added.
The tubes were set up in duplicate as in Table 2.1.
Reagents
A - 2.0% (w/v) Na2 C03  in 0.1 M NaOH
B -  0.5% (w/v) C11SO4 . 5 H2 O in 1.0% (w/v) Potassium ta rtra te
C - Alkaline CuSO^  - 50 ml reagent A plus 1.0 ml reagent B
(stable for approximately one day)
E - Folin-Ciocalteau reagent - diluted 1:2 with d is tille d  water
3 ELISA Screening Assays
A m icrotitre plate procedure (Voller 1979) for an indirect ELISA for the 
detection and measurement of anti-human TSH antibodies was developed.
h-TSH antigen preparations
Purified human TSH was kindly supplied for the whole of this work by
Dr R Edwards NETRIA, St Bartholomews Hospital, London, in 200 yg quantities.
The TSH was dissolved in d is tille d  water and aliquoted into vials at 
10 ug/ml. These solutions were then freeze dried and stored at -20°C.
The TSH preparation potency was calibrated against the National In s titu te  
of Biological Standard and Control (NIBSC) standard (68/38) in a standard RIA 
(Dr D Teale, Biochemistry Dept., St Lukes Hospital, Guildford).
TSH potency was found to be:- 1 yg = 10 mU NIBSC standard (68/38)
This h-TSH preparation has been designated TSH(Barts) throughout.
Anti sera x
The mouse anti-TSH and normal mouse sera preparations used to sevt  up the 
solid phase RIA above was, also used in the development of the ELISA methods.
Enzyme conjugates
Horseradish peroxidase (HRP0) (EC 1.11.1.7) and alkaline phosphatase 
(EC 3.1 .3 .1 ) are perhaps the most widely used in enzyme immunoassays ( Wisdom 
1976). The enzyme conjugates are usually prepared by covalent linking of the 
enzyme and protein (antigen or antibody).
Conjugate Procedure
The periodate method of Wilson and Nakane (1978) and detailed by Voller 
(1979) was used for conjugation of donkey anti-mouse immunoglobulin and HRPO.
The donkey antimouse immunoglobulin fraction was prepared as described 
earlier in Section 2.2 .1. The immunoglobulin concentration of the 
preparation was determined by assuming 1 mg/ml IgG has an optical density of 
1.45 measured at 280 nm (OD2 8 O)• Protein concentration of the
preparation was. 42.76 mg/ml. 0.37 ml antibody preparation was diluted in 
1.63 ml 0.01M carbonate bicarbonate buffer pH 9.5 immediately before use.
8.0 mg horseradish peroxidase (RZ 2.9 Sigma Chemical, Poole, Dorset) was 
dissolved in 2.0 ml d is tille d  water and 400 yl of freshly prepared 0.1M 
sodium periodate (Na IO4 ) (BDH Chemicals Ltd, Enfield, Middlesex) was added 
and the mixture stirred at room temperature for 2 0 :minutes, followed by 
dialysis overnight against 0.001M sodium acetate buffer pH 4.4 at 4°C.
The following day 20 yl of 0.2M carbonate bicarbonate buffer was added 
and immediately the prepared anti globulin preparation consisting of 
approximately 16 mg Ig in 2.0 ml carbonate bicarbonate buffer was added; and 
the mixture stirred for 2  hours at room temperature. 1 0 0  yl of freshly made 
sodium borohydride (Na BH4 ) (4 mg/ml in d is tille d  water) was then added and 
allowed to stand at 4°C for a further 2 hours. After this time the conjugate 
preparation was divided into two. One half approximately 2.32 ml was 
precipitated with an equal volume of saturated ammonium sulphate and the 
precipitate washed twice with 50% (v/v) ammonium sulphate followed by exten­
sive dialysis against 0.15M PBS pH 7.4. This conjugate was then mixed with 
an equal volume of glycerol (BDH Chemicals Ltd) and 0.01% (w/v) thimerosal 
(Sigma Chemicals Ltd) was added as preservative. The conjugate was aliquoted 
into 0.5 ml lots and stored at 4°C. This was termed conjugate I I .
The second half of the conjugate was filte red  on a Sephadex G200 (Sigma 
Chemicals Ltd) column 35 cm x 2.5 cm equilibrated and eluted with 0.15M PBS 
pH7.4 containing 0.1% BSA. 2 ml factions were collected,and the OD2 3 0  anc* 
OD4 0 3  measured. The active fractions were pooled, an equal amount of 
glycerol added plus 0.01% thimerosal. The conjugate was dispensed into 
0.5 ml aliquotes and stored at 4°C. This was designated conjugate . I I I .
Conjugate I consisted of a pretitrated goat anti-mouse horseradish 
peroxidase preparation kindly donoted by Dr A Voller, Nuffield Laboratories 
of Comparative Medicine, Regents Park, London. This conjugate was used 
diluted at 1:6000. A substrate incubation time of 30 minutes was suggested 
to be suitable.
Assessment of conjugates
Conjugate I I
This conjugate was titra ted  by serial dilution between 1:100 and 1:12800 
against solid phase normal mouse serum as the positive serum and normal sheep 
serum as the negative control. Both diluted 1:8000 in ELISA coating buffer 
(see below). Coating buffer alone was used as the nonspecific binding
control. Conjugate I at 1:6000 dilution was included (x4 wells) as conjugate 
control. The assay was set up as described in Method A below. Both
polyvinyl chloride and polystyrene plates were used.
Conjugate I I I
The absorbance at 280 nm and 403 nm of each fraction eluted from the 
Sephadex G200 column was determined on an SP1800 Uni scan Spectrophotometer.
The fractions having the required 0 0 4 3 3 ratio of between 0.3 and 0.6
(Wilson and Nakane 1978) were pooled and titra te d  by serial dilutions between 
1:100 to 1:12800 as for conjugate I I ,
Testing of solid phase antigen and m icrotitre plates
Polyvinyl chloride and polystyrene m icrotitre plates (Dynatech
Laboratories Ltd, Billingshurst, UK) were assessed for th e ir  s u ita b ility  for 
use in the indirect ELISA system.
The assay used in it ia l ly  in the nonspecific identification of hybridomas 
producing antibodies was designated Method A. Next, specific anti-TSH 
antibody secretors were identified from amongst those antibody secretors by 
the assay designated Method B.
ELISA buffers
These buffers are used throughout in a ll ELISA assays.
Coating buffer
0.1M carbonate bicarbonate buffer pH 9 .6 :- 1.59 g Na2 C0 g, 2.93 g NaHCOg 
per l i t r e  d is tilled  water. Two litre s  were made up each time and stored at 
room temperature for not more than 2  weeks.
Washing/diluent buffer
0.15M Phosphate buffered saline pH 7 .4 :- 8.0 g NaCl, 0.20 g KC1, 1.15 g 
NagHPO^  and 0 . 2 0  g KHgPO^  were dissolved in one l i t r e  d is tille d  water to 
which was added 0.5 ml Tween 20. 3 lit re s  were prepared each time and stored
at room temperature. At the time of use 0.1% (w/v) bovine serum albumin was 
added.
Substrate Solution
Phosphate c itra te  buffer pH 5.0 was prepared consisting of 24.3 ml of 
0.1M c itr ic  acid and 25.7 ml of 0.2M Na2 HP0 4  plus 50rml d is tille d  water. In 
this buffer 40 mg ortho-phenylenediamine was dissolved immediately before use 
and 40 yl . of 30% H2 O2  was added. The solution was thoroughly mixed. (The 
substrate is light sensitive and so must be handled with care).
Method A
Normal mouse serum and normal sheep serum were each diluted 1:500, 1:10^, 
1:5 x 10^, 1:5 x 10®, 1:5 x 10® in ELISA coating buffer.” 150 yl of the 
diluted sera were added to the assay wells and incubated for 2  hours or 
18 hours at 37°C in a Dynatech plate incubator. Wells in which mouse serum 
had been omitted were developed as assay blanks.
During this time the proteins in the coating solution were passively 
adsorbed onto the well surfaces.
The wells were then aspirated and washed three times with ELISA washing 
buffer, 200 y l/w e ll. The plates were then inverted and tapped to remove
excess liquid . Carry over of loose material from one stage to the next 
interferes with the .precision of the assay.
The Conjugate I was diluted 1:6000 in washing/assay diluent buffer and 
200 yl added to each well which were incubated for 2 hours at 37°C. The 
wells were then aspirated and washed alternately three times. F inally the 
ELISA substrate solution was added at 200 yl/w ell and incubated for 30 
minutes at 37°C. The enzyme ac tiv ity  was then stopped by lowering the pH 
with 2.5M H2 SO4  and the wells read on a spectrophotometer at 490 nm. 
(Dynatech Laboratories Ltd, Billingshurst, UK mini reader).
Method B
Aliquotes of freeze dried h-TSH were dissolved in ELISA coating buffer
and diluted to give 2 .0 , 1.0 and 0.5 yg h-TSH/ml solutions.
2 0 0  yl samples were placed in the assay wells and incubated for 18 hours 
at 4°C in a humidity box after which the wells were aspirated and washed 
three times as in Method A.
150 yl of mouse anti-h-TSH, normal mouse sera diluted as for Method A in
ELISA assay diluent, or diluent buffer alone used as blank control was added
and incubated for 2 hours at 37°C in a Dynatech plate incubator. Conjugate I 
and substrate solution was then added as in Method A.
V ariab ility  of binding to solid phase
Wells were sensitized with 200 yl 0.1% (v/v) glutaraldehyde (BDH Chemical
Ltd, Enfield, Middlesex) in coating buffer incubated for 3 hours at 37°C
followed by washing three times with coating buffer. 200 yl of h-TSH diluted
at 1 . 0  yg/ml was then incubated overnight.
The other set of wells remained unsensitized and 200 yl of 1.0 yg/ml 
h-TSH in coating buffer was incubated overnight. The remainder of the assay 
was as described above for Method B.
2.3 RESULTS
2.3.1 Immunoadsorbent Solid Phase RIA
Purified donkey anti-mouse immunoglobulin
At 280 nm an optical density of 1.0 (in a 1.0 cm curette) = 0.69 mg/ml 
gamma globulin. (Hudson and Hay 1980). Therefore the protein concentration 
of the purified donkey anti-mouse gamma globulin fraction was determined 
using this conversion factor. Thus:-
0D28Q of a 1:100 dilution of the dialysed preparation, ie , 0.1 ml Ig 
solution + 9.9 ml PBS.
= 0.62
0D undiluted sample = 62.00
Since 1.0 mg/ml Ig solution gives OD2 go = 1*45
Therefore [Ig ] in solution = 42.76 mg/ml
There were 50 ml dialysate = 2.14 g immunoglobulins.
Protein content o f the immunoadsorbent
From the standard curve which was linear over the range tested (Lowry et 
al 1951) i t  was estimated that for immunoadsorbent A (assuming no loss of 
aminocellulose in the immunoadsorbent preparation), the protein bound was 
approximately 93.75 mg protein/g aminocellulose. This was 53.13% less 
protein bound than obtained by Gurvich et al (1961) by the same method.
Immunoadsorbent B on the other hand contained 237.5 mg protein/g amino- 
cellulose. This was 18.75% higher protein bound than obtianed Gurvich et al 
(1961).
Separation of bound label from free
In order to assess the amount of immunoadsorbent to be used in the assay, 
a series of dilutions of the immunoadsorbent was set up with the same amount 
of antibody and labelled hormone per tube.
1) Immunoadsorbent A
Figure 2.2a showed that the immunoadsorbent separated <33.3% of that 
expected using neat immunoadsorbent. At 1:8000 dilution of the pooled 
mouse anti-TSH 30% bound label was expected to be separated (see figure 
3 .3 ). The nonimmune mouse sera gave correspondingly low binding <1.0%.
After 18 hour incubation (figure 2 .2b), the amount of bound label 
separated had increased to 16.5% using undiluted immunoadsorbent -  s t i l l  
below that expected. The binding by nonimmune sera had also increased 
however.
A new preparation of the immunoadsorbent was produced with 253% more 
donkey anti-mouse immunoglobulin protein bound, in an attempt to increase 
the immunoadsorptive capacity of the immunoadsorbent.' The % bound was 
calculated as follows:
% Bound = x CPM - x NSB x^qq 
total counts
2) Immunoadsorbent B
Figure 2.3a showed a much improved separation of bound label from 
free. With this immunoadsorbent B the amount of bound label separated 
had increased from 16.5% observed with undiluted immunoadsorbent A to 52%
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using the pooled mouse anti-TSH with 18 hours f irs t  incubation. However 
maximally bound label was separated with the immunoadsorbent diluted 1:5 
with assay diluent. The maximum bound, separated with this immuno­
adsorbent was 55%; greater than expected using liquid phase double 
antibody separation (figure 3 .3 ). The increased anti-mouse protein bound 
to the aminocellulose appears however to have not only increased the 
specific separation properties, but also to have increased the non­
specific binding (NSB) ie , binding of label in the negative controls. 
With neat immunoadsorbent, NSB had increased to >10%. I t  is to be noted 
that the increase in binding in the negative controls is  linear, 
increasing with increasing immunoadsorbent added (figures 2.2 and 2.3a).
The length of time of the f irs t  incubation period however also has,
an effect, since an overall increase in binding in the negative tubes was
observed for 18 hours incubation at a ll concentrations of immunoadsorbent 
used (figure 2 .3 ). The binding in the negative controls with 1:5 
dilution of immunoadsorbent was however only 5.5%. Figure 2.3b is the 
curve obtained for the methotrexate separation.
Time course of antigen antibody binding
I t  became apparent from figure 2.2 that a 2 hour incubation of antibody 
and labelled hormone was' not sufficient to produce a reasonable amount of
binding above the negative control to give good re lia b ility . This was
especially as the antibody content of the preparations the assay was intended 
to detect was in i t ia l ly  expected to be very small. Since time is of the 
essence once the hybrids are detected, a 5-day incubation time (H all, Amos 
and Ormston 1971) was inappropriate but i t  was by no means certain that a
4 hour incubation (Soos and Siddle 1982) would be adequate in our system.
A rea lis tic  overall assay time was required.
Figure 2.4a and b shows that there was no difference in the amount of 
label bound at either temperature with immunoadsorbents B. There was also no 
difference in the negative controls % bound. At least 18 hour incubation of 
label and antibody was indicated (figure 2.4b). This gave a reasonable assay 
time, not too prolonged so as to lose valuable time and possibly hybrids. 
The indication was for incubation at 4°C for longer incubation times.
T itra tion  of ^ i . - .h -T S H
100 yl of a 1:40 dilution of ^ I-h -T S H  hormone was recommended
(Dr D Teale, Dept. C linical Biochemistry, St Lukes Hospital, Guildford). The
labelled hormone was titra ted  to determine whether this quantity was optimal 
in this system. Duplicate totals and NSB tubes were set up for each label 
dilution.
Figure 2.5 shows that using a greater amount of label than that 
recommended had l i t t l e  effect on the % bound, but as less label was used a 
greater percentage was lost in the non-specific binding, while re la tive ly
more label was extracted as bound in the pellet. The recommended amount' of
label was therefore satisfactory.
Time course immunoadsorbent binding and assay re lia b ility
Figure 2.6- shows that after 1 hour incubation then maximum separation of 
bound label was achieved, further extension of the incubation time does not 
further increase the binding.
The determination of the inter and intra assay coefficient of variation
(CV) described in the next section is presented for the optimized assay in 
Table 2.3 below. .
2.3.2 Enzyme-Linked Immunosorbent Assay 
Horseradish peroxidase conjugates
The working dilution of the conjugates was determined to produce an assay 
system which could be completed within one day. A long conjugate and 
substrate incubation time w ill be required with highly diluted conjugates 
(Voller et al 1979). On the other hand where the results are required very
quickly short incubation times may be combined with the use of more 
concentrated conjugates. The choice of conjugate concentration had to be 
taken in relation to the background binding that was produced. The higher 
the concentration of conjugate- used the higher the expected background 
levels.
Conjugate I was used as reference. Diluted at 1:6000 i t  was determined 
that with a solid phase preparation of 1:8000 normal mouse serum i t  gave very 
strong positive results OD^q = 1.05 with very low background <0.20 (see 
figure 2.11). Both conjugatell and I I I  was assessed relative to conjugate I 
therefore.
Corrected ELISA 0D for ELISA method A was calculated = Absorbance of 
sample x 1.05/absorbance of reference.
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FIGURE 2.5 100 yl of ^  I-h-TSH titra ted  with pooled mouse
anti-TSH ( • )  and normal mouse serum ( a )  both diluted 
at 1:8000 and used at 100 yl/tube. Immunoadsorbent B 
diluted 1:5 was used at 200 yl/tube. The anti-TSH 
and label was incubated for 4 hours at 4°C and the 
immunoadsorbent incubated for 2 hours at room 
temperature.
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FIGURE 2.6 Time course of immunoadsorbent separation of
antibody bound label. Immunoadsorbent B diluted 1:5 
and used at 200 yl/tube. ( • )  pooled mouse anti-TSH; 
/.(*) normal mouse sera diluted 1:8000 was used at 
100 yl/tube. The anti serum and 100 yl ^ I-h -T S H  
was incubated for about 18 hours followed by incuba­
tion with the immunoadsorbent at room temperature 
for various time periods. The immunoadsorbent bound 
label was separated by centrifugation and the pellet 
counted SEM for n = 3 pairs.
Conjugate I I
A dilution of 1:1600 of conjugate I I  gave the required assay charact­
eristics outlined above. Specifically, the optical density of 1.16 was 
obtained with two 2 hour incubation periods (coating and conjugate 
binding), and a 30 minute substrate incubation time. The background 
binding obtained with a negative sera (normal sheep serum) was 0.10 in 
the polyvinyl chloride plates (see figure 2 .7 ).
In the polystyrene plates the dilutions of conjugate was lower 1:1040 
to give the same 0D4gg = 1.16 value under the same assay conditions. The 
final volume of this conjugate including glycerol was 5.6 ml.
Conjugate I I I
Figure 2.8 shows the OD2 8 0  and OD4 Q3  p ro file  of the fractions eluted 
from the sephadex G200 fractions. The horseradish peroxidase content of 
each fraction is indicated by the OD4 Q3  pattern, whilst the total protein 
content is indicated by the OD2 3 Q pro file .
Figure 2.7 shows that a dilution of 1:560 gave an OD^ gg in the ELISA 
test of 1.16 in the polyvinyl chloride plates when compared to conjugates 
I and I I .  This is to be expected since the final volume of the pooled 
fractions including glycerol was 40 ml, that was 7.14 times more d ilute  
than conjugate I I ;  and, in addition, only fractions with an 0 D4 g3 :0 D2 Qg 
ratio of between 0.3 and 0.6 were included in the pooled sample. Only 
optimal conjugate molecules were included in conjugate I I I  which 
therefore did not contain all the antibody or horseradish peroxidase 
contained in conjugate I I .  The negative controls for the sephadex
filte red  conjugate produced very low optical densities at all d ilutions. 
Both conjugates were also investigated for use in immunocytochemistry in 
Section 5.2.2.
The major advantage of f ilte r in g  the conjugate over ammonium sulphate 
purification in the ELISA procedure appears to be a final conjugate 
preparation with a much reduced background. There was very l i t t l e  
difference between the apparent bound in either plate types when 
Conjugate I I  was used, while the difference in apparent adsorption 
between the plates was more marked with Conjugate I I I .
>2
.0
o
00CJ
O
CO
Q>
o
CO
d>I 8
a > - ^
COCM
O!--)
CU
o  T3O •r-O S-CO o
• • r—
«—1 -ECJ
to -O i-c a) I— 3
o 4-J >>o
•r— 3 C - C■ r—•1—
3 •i— >  CM
• a > i•r— r— * a
■ a 03 o  c£_ Q. 03
i—i cu»—i to C  CD
*—i O  £=
Q . •r-
CU <U .«+->
+-> CU.—  ^(73ea J3 <J O
c n to « CJ
3 o  ,•r-) r “ '  c .
SZ <T3 3
o £ fO oo iZ t.  J3O CU
o 3 to CMQ.
CC
O00CM
a > .
a>
o
00t>o
I--t
oo
CM
O
00o
o
toc:
o
•r~4->3
CU4->rtJO)3
OO
o
a .ccac r^ *CM
cc 
—> CD
ELISA OD^ gg
OP
TIC
AL
 
DE
NS
ITY
 
(O
D)
0.5
0.4
0.3
0.2
0.1
FIGURE 2.
•o-°
FRACTION NO
8 Sephadex G200 filte re d  fractions of Conjugate I I I  
ODoon = ( • )  and 0D40o = (o). The column was 
35 x 2.5 cm. Elution buffer : PBS 0 .15M pH7.4. The 
fractions with O D ^  : ODpgg of between 0.3 and 
0.6 were pooled, le , fractions 34-40.
Assessment of adsorption to m icrotitre plates
Conjugate I was used at 1:6000 d ilution. Figures 2.9 and 2.10 show that 
in method A the polyvinyl chloride plates adsorbed a greater amount of 
specific protein than the polystyrene plates after 18 hours incubation. The 
inclusion of bovine serum albumin in the washing buffer greatly reduced the 
background binding which was higher in the polyvinyl chloride plates compared 
with the polystyrene plates.
After 2 hour incubation at room temperature, binding to the polystyrene 
plate was minimal compared with the apparent binding in the polyvinyl
chloride (PVC) plates (figures 2.11 and 2 .12). After such a short incubation 
time the apparent binding to the PVC plates was in total also reduced
compared, with that observed after 18 hours incubation, and the background 
non-specific binding was much higher in the polystyrene plates.
Assuming :on average 12.0 mg/ml mouse immunoglobulin (Hudson and Hay 1980) 
in the serum, then the assay using polyvinyl chloride plate incubated fo r 2 
hours at room temperature could detect as l i t t l e  as 0.3 ug/ml immunoglobulin 
which is a 1:4 x 10  ^ d ilu tion; and with a 18 hour coating incubation period 
again in polyvinyl chloride plates the detection was as l i t t l e  as 0.13 ug/ml
a dilution of 1:9 x 10  ^ of mouse serum.
The lowest positive result was taken as twice the highest negative value 
obtained. Reference positive and negative sera were included in a ll assay 
plates.
Hybridoma cultures were expected to produce up to 10 ug/ml immuno
globulins. The assay should therefore be able to detect even the early 
stages of antibody production. The intra assay % CV is  presented in 
Table 2.3.
For the specific anti-TSH method B assay polystyrene plates only were 
used with 18 hour incubation with coating antigen solution. Figure 2.12 
showed that protein binding after 2 hour incubation was not very high as 
compared with 18 hour incubation, figure 2.10. The background using 
polyvinyl chloride plates with antigen adsorbed in the indirect assay tended 
to be very high (Dr A Voller personal communication). Therefore a 18 hour 
coating incubation period was used to investigate the optimum bound antigen 
concentration to be used to detect the specific antibodies.
Figure 2.13 shows 0.5 ug/ml h-TSH gave almost as good a result as 1 ug/ml
or 2 ug/ml. Although more binding was observed at 1 and 2 ug/ml i t  was not
significantly higher.
The coefficient of variation (defined below) was unacceptably high; and 
in some cases edge effect phenomenon (Denmark and Cheesman 1978) was
observed.
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FIGURE 2.9 Polyvinyl chloride plates coated with 
various dilutions of 
normal mouse serum wash without BSA (• )
normal mouse serum wash with BSA (o)
normal sheep serum wash without BSA (A)
normal sheep serum wash with BSA (A)
Incubation of coating solution for 18 
hours at 4°C. Conjugate I diluted 1:6000 
SEN! for n = 4.
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FIGURE 2.10 Polystyrene plates coated with various 
dilutions of
normal mouse serum wash without BSA (• )
normal mouse serum wash with BSA (o)
normal sheep serum wash without BSA ( a )
normal sheep serum wash with BSA (a)
Incubated w ith coating so lu tion  fo r 18
hours a t 4°C. SEM fo r n = 4.
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FIGURE 2.11 Polyvinyl chloride plates coated with 
various dilutions of 
normal mouse serum wash without BSA ( • )
normal mouse serum wash with BSA (o)
normal sheep serum wash without BSA ( a )
normal sheep serum wash with BSA (a )
Incubated w ith coating so lu tion  fo r 2 hours
a t room temperature. SEM fo r  n = 4.
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FIGURE 2.12 Polystyrene plates coated with 
various dilutions of 
normal mouse serum wash without BSA (•)
normal mouse serum wash with BSA (o)
normal sheep serum wash without BSA ( a )
normal sheep serum wash with BSA (a )
Coating solu tion incubated fo r 2 hours at
room temperature. SEM fo r  n = 4.
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Control of v a ria b ility  of adsorption to solid phase
Table 2.2 shows that glutaraldehyde sensitization (Stafford and Ki1 gall an 
1980) of the plates prior to incubation of coating protein in the wells 
resulted in a greatly increased adsorption to the wells, evidenced by the 
44.63% increased 0D over unsensitized wells. To test whether the means of 
the two samples differed significantly the Students t-te s t was applied for 
samples where equal population variances cannot be assumed. A t 84 = 7.57 was 
obtained which was very highly significant at <0.1% on a 1 -ta il te s t. Thus 
the glutaraldehyde treatment has provided a significantly better adsorption 
to the wells than when no pretreatment was used.
TABLE 2.2
Sensitization of wells with 0.1% 61utaraldehyde compared to unsensitized 
assay wells prior to coating with TSH antigen at a concentration of 1 ug/ml.
Treatment ELISA 0D
X
(s )
S.D.
(s2 )
variance
% C.V. N t
Glutaraldehyde 
Sensitized wells 
+ve controls (A)
Unsensitized wells 
+ve controls (B)
1.3860
0,9583
0.2242
0.2803
0.0503
0.0786
16.17
29.25
50
36
7.534
•kicie
Sensitized wells 
-ve control (C) •
o+1CM«=!•00O.o 013 15.44 10
Unsensitized wells 
-ve control (D) 0.077±0.014 15.94 10
t  = X of A - X of B
S21 + S22 
\1  Nj N2
= 1 .3 8 6 0  - 0.9583 = 0.04277
 :-------•------------------ 0.0565
\ 0.0503 + 0.078650 36
t 84 = 7.57 ***
The coefficient of variation (CV) was determined as follows:
CV >  (SD/x)100
SD = standard deviation; x = sample mean; N is the number of samples. 
The standard error on the mean (SEM) = SD//N.
The %CV was reduced dramatically from 29.25% to 16.17% with sensitization 
of the wells. The negative controls were not affected by the treatment and 
NSB remained acceptably low.
As a result of this observation the assay was optimised using 0.1% 
glutaraldehyde sensitized plates. Figures 2.14 and 2.15 show the adsorption 
profiles using different amounts of h-TSH antigen and different amounts of 
anti sera.
I t  was decided to use 1.0 ug/ml h-TSH in coating solutions for the 
indirect ELISA since i t  gave the best binding curve (figure 2.15) with 
maximum binding and low NSB, figure 2.14.
TABLE 2.3
The re lia b ility  of the optimised assay procedures was demonstrated by the 
calculation of the intra and inter assay %CV. (The formula for the 
calculation of the standard Deviation in the inter assay %CV determination is 
presented in Chapter 5 .) Normal mouse serum and normal sheep serum; mouse 
anti-h-TSH and normal mouse serum used in ELISA A and in ELISA B and the RIA 
respectively at a dilution of 1:8000.
Assay method sample mean SD 
x 0D490
N %CV
ELISA A
in tra  assay 
1.140 0.099 48 8.7
ELISA B . 1.386 0.224 50 16.17
x % bound label SD N %CV
Solid phase RIA 48 2.85 10 5.9
in ter assay 
49.5 6.12 3 12.4
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FIGURE 2.14 Binding of h-TSH to 0.1% glutaraldehyde sensitized polystyrene 
plates; Mouse anti-TSH 1:8000 ( • ) ;  1:16000 (o) and 1:32000 (■) 
and corresponding normal mouse negative controls 1:8000 ( • —• )  
1:16000 (o—o) and 1:32000 (■—■). Conjugate I used at a 
dilution of 1:6000; SEM for n = 4.
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FIGURE 2.15 h-TSH coating plate at 0.5 yg/ml ( a )
1.0 yg/ml ( • )  and 2.0 yg/ml (o). 
Incubated with various dilutions of 
mouse anti-human TSH anti sera and 
normal mouse sera as negative 
controls. Wells presensitised with 
0.1% Glutaraldehyde.
The inter-assay variation in the ELISA methods was controlled by 
including reference positive samples in all assay plates (Voller 1979).
The corrected 0D490 values for ELISA method B were calculated:
0D4g0 = Test OD value - Blank control x 1/Adsorbance of reference positive.
The reference positive sample chosen to give an OD^ gQ = 1  consisted of 
solid phase antigen at 1 yg/ml; mouse anti-h-TSH diluted at 1:12000 and 
conjugate I diluted at 1:6000 (see figure 2.15).
2.4 DISCUSSION AND CONCLUSIONS ,
I t  was necessary to develop the solid phase RIA and the ELISA for 
screening the hybridoma cultures. The liquid phase RIA was used to screen 
the mice sera after immunisation (see Chapter 3 ), but was found to be
unsuitable for detecting low levels of hybridoma antibody produced in the
early stages of growth.
2.4.1 Immunoadsorbent
With the solid phase immunoadsorbent separation system, separation of 
bound label from free label was achieved merely by centrifugation. 
Optimization of the complex precipitation conditions and such problems as 
prozone which may occur in the second antibody precipitation of antigen- 
antibody complex (Midgley 1969) was avoided.
This separation system also avoided many of the problems related to
obtaining and characterization of a good precipitating second antibody. Not
all anti globulins are suitable for use as precipitating second antibodies 
(Morris 1981).
In addition the need for carrier serum derived from the same species as 
the primary antibody to assist precipation was circumvented.
Hunter (1979) suggested that this immunoadsorbent method character­
is tic a lly  gave high precision possibly because the separation step was well,
defined therefore misclassification error was minimised. No system 
completely separates the free from the bound label into d istinct compartments
and va ria b ility  in this contributes to error in the percentage bound
separated compartment. By reducing the v a ria b ility  by clearly defining the 
separated phases, the assay can overcome these d iffic u ltie s  observed in the 
conventional second antibody system.
Providing the immunoadsorbent binding sites are not limited all primary 
antibody with or without label bound should be removable from solution. 
Even very minute quantities of specific antibody should therefore be 
detectable by bringing down bound label in a defined and precise way. 
Misclassification in the procedure of monoclonal antibody production can be 
time consuming and very costly.
One major disadvantage of the immunoadsorbent separation system however 
may be in the possible loss of avidity due to the coupling of the immuno­
adsorbent and concomitantly lead to loss of sensitivity (Arends 1971). Hales 
and Woodhead (1980) have however experienced no such loss of immuno- 
reactiv ity .
Immunoadsorbent B is that which was chosen for use. I t  gave a high 
percentage bound with minimal non-specific adsorption at 1:5 d ilution. The 
low non-specific adsorption appears to be characteristic of this type of 
immunoadsorbent (Gurevich et al 1961 and Wide 1969). Gurevich et al (1961), 
Addison (1972), Hales and Woodhead (1980) used 1.0 g protein antigen per
1.0 g diazotized cellusose while Wide (1969) used immunoglobulin precipitated 
from 0.1 ml antisera with 100-400 mg activated polymer to achieve a satis­
factory immunosorbent. For this work 0.5 g and 1.5 g precipitated immuno­
globulins were used. .The immunosorbent B gave satisfactory results. I t  is 
important to note that Gurevich et al (1961) suggested increasing the bound 
protein does not necessarily increase the capacity (the amount of protein 
capable of uniting with . 1.0 g aminocellulose) of the immunoadsorbent. 
Possibly due to increased steric hinderance of binding with increased protein 
bound to the immunoadsorbent. However, with a possibly low t i t r e  antisera, 
then increasing the amount of precipitated protein may also increase the 
amount of specific binding. The capacity of the aminocellulose is however 
lim ited. Only approximately one active site exists per 40 glucose residue
(Hales and Woodhead 1980).
This assay was fa ir ly  rapid compared to a standard h-TSH RIA (Hall et al 
1971) which could take up to 5 days before the results were to hand. 
Approximately 20 hours and this assay was complete. The procedure was 
greatly simplified with the use of the immunoadsorbent; and in terms of cost, 
while using a great deal of second antibody in the production of the 
immunoadsorbent (the unbound protein was saved from the washing procedures 
and may have been reused), this system did not require any additional sera or 
precipitation accelerating agents. I t  was therefore very cost e ffective .
The final assay procedure therefore was as detailed in Chapter 3 .2 .4 . 
The assay was very reliab le with an inter assay CV of 5.9% and an intra assay 
CV of 12.4%.
2.4.2 In d ire c t ELISA
The working dilutions of conjugates I I  and I I I  were found to be 1:16000 
and 1:560 respectively. Both conjugates performed satisfactorily  in the 
m icrotitre plate ELISA assay. However, the sephadex G200 filte re d  conjugate 
gave consistantly lower non-specific binding in the negative controls. Both 
ammonium sulphate and G200 purification were just as easily done. There was 
very l i t t l e  difference between them in use except for the dilution factor and 
the background d iffic u ltie s  found mainly in use in immunocytochemistry (see 
Chapter 5 .3 .1 ). For use in ELISA the ammonium sulphate method is quite 
adequate. There is less material to store and the conjugate is therefore 
easier to store in the more concentrated state. Both conjugates were s t i l l  
very active after 1.75 years stored as described at 4°C.
I t  must be noted here that sodium azide inhibits horseradish peroxidase 
and therefore should not be used as the bacteriostat (Voller et al 1979). We 
have found that thimerosal is very suitable for this purpose.
The primary demands on these assays were that they were quick to perform, 
reproducible, sensitive and amenable to large scale sample analysis 
preferable in a semiautomatic procedure.
With these in mind the m icrotitre plates were chosen for use in the ELISA 
assay. Washers, incubators, multi pipetters and spectrophotometer equipment 
are available commercially for these plates therefore simplifying the 
procedure enormously.
McLaren et al (1981) summarizing the sources of error in the indirect 
ELISA have indicated that low sensitivity can be the result of any or a ll of 
the following:-
1) The choice of the solid phase support: hence the investigation of 
the polyvinyl chloride vs the polystyrene plates. The polyvinyl chloride 
plates were chosen for 2  hour coating with antibody solution for the in it ia l  
non-specific screening assay. The low background non-specific binding and 
higher protein binding capacity evidenced by the higher 0D compared to that 
observed in the polystyrene plates dictated th e ir choice.
The polystyrene plates were chosen for coating with antigen over a 18 
hour incubation period. This was convenient as the coating procedure was 
arranged for the day before the actual screening was due to be done. 
Polystyrene plates exhibited low non-specific binding with high specific 
binding over this period (figure 2 . 1 0 ) and were generally suggested to be 
better for specific antigen binding (verbal communication A V o lle r).
2) Antigen concentration of the coating solution is c r it ic a l .  Under­
coating gave very low binding (figures 2.14 and 2.15). While overcoating 
results in the high dose hook effect (Miles and Hales 1968) (figure 2 .14).
1.0 ug/ml h-TSH . antigep (figure 2.15) in this work was found to be optimum 
giving a proportional response over the range measured (figure 2 .15). Too 
high or too low antigen coating may result in low or very high concentrations 
of antibody not being accurately detected (Figure 2 .14). This effect was
also demonstrated by Engvall and Perlmann (1972). The optimal antigen 
coating concentration and adsorption times must therefore be defined for each 
assay (Herrmann and Collins 1976).
3) As suggested in Section 2.3.2 the effectiveness of the conjugate used 
is important bearing in mind the constraints on this assay, the conjugate 
titre s  were chosen therefore to yield an observable maximum response in the
shortest possible time. . Because the observable activ ity  of an enzyme is 
affected by many factors, the chief of those, being the enzyme and substrate 
concentration, temperature, pH, the presence of enzyme inhibitors and
incubation time, these must be s tr ic tly  controlled.
4) The so lub ility  of the enzyme substrate (Voller et al 1979) is
c r it ic a l. Hence orthophenylene diamine was used.
Two additional characteristics of importance in this assay were the assay 
specificity and the precision. The specificity would of course be affected 
by the quality of the antigen used on the solid phase. Highly purified h-TSH 
was kindly donated for this work (see Section 2 .2 .3 ). The non-specific 
binding effects were negligible and each step in the assay was carefully  
controlled.
There was d iffic u lty  with the precision of ELISA method B to begin with, 
and after eliminating experimenter's errors (Woodhead e t a l  1981) such as 
pipetting errors involved in dilution and f i l l in g  wells and the elimination 
of carry over of material from one step to the next, i t  was decided that the 
poor precision observed was due to variable adsorption of protein by the 
polystyrene wells (Wisdom 1976, Denmark and Chessum 1978, Herrmann and 
Collins 1976). Glutaraldehyde treatment as described by Stafford and 
Ki1 gal 1 an (1980) was found to alleviate the problem. A satisfactory 
procedure (detailed in Section 3 .2 .4 ) was therefore established within the 
constraints set by the technology for screening purposes.
Figure 2.16 is a photograph of a developed ELISA plate.
Both solid Phase RIA and the indirect ELISA systems are suitable for
monitoring the immune response to h-TSH as well as screening for specific
monoclonal antibodies. But i t  must be remembered that the antimouse 
immunoadsorbent or the antimouse enzyme label may be used as universal 
reagents to detect any specific antibodies raised in mice or that are mouse 
originated -monoclonals.'/The "assay universality of the immunoadsorbent was 
demonstrated in the methotrexate assay.
FIGURE 2.16
Conjugate I I  t i t ra t io n  in row A, B and C; with conjugate I reference in 
rows D. Rows E, F and G contain normal sheep sera and is negative control 
for conjugate I I .  Row H is negative control for Conjugate I .  Buffer blank 
was the final 2 wells row C.
CHAPTER 3
The Generation of Monoclonal Antibodies 
Against human Thyroid Stimulating Hormone (h-TSH)
INTRODUCTION
Monoclonal antibodies are derived by the fusion of biochemically marked 
permanently growing myeloma cells and antigen primed spleen ce lls .
The myeloma cell lines available have been discussed in Chapter 1. For
this work P3-NSI/l-Ag4-l (NSI) was used.
The specific antibody secreting cells on the other hand have to be
induced in appropriate animalSi For this work Balb/c female mice were used
as specific antibody secreting spleen cell donors.
The work described in this chapter details the induction of specific
antibody secreting spleen cells and the monitoring of the immune response. 
The growth characteristics of NSI cells was examined under normal growth 
conditions; in HAT supplemented media and fungicide treated media.
Finally experiments were performed to secure specific anti-h-TSH 
monoclonal antibodies. S trict aseptic technique was used in all culture 
procedures.
MATERIALS AND METHOD
.1 Preparation of Spleen Cell Donors
Twenty female Balb/c mice (supplied by L it t le  Lions Farm, Ashley Heath, 
Ringwood, Herts) aged approximately 12 weeks were prepared in three groups A, 
B and C by repeated immunization of the spleen cell donors. The immunization 
schemes and inocula contents were as outlined in Table 3.1. The inocula was 
made up as water-in-oil emulsion and each animal was given 0 . 2  ml in tra - 
peritoneally (IP ).
21-28 days a fter each inoculation the next boost was given. The animals 
were marked with an indelible marker on the ta ils  and the highest responders 
after the final challenge were used for fusion.
Serum collection
Blood was collected by retroorbital puncture 14-18 days a fter each 
inoculation. The blood was separated and the serum stored as described in 
section 2 . 2 . 2  until required.
TABLE 3.1
Immunization schemes and immunogen content
Immunogen content per animal
Immunization of 
Group A animals
h-TSH yg Sterile  
H20 yl
Marcol 
oil yl
BCG yl Site of 
injection
1 ° 1 0 . 0 60 135 5 IP
o
1
oCVJ 5.0 65 135 - IP
4 days prior 
to fusion
5.0 1 0 0 - - ■ Tail vein
Group B animals
1 ° 1 0 . 0 60 135 5 IP
2° 5.0 65 135 - IP
3° 1 0 . 0 65 135 IP
4 days prior 
to fusion
5.0 1 0 0 - - ■ Tail vein
Group C animals
1 ° 15.0 60 135 5 IP
2 ° 1 0 . 0 65 135 - IP
h-TSH radioimmunoassay
The progress of the response to the immunization was monitored by the 
presence of anti-h-TSH antibodies in the serum by RIA. This was done with 
the kind assistance of Miss Jane Guthridge, West Sussex Area Health 
Authority, Hurstwood Park Neurological Centre, Haywards Heath.
Reagents
a) Assay diluent:
RIA assay diluent consisted of 0.01M Phosphate buffered saline pH 7.4.
b) Labelled hormone
^ I-T S H  diluted with assay diluent as in section 2 .2 .3 . The assay 
diluent contained human chorionic gonadotrophin (HCG) (Dr R Edwards, St 
Bartholomews Hospital, London) at a concentration of 150 U/ml.
c) Second antibody
Donkey anti-mouse (Guildhay, University of Surrey) was used at 1:10 
dilution.
d) Antiserum dilution
The mouse anti sera and positive control Guildhay Sheep anti-TSH were 
diluted with assay diluent 1:500 up to 1:50,000, immediately prior to the 
assay.
Method
To duplicate LP3 tubes. (Luckham Ltd, Burgess H il l ,  Sussex) was added 
100 yl diluted antisera and 100 yl labelled hormone. This was mixed 
thoroughly and incubated overnight at room temperature. Then 100 yl second 
antibody was added followed by 100 yl normal mouse serum and 200 y l 12.5% 
(v/v) polyethelene glycol (PEG). The tubes were then vortexed and incubated 
at room temperature for 30 minutes after which they were centrifuged for 
10 minutes at 2000 rpm. The pellets were counted for 100 seconds.
.2 Maintenance and Investigation of NSI Myeloma Cells
NSI myeloma cells were maintained routinely in tissue culture flasks 
(3050 or 3075 Costar via Howell Ltd UK) in standard culture media at 
densities of between 2 x 10  ^ and 8  x 10^/ml. They were divided every two to 
three days and fresh medium added. The flasks were then placed at 37°C in a 
humid 5% CO2  in a ir environment.
Culture media
Both myeloma cells and hybridoma cells were maintained in liquid culture 
media.
The standard culture medium used throughout was made up as follows:
8 8  ml RPMI-1640 with L-Glutamine (Gibco Bio-cult Ltd, Paisley)
10 ml Foetal ca lf serum (Gibco Bio-cult Ltd) heat inactivated and 
mycoplasma screened.
1.0 ml = 1 mM sodium pyruvate (Flow Laboratories Ltd, Ayrshire, UK)
1.0 ml = 50 units penicillin /50 ug streptomycin (Flow Laboratories Ltd) 
For all cell manipulations the culture medium was pre warmed to 37°C.
Cell v ia b ility
Cell v ia b ility  was determined generally by trypan blue exclusion test 
Tennant (1964). *
Trypan blue 0.4% solution was supplied by Flow Laboratories Ltd. One 
part cell suspension was added to one part dye solution which was allowed to 
stand for 5 minutes before the cells were examined.
4
average number of liv e  cells counted x 1 0
% v ia b ility  =  -------- —— ------------ ----- —— — ------- ----- —=—  x 1 0 0
average total cell numbers counted x 1 0 4
Cell v ia b ility  was also assessed using the phase contrast microscope 
(Oi and Herzenberg 1980).
Freezing and recovery of cells
Freezing and recovery of NSI cells was as described by Nabholz (1980).
Cells in log phase growth were spun down gently on the MSE bench 
centrifuge, 1 0 0 0  rpm for 5 minutes, and resuspended at 2  x 1 0  ^ cells/ml in 
standard culture media. 20% (v/v) dimethyl sulfoxide (DMS0) (supplied by BDH 
Chemicals Ltd, Enfield) in standard culture medium was prepared fresh.
Into each labelled freezing screw capped plastic vial (supplied by Flow 
Laboratories, Ayrshire) was placed 0.5 ml cell suspension and 0.5 ml DMS0 
cryopreservation medium. The tig h tly  closed vials were then placed in a 
styroform insulating box and placed at -80°C overnight. The via ls were then 
transferred to liquid nitrogen storage at -196°C.
Hybridomas were treated in a similar manner except the cryopreservative 
consisted of 10% (v /v) DMS0 and 90% (v /v) foetal calf serum, and the cells  
were resuspended directly in this mixture.
For thawing, the vials were retrieved from the liquid nitrogen store and 
brought rapidly to 37°C in a water bath following which 10 ml standard medium
also warmed to 37°C was added slowly with continual aggitation. The cells  
were then pelleted and resuspended in 2  mis fresh medium and placed in an 
incubator.
NSI growth curve
NSI growth characteristics, that is the optimum density and doubling time 
were determined as described by Hudson and Hay (1980). 2 x 10  ^ NSI myeloma
cells were suspended in 10 ml standard culture medium and incubated. Three 
such cultures were set up. The cell numbers and v ia b ility  were determined 
each day and the cells resuspended in fresh medium. This was continued until 
the cultures began to decline both in v ia b ility  and cell numbers. The 
hybridoma growth characteristics were sim ilarly derived.
NSI sensitiv ity to HAT
2 x 10§ cells/ml were suspended in standard media containing HAT. (HAT 
was supplied as x50 strength solution by Flow Laboratories Ltd, Ayrshire and 
was therefore diluted 1.0 ml HAT in 50 ml standard medium to give xl normal 
strength HAT.) The cell numbers and v ia b ility  was determined every 2-3 days 
when the medium was renewed. NSI cells in HAT medium was also set up with 
each fusion experiment.
NSI sensitivity to a fungistat agent
Unfortunately even with the most rigorous aseptic technique in long term 
culture, fungal and mould contamination can prove a major and persistent 
problem. The spores are airborne and are very resistant to heat, alcohol and 
the usual cleansing agents (Goding 1980). Although badly contaminated 
cultures are usually discarded, occasionally a culture is too valuable to 
lose, or i t  becomes necessary to protect other cultures where contamination 
is a persistent problem. Any anti fungal agent must therefore of necessity 
exert only minimal toxic effects on the cells in culture while at the same 
time exerting the maximum antimycotic effects. NSI is one of the proposed 
fusion partners and therefore represents a suitable model cell system on 
which to test the agent.
Econazole was chosen as the antimycotic agent because of its  reported 
advantages of broad anti fungal, antibacterial ac tiv ity  and broader margin 
between cytotoxic and inhibitory concentrations, its  higher s ta b ility  and 
so lub ility , when compared to the popularly used fungizone (Wyler et al 1979).
NSI v ia b ility , cell proliferation and DNA synthesis are excellent 
indicators of the condition of the culture and as such these parameters were 
examined under the influence of econazole dose recommended for use at 1 yg/ml 
(Wyler 1979).
a) V iab ility  in econazole •
2 x 105 NSI cells/ml were cultured in 5 ml of standard culture media in 
25 ml tissue culture flasks (Costar via Howell Ltd). Two cultures were set 
up:-
1 ) The test culture, maintained in standard growth medium supplemented 
with 1 yg/ml = 1 0  yl econazole solution / 1 0 0  ml medium; (econazole lac tic ; 
econazole base l-(2,4-dichloro-0-(p-chlorobenzyloxy)-phenetyl)-imidazole 
( 1 0  mg/ml) lactic  acid ( 2 0  mg/ml) in aqueous solution; 2 0  ml was kindly 
donated by Cilag-Chemic Ltd, Scheffhausen, Switzerland).
2) The -control culture was grown in unsupplemented standard culture 
medium.
The Cells were maintained for 7 days. Cell v ia b ility  was assessed as
stated above and the % survival was also determined by:-
% survival = Number of . liv e  cel.l,s, in, test x 1 0 0
Number of liv e  cells in control
The v ia b ility  of the cultures was also determined after the cells had 
been cultured in various concentrations 0-1 yg/ml of econazole for 48 hours. 
The cells were incubated in 1.0 ml cultures in lymphocyte culture tubes 
(Nunc).
b) DNA synthesis in econazole
2 x 105  NSI cells were cultured in 1.0. ml volumes in lymphocyte culture 
tubes (Nunc). The cultures were incubated in standard culture medium 
supplemented with various concentrations of econazole 0-1 yg/ml. One set of 
duplicate cultures was incubated with econazole and 5 yCi ^H-thymidine 
(Radiochemical Centre, Amersham International PLC, UK) per tube for 48 hours, 
while the second set was incubated with econazole alone for 46 hours then
o
5 yCi JH-thymidine was added per assay tube for the final 2 hours. The cells  
were then spun down and 2.0 ml 10% (w/v) trich loracetic  acid (TCA) added to 
each pellet. The cells were then harvested on 2.5 cm Whitman glass fib re  
papers. These were washed twice with 10% TCA and then a ir  dried before
counting for 1 0  minutes in 8  ml s c in tilla n t.
■ S c in tilla tion  F lu id :-
The sc in tillan t was made up as follows:
Toluene
Metapol HC 100
2,2'-p-Phenylene-bis (5-phenyloxazole) (PoPoP) 
2 ,5-Diphenyloxazole (PPO)
3.33 1 
1.67 ml 
1 . 0 0  g 
25.00 g
Each powder was mixed thoroughly in the toluene before the next was 
added. When a ll the ingredients were fin a lly  added the mixture was stirred  
for about 24 hours before use. The preparation was stored in a dark bottle .
3.2.3 H.ybridoma Production
A great many protocols exist. However they are a ll very similar with
only minor variations in the PEG fusion regime described. The most important 
of these include the addition of DMS0 investigated by Fazekas De St Groth and 
Scheidegger (1980), and variations in the molecular weight of the PEG used 
and the fusion incubation time (Davidson e ta !  1976, Gefter et al 1977, 
Pontecorvo 1977).
Preparation of NSI for fusion
NSI cells were maintained routinely as described above so that they were 
kept in exponential growth continually. On the day before they were required 
for fusion (day - 1 ) ,  the cells were counted and the v ia b ility  determined. 
Below 90% v ia b ility  the culture was usually not used. The cells were s p lit
to 1 x 105/ml in 50 ml standard culture media. (This allowed on average one 
complete division of the cells in the culture by the time they were required. 
About 107  cells were required for fusion.) On the day of fusion (day 0) the
v ia b ility  was rechecked and the cells resuspended in fresh medium in a
conical Falcon centrifuge tube. They were then kept in the incubator until 
required.
Preparation of immune spleen cells/feeder layer cells
The hyperimmunized female Balb/c mouse/control mouse (for feeder layer) 
was k illed  by cervical dislocation. I t  was placed on a dissecting board 
right side down and drenched with 70% (v/v) alcohol. The spleen - a dark red 
bean shaped organ was removed using s te rile  procedure. The spleen was 
transferred to a s terile  petri-dish containing 10 ml standard medium. The
dish containing the spleen was placed in the laminar flow cabinet in which
all further work was done. The spleen was cut into pieces and teased apart
through a wire sieve to release the spleen cells . These were collected in a 
S terilin  centrifuge tube and the suspension allowed to stand for 5 minutes to 
allow the large lumps to settle  out. The supernatant containing the
suspended cells was decanted into another tube and centrifuged for 5 minutes.
The cells were then resuspended in 5.0 ml fresh standard medium.
0.5 ml spleen cell suspension was diluted to 10 ml in Tuerks solution. 
The number of cells in this preparation was then counted. The feeder layer 
spleen cells were prepared on day-1 and diluted such that 2 mis of 1.5 x 10^ 
cells/ml or 200 yl of 1.5 x 10  ^ cells/ml were plated into 24 or 96 well 
culture plates respectively and incubated. The, hyperimmune cel Is for fusion
were prepared on day 0. The cell numbers were determined as follows:
Average cells counted = x
Number of cel 1 s/ml = x x 10^
Cell dilution -  1/20
hence x x 1 0  ^ x 2 0  cell s/ml
5 ml spleen cell = x x 10  ^ x 20 x 5 total cells/spleen
Tuerk solution:- 1.0% (v/v) glacial acetic acid which, destroys erythrocytes, 
and a tinge of gentian violet which stains leucocytes.
Fusion solutions
1) 50% (w/v) polyethelene glycol (PEG) molecular weight 1500 (supplied
by BDH Chemicals Ltd, Enfield, Middlesex) in serum free medium (Oi and 
Herzenberg 1980). This was made up as follows: 12.5g PEG was autoclaved and
kept hot. To this was added 12.5 ml warmed serum free medium.
2) The fusion solution was la ter modified as follows:
a) 41.6% PEG 1500 containing 15% DMS0 in serum free medium. This 
was made up so that 50 g PEG 1500 was sterilized  with 15 ml DMS0 to which 
was added 55 ml serum free medium;
b) the second solution consisted of 25% PEG 1500 in serum free 
medium made up of 12.5 g autoclaved PEG 1500 plus 37.5 ml serum free 
medium (Sikora et al 1982).
3) This fusion solution was made up of 12.5 g PEG 4000 (BDH Chemicals 
Ltd) which was autoclaved with 11.5 ml normal saline (Normal saline 0.14M 
consisted of 8.5 g sodium chloride per l i t r e  of d is tille d  water), and 1.25 ml 
DMSO (BDH Chemicals Ltd). This constituted a 50% PEG solution containing 5% 
DMSO (Fazekas de St Groth and Scheidegger 1980).
Fusion and plating out
All solutions were used at 37°C. The two cell suspensions - NSI and the 
hyperimmune spleen cells were mixed thoroughly in a large 50 ml Falcon 
centrifuge tube and the supernatant thoroughly drained off after the cells  
were pelleted.
a) TSH fusion 1 and 2
The pellet was loosened by tapping the container and to the cell mixture
was added 0.8 ml fusion solution 1 whilst stirring  continuously. The PEG
solution was added over 1 minute. Then 10 ml serum free medium was added 
very slowly over a period of 5 minutes. The fusion mixture was then pelleted 
gently and resuspended in 10 mis standard medium. This was made up to 100 ml 
so that 1 ml of this fusion mixture was distributed to each culture well
containing feeder cells from which 1 ml of supernatant had been removed.
b) TSH fusion 3 - 6
To the loosened mixed cells 0.5 ml of fusion solution 2a was added. The 
cells were gently agitated for no more than one minute. Next 0.5 ml fusion 
solution 2 b was added to the cells with gentle agitation for 2-3 minutes. 
4 ml medium containing 20% (v /v) foetal ca lf serum was then added followed by 
20 ml medium containing 20% (v/v) foetal ca lf serum. 1.5 ml supernatant was 
removed from the wells containing feeder cells and replaced with 0.25 ml
fusion mixture topped up f in a lly  to 2  ml with medium containing 2 0 % (v/v) 
foetal calf serum.
c) TSH fusion 7 and 8
The procedure followed was essentially the same as in TSH fusion 1 and 2 
with the exception that fusion solution 3 was used. For fusion 7 the fusion 
mixture was suspended in a total volume of 60 ml and plated out 1 0 0  yl per 
well a fter 1 0 0  yl supernatant had been removed from the wells containing 
feeder cells.
The plates were then incubated at 37°C in a humidified 5% C02  in a ir  
incubator. The cell content of each fusion has been tabulated in Table 3.2 , 
and figure 3.1 summarises the fusion protocol and hybrid maintenance used.
HAT selection
On day 1, one half the culture medium volume was removed from each well 
and replaced with twice strength (HAT x2) HAT in standard culture media.
(HAT x2 = 2 ml HAT x50 concentrate in 50 ml standard medium)
The plates were incubated as described and every 2 days thereafter one half 
of the medium was replaced with xl HAT in standard medium.
On day 12 the HAT was replaced by xl HT solution in standard medium. 
(HT was also supplied by Flow Laboratories Ltd as a x50 solution.) HT 
supplement was continued for about 8  weeks in continuous culture. When early 
fusion products were recovered from frozen stocks th is was done in HT 
supplemented medium which was maintained for a similar period.
Expanding positive cultures/clones
As soon as positive wells were identified the cells were sp lit and placed 
with feeder cells into progressively larger cultures, ie from 2 0 0  yl cultures 
to 1-2 ml cultures, then on to 5-10 ml cell cultures and f in a lly  to 50 ml 
culture volumes. The master wells were maintained for comparison in future 
assays. The medium was replaced every 2 days as previously described.
3.2.4 Screening Assays
Fusions 1-6 were screened by the standard RIA described above and used
j
for monitoring the antibody response to h-TSH. The only exception was that 
HCG was omitted and the samples were counted in the f ir s t  instance for 10 
seconds, and later for 100 seconds. The double antibody assay precipitation  
was checked by reassaying some culture supernatants neat or diluted 1:50. 
Finally the assay was set up as described; but the phase separation was 
accomplished by the addition of 1 ml 20% (w/v) PEG and 100 yl normal non- 
immune mouse serum. The tubes were mixed and incubated at room temperature 
for 1 0  minutes a fter which they were centrifuged for 2 0  minutes at 2 0 0 0  
revolutions per minute (rpm). The pellets were counted for 300 seconds.
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FUSION
0.8 ml warmed 50% PEG 4000 in 
normal sal ine + 5% DMSO.
Cells allowed to agglutinate 
for no more than 1 minute.
1 0  mis serum-free medium added 
slowly over 5 minutes.
Centrifuge mixture setting 2.
MSE bench centrifuge for 5 minutes.
Resuspend fusion mixture carefully. 
Plate out into chosen number of wells.
Replace h culture medium with HAT x 2.
Replace h culture medium with HAT x 1.
Renew ^ culture medium every 2 days thereafter.
Replace HAT x 1 medium with HT x 1 medium at 
f i r s t  cell expansion.
Renew medium every 2 days.
The positive control in the RIA was mouse anti-TSH at 1:500 d ilution. 
Normal nonimmune mouse sera diluted 1:500 and NSI spent culture media was the 
negative control.
Fusion 7 and 8  were screened by the ELISA and solid phase RIA developed 
specifically for this purpose.
Enzyme-linked immunosorbent assay (ELISA)
The ELISA methods u tilized  were:- 
Method A - for the detection of any antibody secreting hybridomas.
Method B - for the identification of those hybridomas secreting specific anti 
h-TSH antibodies.
In method A duplicate polyvinyl chloride m icrotitre wells were coated 
with hybridoma supernatant diluted 3:1 in ELISA coating buffer, and duplicate 
positive control mouse anti-TSH and negative control normal sheep sera 
diluted 1:8000 in coating buffer were incubated for 2 hours at 37°C.
TABLE 3.2 
Conditions of fusion
Fusion
No.
x number of cells/fusion NSI Ratio
NSI:
Spleen
No. 
wells 
piated
Fusion
solutionNSI myeloma Spleen cells % V ia b ility
TSH 1 
TSH 2
1 . 0  x 1 0 7
1 . 0  x 1 0 7
1.05 x 108
9.6 x 107
93.7
90.4
1:10.5
1:9.6
96
96
50% PEG 1500 
in serum free 
medium.
TSH 3 1.7 x 107 1.74 x 108 93.14 1 : 1 0 . 2 96
TSH 4 1 . 0  x 1 0 7
TSH 5 1.5 x 107
TSH 6 1.3.x 107
(Picked up
fresh NSI
from Frozen
store)
TSH 7 2 . 2  x 1 0 7
1 0 7 93.3 1:9.9 96
1 0 8 82.9 1 : 1 0 96
I—* O 0
0
87.6 1 : 1 0 48
COor-H 93.1 1:10.5 576
1 0 8 94.2 1 : 1 0 96
41.61 PEG 1500 
+ 15% DMSO in 
serum free 
medium and 
PEG.
50% PEG 4000 
5% DMSO in
TSH 8  1 x 107  1.04 x     normal
In method B glutaraldehyde sensitized polystyrene m icrotitre wells were 
coated overnight with a solution of 1.0 yg h-TSH/ml in coating buffer. The 
plates were incubated in a humidity box in the cold room (about 4°C).
The wells were washed as described in Chapter 2. 100-150 yl hybridoma
supernatant was added to duplicate wells according to the arrangement below 
in Table 3.3 and incubated for 2 hours at 37°C.
TABLE 3.3
M icrotitre plate layout for ELISA method B
Well number Test antigen Antibody
Antimouse HRP0 
conjugate
1 - 8 8 + hybrid supernatant +
89 - 90 + (a) positive control sera +;
91 - 92 + (b) negative control sera +
9 3 - 9 4 + (b) negative control +
9 5 - 9 6 - positive control sera +
a -  mouse anti-h-TSH diluted 1:12000
b = normal nonimmune mouse sera diluted 1:12000 or NSI supernatant
Following this stage the methods were identical. The wells were washed 
as before and 2 0 0  yl goat antimouse-horseradish peroxidase diluted 1:6000 or 
donkey antimouse-horseradish peroxidase diluted 1:1600 in ELISA assay diluent 
was added to the wells which were incubated for 2 hours at 37°C. Following 
washing 200 yl substrate solution (section 2 .2 .3 ) was added to the wells and 
incubated for 30 minutes at 37°C. The reaction was stopped by the addition 
of 50 yl 2.5M H2 SO4  and the optical density read at 490 nm on a Dynatech mini 
reader. The reader was zeroed on a well containing 200 yl of substrate 
solution plus 50 yl 2.5M H2 SO4 .
Solid phase RIA
l^ I-TS H  was as described in section 2.2 .2 and the immunoadsorbent B was 
diluted 1:5 with assay diluent (section 2 .2 .2 ). The positive mouse an ti- 
h-TSH and the negative mouse control sera have been described above in ELISA 
methods.
LP3 tubes were set up for the incubation which were done in duplicate and 
incubated according to the protocol set out in Table 3.4.
TABLE 3.4
Solid phase RIA protocol used for hybridoma screening
Additions
Test
Tubes
Control
Tubes
NSB
Tubes
Total
Tubes
Assay diluent - - . 1 0 0  yl -
Hybridoma supernatant 1 0 0  yl - - -
Positive mouse anti-TSH 
or negative mouse sera 
diluted 1:8000 in assay 
diluent/NSI supernatant
- 1 0 0  yl -
1 2 5 I-TSH label 1 0 0  yl 1 0 0  yl 1 0 0  yl 1 0 0  yl
y. • incubate 18 hours at 4 °C
Immunoadsorbent B 
1:5 dilution
2 0 0  yl 2 0 0  yl 2 0 0  yl -  •
incubate for 1 hour at room temperature
Assay diluent 1  ml 1  ml 1 ml -
The tubes were then centrifuged at 3000 rpm on the Beckman J - 6  fo r  
15 minutes. The supernatants were aspirated and the pellets counted for 
1 0 0  seconds.
.5 Cloning
Positive primary cultures were cloned by lim iting d ilu tion . Feeder 
layers of nonimmune mouse spleen cells were prepared as described above. The 
hybrid cells were suspended by pipetting up and down with a s te rile  Pasteur 
pipette and then counted. The cultures were cloned using HT supplemented 
medium. The cells of each positive hybrid culture were diluted to approx­
imately 50 cells/m l, 10 cells/ml and 5 cells/ml (Oi and Herzenberg 1980) 
100 yl/well was dispensed into 36 wells, 36 wells and 24 wells respectively 
per 96 well Costar microculture plate. One 96 well plate was used per 
positive culture. The cultures were maintained by replacement of the culture 
media as described before for the primary cultures. At about day 12-14 wells 
containing clones when examined under the phase contrast microscope which 
appeared to be monoclonal were screened for specific antibody production by 
the ELISA method B or the solid phase RIA.
Two or three positive clones were expanded up to 2 ml, 5 ml then 10 ml 
cultures and the supernatants were screened at each stage. Finally aliquotes 
of positive hybrid clones were frozen down and stored at -196°C as described.
3.2.6 Antibody Production
Monoclonal antibody preparations were obtained either from spent culture 
supernatant which contained minimal extraneous immunoglobulins, or in larger 
amounts from ascites flu id  but this preparation containsa small amount of 
other mouse immunoglobulins.
For ascites production each female Balb/c mouse was primed by in traperi- 
toneal injection with 0.5 ml pristane (2, 6 , 10, 14 tetramethyl pentadecane 
supplied by; Aldrich Chemical Co, Gillingham, Dorset), 10 days la te r 1 x 10  ^
hybridoma cells were injected also intraperitoneally in 0 . 2  ml serum free 
culture medium. Each animal was carefully marked for la te r iden tifica tion .
10-14 days later when i t  was evident by the distended abdomen that flu id  had 
collected the mice were k illed  and the flu id  aspirated using a syringe and a 
19 g needle. The flu id  was then c la rified  by centrifugation at 2000 rpm on 
the MSE bench centrifuge for 15 minutes after which the ascitic flu id  was 
aliquoted in 0.25 - 0.5 ml amounts and stored at -20°C. Samples from each 
mouse were assayed for specific antibody.
Immunoglobulin content of antibody preparations
The ascitic flu id  obtained from the mice after ascertaining the positive 
antibody content by ELISA and or solid phase RIA, were assayed by cellulose 
acetate electrophoresis (Kohn 1976). The technique is used routinely to 
characterize serum monoclonal immunoglobulin (Keshgegian and Peiffer 1981).
a) Cellulose acetate electrophoresis
Electrophoretic buffer -  Barbitone buffer of 0.05 -  0.07M, pH 8 . 6  was 
made up as follows
Diethyl barbituric acid 
Sodium diethyl barbiturate 
D istilled  water 
Thimerosal
7.36 g 
41.20 g 
4.0 litre s  
0 . 0 1  % w/v
\
Stain - Ponceau S stain solution consisted of 0.2% (w/v) in 3% (w/v) 
aqueous trichloracetic acid.
The strips were cleared by washing in three changes of 5% (v/v) aqueous 
acetic acid.
Nigrosin stain solution consisted of 0.001% Nigrosin in 2% (v/v) aqueous 
acetic acid. The strips were cleared by washing in three changes of 2% (v /v) 
aqueous acetic acid.
Method
Electrophoretic buffer was placed in the tank (Shandon Southern Products 
Ltd, Cheshire) covering the electrodes. Thoroughly soaked f i l t e r  paper wicks 
formed the connection between the buffer in the electrode compartment and the 
shoulder pieces on which the cellulose acetate membranes (CAM) rested.
The CAM strips were marked with the sample number and then thoroughly 
soaked in buffer. The membranes were blotted with f i l t e r  paper to remove 
excess buffer. The samples diluted 1:10 with electrophoresis buffer were 
then applied to the sample applicator bed and the applicator (Shandon 
Southern Products Ltd) was dipped into the samples. Sample solutions taken 
up by the applicator were then pressed firm ly onto the CAM at the midpoint of 
the s trip . With this application about 5 yl of each sample was applied
uniformly and simultaneously to the s trip .
The CAM with the applied samples was then placed in the electrophoresis 
tank resting on the two f i l t e r  paper wicks. Care was taken not to handle the 
CAM with fingers and forceps were used throughout the procedure when handling 
the strips. The tank lid  was firm ly closed and the power supply was then
connected and switched on. The voltage was adjusted to about 160 V.at a 
constant current of 10 mA. The samples were electrophoresed fo r 30 minutes. 
The CAM was then removed from the tank.and stained for 5 minutes in the
Ponceau S staining solution, or in nigrosin staining solution for 10 minutes. 
These were then destained in several changes of washing solution. The wet 
Ponceau S stained CAM strip was then sandwiched between two pieces of glass 
and scanned on the Vitatron TLD 100 densitometer.
The total protein content of the ascitic flu id  samples was determined by 
the Lowry et al method (1951) (see Chapter 2 ), and from the integrated 
densitometor scan of the CAM electrophoresis strips the percentage immuno­
globulin in the sample was obtained. This was used to quantitate the 
absolute amount of immunoglobulin in the total protein.
A human IgG serum monoclonal sample and antihuman IgG was kindly supplied 
by Dr J Kohn, Protein Unit University of Surrey, Guildford. The human para­
protein sample was electrophoresed as described following which the separated 
protein was immuno-fixed.
Immunofixation
The method described by Ritchie and Smith (1976) was used. After
electrophoresis the CAM strip was le f t  in position in the tank. The
antiserum was diluted 1:3 in immunofixation buffer. This consisted of 0.5M 
phosphate buffer pH7.2 containing 2% (w/v) PEG 6000. Cellulose acetate
strips were cut which fitte d  exactly over the electrophoresed proteins. The
strips were impregnated with the diluted antiserum and was then carefully
laid over the electrophoresed proteins. The tank lid  was replaced and the 
preparation incubated for 10 minutes. The CAM was then washed under gently 
running tap water, to remove excess antiserum solution. Finally they were 
washed 3 x 30 minutes in 3% (w/v) saline containing 0.05% (v/v) tween 20. 
The CAM strips were stained in nigrosin as described above.
Single radial immunodiffusion
Single radial immunodiffusion was used to determine the amount of mouse 
immunoglobulin in the supernatant samples after the hybridomas had been 
-allowed to grow to stationary phase.
Square glass slides were precoated with a solution of 0.5 g agar in 
1 0 0  ml d is tille d  water and were allowed to dry at room temperature.
The top agar was made up as follows:-
3% (w/v) PEG 6000 (BDH Chemicals Ltd, Enfield) was dissolved in 0.15M
phosphate buffered saline pH 7.4. To this was added Noble agar (Difco 
Laboratories, East Molesey, Surrey) 1.5% (w/v), in a boiling water bath until 
the agar was completely dissolved. 12 ml aliquots were stored at 4°C until 
required.
When required the aliquots were melted in a boiling water bath then 
transferred to a 56°C water bath.
256 yl sheep antimouse immunoglobulin IgG2 a (supplied by Serotec Ltd, 
Oxon) was added to the 12 ml dissolved agar and thoroughly mixed. This gave 
an anti sera distribution of 4 yl per square cm of plate. The agar was poured 
onto the levelled plate. The mouse reference sera MFI (supplied also by 
Serotec Ltd) was double diluted 1:20 -  1:1280 in phosphate buffered saline 
and 5 yl samples of this reference sera and 5 yl of the supernatants were
placed in duplicate wells cut in the agar. The plates were placed in a 
humidified box and incubated at room temperature for 48 hours. The plates 
were rinsed in 0.15M phosphate buffered saline overnight then stained. The
plates were immersed in staining solution for 5 minutes. The staining
solution consisted of 1.25 g coomassie b r illia n t blue R250 (BDH Chemicals 
Ltd, Enfield) in 235 ml of 0.02% (v/v) glacial acetic acid. They were then 
destained in several changes of the 0.02% (v/v) glacial acetic acid.
3.3 RESULTS
3.3.1 Anti-TSH Response
All 10 mice in group A gave an antibody response to the immunogen h-TSH. 
Some however gave a higher response observed in the anti serum t it re s ,  
reflecting the individual v a ria b ility  of the immune response to the same 
immunogen. The anti serum dilution curves obtained after the primary and 
quaternary challenge are presented in figures 3.2 and 3.3. All the 5 animals 
in group B also showed high antibody response determined only a fte r the
te rtia ry  challenge. The anti serum dilution curves are presented in figure
3.4 which also include the curve for a pooled mouse anti-h-TSH preparation.
I t  was necessary to obtain sufficient positive anti sera to use as control 
in the assays. The pooled anti-TSH sera was used for this purpose.
The increased immunogen content in the inoculum in the third challenge of 
group B animals did not appear to increase the response to any great extent 
since % bound even at the lower dilutions were similar to that obtained after 
the primary challenge in group A. Group C sera were not assayed although the 
sera were collected and stored. The animals giving the highest response were 
used in fusion. * '
3.3.2 Investigations of NSI Myeloma Cells •
NSI growth characteristics
The growth characteristics of NSI myeloma cells and the density depend­
ence was demonstrated in figure 3.5. The cultures were maintained under 
conditions where nutrients were not lim iting . The numbers of live  cells in 
the culture and hence the cell v ia b ility  rapidly declined when the cell 
density was in excess of 7.9 x 10  ^ cell s/ml.
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FIGURE 3.3 Anti serum dilution curves from 10 mice immunised as 
above a fter 4° boost.
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FIGURE 3.4 Antibody responses of the 5 group B animals after
3° inoculation. Pooled mouse anti-TSH (A—a ) positive 
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FIGURE 3.5 Starting cultures 2 x 10^ cell s/ml, growth media 
was renewed every day therefore nutrients were 
not lim itin g .
(a —a ) = total cells/ml in culture
{ • —•) = number of viable cells in culture
(O—O) = % v ia b ility  of the culture.
The average cell numbers from 3 cultures were 
plotted.
Cultures maintained between these lim its of 2 x 10  ^ and 8 x 10^/ml 
therefore and providing other factors such as nutrient and environment were 
optimally maintained should give consistently healthy cultures. Figure 3.6 
is a logarithmic growth plot demonstrating the precise exponential growth 
phase during which the cell population was doubling and the asymptote which 
defines the density lim it.
The generation time was calculated by:-
T
where T 
t  
N
"o
T was found to be 20.93 hours. See Table 3.6.
The cell densities at which the NSI cultures were maintained were there­
fore ideal for the survival of actively growing viable cultures. Figure 3.7 
is a photograph of actively growing NSI cells taken under phase contrast x200 
magnification.
NSI growth in HAT
Since the selection procedure was intended to ensure only hybrids 
survived in culture i t  was necessary to check the myeloma cells performance 
in HAT. Figure 3.8 shows that at day 0 NSI v ia b ility  was >90%. By day 5
however, the v ia b ility  of the cells in the test cultures was reduced to 0 
while the v ia b ility  of the control cultures remained >90% and these cultures 
had to be sp lit on day 3. No cell proliferation was observed in the HAT 
cultures.
The effects of econazole on NSI growth
The v ia b ility  of NSI cells in the control cultures was found to vary only 
marginally over the seven day culture period (figure 3 .9 ). Such v a ria b ility  
as was observed was due mainly to density effects. The test cultures however 
showed a very dramatic fa ll in v ia b ility . On day 3 the test cultures had a 
v ia b ility  lower by a factor of 2.7 compared to the control. By the 7th day 
the v ia b ility  of the test cultures was reduced to zero. Cell pro liferation  
was observed to be greatly inhibited in the test situation (figure 3 .1 0 ).
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FIGURE 3.6 Logarithmic growth plot of NSI (■—■) and 
a hybridoma SY/T8/2 (a —  a ) growth data.

FIGURE 3.7
NSI cells in suspension culture at x200 magnification.
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FIGURE 3.8 2 x 10 cells/ml set up per culture, the test 
culture (o—o) was grown in HAT x 1 media while 
the control culture ( • —• )  was grown in 
unsupplemented standard media. The control 
culture was sp lit to 2 x 10  ^ cells/ml on day 3. 
The mean of thpee cultures were plotted.
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FIGURE 3.9 V iab ility  of NSI control culture (# — • )  grown in
standard media, and test culture (O — O) grown in
standard media supplemented with lyg/ml econazole
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FIGURE 3.10 Survival and proliferation of NSI cells in the 
control culture ( • — • )  and in the test culture 
(O— O), grown in medium supplemented with 
1 yg/ml econazole. % survival expressed with 
respect to the culture at day 0 .
Indeed by day 3 the viable ce ll numbers in the test cultures was 84% below 
that in the controls. In addition under phase contrast microscopy the cell 
morphology was observed to be altered in the presence of the econazOle.
All concentrations of econazole tested were observed to have a marked and 
unacceptably damaging effect on the NSI cells. After the in it ia l sharp 
decline in cell v ia b ility  (figure 3.11), and the percentage survival (figure 
3.12) when the cells were grown in 0.125 yg/ml, the test cultures appeared to 
stab ilize . Above 0.5 yg/ml econazole in the Culture media the decline was 
again dramatic although some 4 times slower than the in it ia l fa l l .  The dose 
o f econazole which reduced the test cell populations by 50% (ED5 0 ) was 
0.97 yg/ml less than the recommended antifungal effective dose (Wyler et al 
1979).
The apparent immediate decline in v ia b ility  and survival of the test 
cultures in 0.125 ug/ml econazole was also demonstrated by ^H-thymidine 
incorporation by the cells (see figure 3.13). However as econazole concentr­
ation was increased to 0.5 ug/ml, the amount of DNA synthesis was observed to
o
be greatly enhanced as was shown by the increased H-thymidine incorporation. 
In this concentration range i t  may be postulated that the increased DNA 
synthesis was in trin s ic a lly  linked to , and was responsible for the observed 
culture tolerance and the culture stabilization observed.
Above 0.5 ug/ml econazole, DNA synthesis began to decline as did 
v ia b ility  and percentage cell survival.
Fusion Experiments
The results of fusions 1-6 were very disappointing in terms of stable 
positive hybrids derived. At the time of the in it ia l screening the number of 
wells with hybrids was variable with a greater percentage of wells observed 
to contain hybrids when fewer wells were plated in it ia l ly .  Table 3.5 
summarises the results of fusions 1 to 8 .
For fusion 1-3 the numbers of wells with hybrids were not counted but all 
wells were assayed. However the wells which contained actively growing 
hybrids were indicated by the change in colour of the culture medium from 
salmon pink to pale yellow.
All wells were nevertheless examined under the phase contrast microscope, 
since new hybrids were sometimes too small to effect this obvious pH change. 
The numbers of wells with hybrids were counted in the other fusions.
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FIGURE 3.11 The concentration dependent effect of econazole on the 
48 hour v ia b ility  of NSI myeloma cells
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FIGURE 3.12 The dose response curve plotted on a 
log linear scale showing survival of 
NSI cells a fter 48 hours incubation in 
econazole. The survival is expressed 
as a percentage of the control 
cultures (E05 0  = 0.97 yg/ml).
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TABLE 3.5 
Summary of fusion experiments
TSH Fusion Experiments
1 2 3 4 5 6 7 8
No. of fusion walls 96 96 96 96 ' 96 48 - 576 96
No. of wells with hybrids - - - 69 18 45 199 86
% wells with hybrids - 71.9 18.75 93.75 34.55 89
No. positive primary 
cultures detected by 
1iquid phase RIA
5 10 8 0 0 0 - -
Ig Secretors detected by 
ELISA A
- - - - ' ‘ -  . -  . 70 29
Anti-h-TSH secretors 
Detected by ELISA B or 
solid phase RIA
- - - - 13 8
No of stable cultures 
cloned by lim iting dilution
- - 8 - -  . 7 4
No. monoclonal cultures 
frozen
- - - . - 13 14
In both RIA methods used for screening, positive cultures were 
arb itra rily  taken to be those binding greater than 1.5 times the amount of 
radiolabelled hormone bound by the negative controls. In the ELISA methods 
positive cultures were taken to be those having an optical density of twice 
that observed in the negative controls.
No positive monoclonal cultures were obtained fromfusion 3 cloning and 
the primary cultures all lost positive ac tiv ity . Attempts were made to  
recover positive cultures from frozen stocks but these were found to have 
also lost positive antibody production.
Positive antibody ac tiv ity  was found to be lost in all primary cultures 
of fusions 1 and 2 by the second assay, therefore no frozen stocks were 
obtained. I t  must be noted that a ll the positive cultures identified  by 
liquid phase RIA were only weakly positive by the c rite ria  for p o s itiv ity . 
No positive cultures were detected in fusions 4-6. However 7 primary 
positive cultures and 13 monoclonal cultures were isolated from fusion 7 and 
sim ilarly 4 primary positive cultures and 14 monoclonal cultures were 
obtained from fusion 8.
Frozen cells stored in liquid nitrogen
1) 80 vials each containing 1-2 x 10® NSI myeloma cells were frozen.
2) 8 primary cultures from fusion 3 were frozen.
3) 6 positive primary cultures from fusion 7 were frozen (5 v ia ls /cu ltu re ).
4) The 13 monoclonal hybrids from fusion 7 were also frozen (5 v ia ls /
culture).
5) 4 positive primary cultures from fusion 8 were frozen (10 v ia ls /cu ltu re ).
6) 14 monoclonal hybrids from fusion 8 were also frozen (5 v ia ls /cu ltu re ).
7) 6 monoclonal cultures recloned from one of the 14 from fusion 8.
The monoclonal and primary cultures from fusion 7 proved d if f ic u lt  to 
recover from the frozen stocks and where such cultures were eventually 
revived antibody production was found to be absent.
No such d iffic u lty  was observed with the positive products of fusion 8. 
The 14 monoclonal cultures from fusion 8 was designated SY/T8/1-14 of
which SY/T8/1-6 were selected for further study and characterization. Table 
3.6 presents the growth characteristics of these 6 cell lines and figure 3.6 
contains the logarithm ic growth curve of one cell line . The binding of 
radiolabel TSH and optical densities observed for the positive cultures are 
given in Table 3.7. Figure 3.14 is a photograph of a monoclonal culture.
TABLE 3.6
Growth characteristics of hybridoma lines and NSI myeloma ce lls . All 
hybridomas were grown in 10% foetal calf serum supplemented RPMI 1640.
Cell line Doubling time (hours) Density lim it (cel 1 s/ml)
NSI 20.93 7.9 x 105
SY/T8/1 24.08 1.0 x 106
SY/T8/2 17.20 3.6 x 105
SY/T8/3 17.20 5.0 x 105
SY/T8/4 20.64 6.3 x 105
SY/T8/5 18.06 4.5 x 105
SY/T8/6 28.89 4.8 x 105

FIGURE 3.14 
A Hybridoma Clone at x200 magnification.
TABLE 3.7
Binding of radio-labelled h-TSH by monoclonal antibodies and enzyme- 
labelled anti-mouse in specific ELISA. Reflecting the presence of anti-TSH 
antibodies.
Solid Phase RIA ELISA B
Sample
x CPM % Bound 0D490
Total 11906 - -
Positive control one 
primary culture supernatant 3073 25.8 0.78
Positive control mouse 
anti-h-TSH (pooled) 3595 30.2 1.20
Negative control NSI 
supernatant 283 2.4 0.13
Supernatant SY/T8/1 915 7.7 0.41
Supernatant SY/T8/2 978 8.2 0.59
Supernatant SY/T8/3 859 7.2 0.77
Supernatant SY/T8/4 1110 9.3 0.56
Supernatant SY/T8/5 1098 9.2 0.54
Supernatant SY/T8/6 1183 9.9 ; 0.55
Supernatant SY/T8/7 976 8.2 0.51
Supernatant SY/T8/8 1190 9.9 0.60
Supernatant SY/T8/9 689 5.8 0.67
Supernatant SY/T8/10 907 7.6 . 0.62
Supernatant SY/T8/11 1348 11.3 0.59
Supernatant SY/T8/12 . 921' 7.7 0.67
Supernatant SY/T8/13 831 6.9 0.57
Supernatant SY/T8/14 942 7.9 0.59
A s c itic  f lu id  co lle c tio n
Various amounts of ascitic flu id  (table 3.8) was collected from the cell 
primed animals. None of the animals developed solid tumors although 2 mice 
died before the ascitic flu id  could be collected.
TABLE 3.8
Ascitic flu id  collected from cell primed animals
Cell line No. animals Ascitic flu id  (ml) Days after in jection
SY/T8/1 4 9 11-12
SY/T8/2 4 6.3 11-12
SY/T8/3 4 7.8 11-12
SY/T8/4 3 4.5 12-14
SY/T8/5 4 9 12-14
SY/T8/6 2 4.5 12
.4 Antibody Content
a) Ascitic flu id
Figure 3.15 is a photograph of the cellulose acetate electrophoresed 
samples showing the monoclonal immunoglobulin peaks prominently. From these, 
integrated densitometer readings allowed the resolution of the percentage 
monoclonal immunoglobulin in the total protein sample electrophoresed.
Figure 3.16-18 dep-icts the densitometer traces of the 6 ascitic  flu id  
samples. The amount of protein in the monoclonal immunoglobulin peaks.was 
very high in some cases (see table 3 .9 ). The control used was a known human 
IgG paraproteinaemia sample (kindly supplied by Dr Kohn, Protein Unit, 
. University of Surrey, Guildford).
The corrected % paraprotein in the electrophoresed sample was calculated 
thus:-
% Ig = Integrator No of Ig peak x Weight (mg) of Ig portion of peak
Total Integrator No of sample Total weight (mg) peak
b) Supernatant
From the linear calibration curve for the single radial immunodiffusion 
measurement of supernatant immunoglobulin, the immunoglobulin concentrations 
were determined (see table 3 .9 ).
Human serum 
sample immuno- 
f  i xed
nit'***'c «“tc.
I I'  'L 1' 6 3- *  -Jfr <»' f  1he
M*td
 v --------
Monoclonal antibody Human
samples monoclonal
serum
FIGURE 3.15 Cellulose acetate electrophoresed monoclonal antibody samples.
The ascitic flu id  samples were diluted 1:10 and the supernatant 
samples (1 ‘ 2 ‘ 3 ‘ etc) were used neat. The control human Ig 
samples were included for identification of the monoclonal 
immunoglobulin peaks.
a)
Ig Peak
Origin
Albumin Peak
b)
Ig Peak
Origin
bumin Peak
FIGURE 3.16 Integrated Densitometer traces of cellulose 
acetate electrophoresed ascitic flu id  
antibody preparation.
a) Ascitic flu id  antibody S.Y/T8/1
b) Ascitic flu id  antibody $y/T 8 /2  
Total peak (------- )
Ig peak (—  -)
a)
Ig Peak
Origin
Albumin Peak
b)
Ig Peak
Origin
Albumin Peak
FIGURE 3.17 Integrated Densitometer traces of cellulose 
acetate electrophoresed ascitic flu id  
antibody preparation.
a) Ascitic flu id  antibody SY/T8/3
b) Ascitic flu id  antibody SY/T8/4 
Total peak
Ig peak (------- )
FIGURE 3.
a)
Ig Peak
Or i gi n
Albumin Peak
b)
In Peak
Origin
Albumin Peak
8- Integrated Densitometer traces of cellulose 
acetate electrophoresed ascitic flu id  
antibody preparation.
a) Ascitic flu id  antibody SY/T8/5
b) Ascitic flu id  antibody SY/T8/6  
Total peak
Ig peak (------- )
TABLE 3.9
Ig content of monoclonal antibody preparations from supernatant 
(SN) and ascitic flu id  (AF).
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DISCUSSION AND CONCLUSIONS
1 Spleen Cell Donor Response to Immunization
Immunization serves two purposes:
1) to effect the expansion of antigen specific clones within the animals 
and in the spleens in particular;
2) to produce antigen stimulated actively dividing B lymphocytes for 
fusion.
Although the nature of cells which fuse best is not precisely known, i t  
has been implied in Chapter 1 that the specific antibody content of a serum 
reflects the antigen dependent stimulation, proliferation and maturation of 
antigen binding cells. Thus the antibody content of the immunized mice 
indicated the enrichment of the antigen binding clones required for fusion 
(Siddle and Soos 1981). Additionally Andersson and Melchers (1978) indicated 
that fusion occurs preferentially  with rapidly dividing blast cells . For 
this reason fusion is done 3-4 days after the final boost in order to obtain 
cells in rapid mitosis (Davis et al 1969, Nossel 1975) rather than at the 
height of antibody production which would be expected to occur at about day 
7-8. By this time mitosis would have ceased, and the majority of cells would 
be small mature lymphocytes producing antibody. The route of introduction is  
also thought to influence the site of maximum antigen localization and 
processing. This, together with the preferential antigen independent spleen 
seeking activ ity  of B cells (Weissman et al 1974) indicated the final 
intraveneous challenge, and the spleen as the most appropriate donor organ.
Hyperimmunization by multiple challenge has been suggested to be 
inappropriate (Oi et al 1978). However i t  has also been suggested that the 
quality of the antibody in terms of a ffin ity  matures with time as the immune 
response matures (Eisen and Siskind 1964, Nossal 1975, Odell et al 1969) 
especially when low concentrations of antigen are used. In explanation i t  
was suggested that as the response progressed and antigen levels decrease so 
only cells with high a ff in ity  receptors were able to capture sufficient 
antigen to produce further cell divisions (Steiner and Eisen 1967). By th is  
process progressive immunization would be expected to result in higher and 
higher a ffin ity  cells available for stimulation. Since our objective was to 
produce high a ffin ity  monoclonals we concluded that an extended immunization 
schedule would probably yield the desired high a ff in ity  product. On these 
premises the described protocol was adopted for immunization to maximise the 
specific high a ffin ity  clone types available for fusion.
.2 Characteristics of NSI myeloma cells
The NSI myeloma cells were found to grow optimally up to a density of 
8 x 10^/ml a fter which the culture rapidly declined both in v ia b ility  and 
cell numbers. Indeed this was also the case with the hybridomas examined. 
These grew to a maximum density which was not maintained for long and the 
cultures rapidly declined thereafter. Five of the hybridomas were very 
intolerant of high density. Hybridoma SY/T8/1 on the other hand grew up to a 
very high density under the same growth conditions.
The central importance of the NSI sensitivity to HAT selection 
(L itt le fie ld  1964) was described in Chapter 1; and such sensitiv ity  was 
clearly demonstrated in figure 3.8. Under this selection regime NSI myeloma 
cells which did not contain the intact HGPRT enzyme was effective ly elim i- 
nated from the culture. I t  was therefore vita l that the NSI cultures were 
examined under HAT selection regularly in case normal revertants appeared 
spontaneously within the cell population. Such normal revei^ants would be 
distinguished by th e ir a b ility  to grow in HAT media. Revertant NSI cells  
used in fusion would endanger any positive hybrids by overgrowing these cells  
and using up vita l culture resources. Many hybrid cells are slower growing 
than the NSI cells (table 3 .6 ).
Hybrid in s tab ility  described in Chapter 1 also appeared to be exacerbated 
by the trauma of freezing and thawing. Many primary and monoclonal cultures 
with continued antibody production could not be resuscitated.
We found however
that extended culture time after fusion and cloning alleviated the problem. 
This however greatly increased the risk of hybrid loss due to contamination. 
Early hybrid products in addition to the longer growing cultures were 
therefore stored..
3 Contamination control
The problems of fungal contamination control with econazole was not 
resolved. S tric t aseptic techniques were relied upon to maintain the
s te r il ity  of the cultures. This was accomplished successfully, with only 
very minor outbreaks of contamination over the whole period of this work. 
Contrary to expectations (Wyler 1979), econazole reduced NSI v ia b ility  
dramatically, impared cell growth and proliferation and induced observable 
and undesirable membrane changes. These findings were sim ilar to the 
reported adverse effects of the most widely used antimycotic agent fungizone 
on chick embryo fibroblast (Dolberg and Bissell 1974) and murine cells
(Hacket et al 1972). Because of its  reported advantages (Wyler et al 1979) 
econazole was tested to be used instead of fungizone, but was found to be 
unsuitable.
.4 Fusions
The f ir s t  six fusions were unsuccessful in terms of stable positive 
hybrids derived. This was possibly due primarily to the unsuitability of the 
screening RIA used for detecting the small quantities of antibodies that were 
in it ia l ly  expected. The quantity of second antibody used for precipitation  
of bound from free was d if f ic u lt  to optimise when the lim its  to be tested 
were unknown. The solid phase RIA and ELISA systems overcame such problems 
and simplified the screening protocols, reduced the assay times and increased 
the handling capacity. With the ELISA system the advantages were very 
obvious. A large number of samples could be easily handled in the microplate 
system and a rapid visual positive/negative assessment was possible. The 
conclusion that the RIA screening procedure was responsible for the lack of 
identification of positive hybrids from the many viable cultures observed was 
reinforced by the observations that PEG separation procedure alone was as 
good as the second antibody separation procedure. A similar amount of bound 
label was observed in the positive controls as when the second antibody was 
used. This suggested the assay procedure was adequate at these antibody 
concentrations but the major question remained open with this assay at the 
very low antibody concentrations. The over-riding indications were therefore 
for the development of the special screening assays described in Chapter 2 
and used successfully in fusions 7 and 8.
Three fusion solutions were used. Solution 1 was abandoned because i t  
was suggested (Fazekas de St Groth and Scheidegger 1980) that low molecular 
weight PEG was toxic to cells . Fusion solution 2 was used successfully by 
(Aldersson and Si kora 1982) but the fusion procedure was made more compli­
cated with no apparent added advantage in terms of increased hybrid numbers. 
We therefore fin a lly  decided to use fusion solution 3 (Fazekas de St Groth 
and Scheidegger 1980) which was very successful in terms of primary cultures 
secreting immunoglobulins and specifically anti-TSH antibodies derived, and 
the simplified fusion procedure. The results confirmed that the success of 
the fusion procedure was dependent on the v ia b ility  of the NSI cells used in 
the fusion. In situations where <90% viable cells were used the number of 
wells with viable hybrid cultures were drastically reduced.
The probability that each positive well would contain only one clone was 
greatly improved with the microculture (96 well) procedure and was a major 
attraction when compared to larger (2 ml) cultures. The cloning procedure 
was therefore simplified. However the microculture procedure entailed two 
major disadvantages:
1) The large numbers, of cultures which had to be handled greatly 
increased the risk of contamination and;
2) Concomitantly increased the work load as was the case in fusion 7.
I t  was therefore concluded that i t  was preferable to work with fewer larger
cultures and expend the e ffo rt at the la ter screening and cloning stages 
rather than maintaining large numbers of primary cultures the majority of 
which were negative.
The monoclonal antibody products
The monoclonal cultures SY/T8/1-6 which were chosen for investigation
were shown to be high antibody producers. In the lite ra tu re  (Goding 1980, 
Galfre and Mil stein 1981, Oi and Herzenberg 1980) 10-100 yg/ml specific
antibody in the supernatants and up to 15 mg/ml antibody in ascitic flu id  was 
reported. The derived monoclonal antibodies produced exceeded that range in 
most cases.
Two monoclonal bands were observed in the CAM electrophoresed ascitic
flu id  samples of SY/T8/2 and 5.
The peaks were s t i l l  apparent even after recloned cell lines were used to
produce the ascitic flu id . I t  was concluded therefore that the second peak 
was probably extraneous mouse immunoglobulins secreted in an immune response 
to the injected cells and the antibody products they produced. I t  must be 
remembered however that the monoclonal antibody and cells are of mouse
origin. The immune response should therefore be minimal. The monoclonal 
antibodies were characterized and assessed in specific application.
CHAPTER 4
The Characterisation Of Monoclonal 
anti-human-TSH Antibodies
4.1 INTRODUCTION
One of the primary advantages of monoclonal antibodies over polyclonal 
antisera is that the precise chemical nature of the antibody is defined.
This according to Mil stein-et-al (1979) is perhaps the major attraction of 
hybridoma technology.
One of the implications of monoclonal antibodies because of the unique 
properties and the lim itless supply, is that the derived antibody may be 
distributed and become established as standard reagents in specific
application. For this to become possible, or even in local application they
must be precisely characterized and described. Not only must the overt 
antigen binding characteristics be defined, but specification of other 
properties such as avid ity , t i t r e  and cross reactivity must be outlined. 
Such empirical descriptions allow the quantitative application of antibodies 
not previously possible.
4.2 MATERIALS AND METHOD
4.2.1 Assessment Of Antibody Preparations
a) Monoclonal antibody t i t r e
The six selected monoclonal antibodies SY/T8/1-6 were titre d  by three
methods
1) The indirect ELISA method B described in Chapter 2. Both ascitic
flu id  and supernatants were titre d  by this method. The antibody preparations
were diluted in ELISA assay diluent. The supernatant was taken from cultures;
which had grown to stationary phase.
2) The solid phase RIA method was also described in Chapter 2. Only the 
ascitic fluids were titre d  by this method.
3) The ascitic fluids were also titre d  by the standard RIA method by the 
kind courtesy of Dr D Teale, Biochemistry Dept, St Lukes Hospital, Guildford.
Displacement curves
In addition to the above titra tio n  and displacement curves were obtained 
using the supernatant antibody preparations from cultures which had grown to 
stationary phase. The wells were previously coated with 1 yg TSH/ml as 
described in ELISA method B.
The supernatants were diluted in ELISA diluent and 100 yl diluted Super­
natant plus 100 pi of 500 mU/1 TSHjgartsj or National Institu te  of Biological 
standards and control - (NIBSC) TSH (68/38) standard was added to quadrup­
lica te  wells for the displacement curves. For the titra tio n  curves the TSH 
solution was replaced by 100 yl assay diluent.
The wells were further incubated for 2 hours at 37°C and the assay 
completed as described for ELISA method B.
NIBSC TSH dilution
TSH ampoule contained 150 mU TSH. This was dissolved in 50 ml d is tille d  
water to give 3.0 mU/ml solution of TSH. 0.5 ml aliquots of this solution 
were freeze dried and stored at -20°C.
To get a 500 mU/1 solution of TSH one aliquot was dissolved in 0.5 ml 
d is tille d  water. This was made up to a final volume of 3.0 ml with d is tille d  
water to give the final TSH solution.
b) Monoclonal antibody cross reactivity
The cross reactiv ity  of each monoclonal antibody preparation was deter­
mined by the inhibition of binding of the antibody to the specific antigen by 
various concentrations of the possible crossreacting antigen. 100 pi of the 
supernatant diluted as in table 4.4 was placed in h-TSH antigen adsorbed 
wells as described for ELISA method B. Then 100 yl of the various dilution  
of the possible crossreacting antigen was added to quadruplicate wells. 
Wells which contained 100 yl of the appropriate antibody dilution and 100 yl 
of assay diluent were taken as 100 percent (%) binding wells.
The binding in the other wells was scored in relation to these 100% 
binding wells.
The results were calculated and plotted as relative percentage (%) 
binding vs antigen concentration:
Relative % binding = jj. x 100
b
where 'a ' is the mean binding (optical density) of wells with the cross- 
reacting hormone and antibody; and ' b1 is the mean binding (optical density) 
of wells containing only the antibody.
The hormones tested for crossreactivity with the monoclonal antibodies 
were those supplied by the National Institu te for Biological Standards and 
Control (NIBSC) Holly H i l l ,  Hampstead, London NW3 6RB.
1) 1st International reference preparation of human pitu itary LH 
(68/40);
2) 2nd International reference preparation of human pitu itary FSH/LH
(78/549);
3) 1st International reference preparation of human Chorionic Gonado­
trophin (HCG) (75/537)
4) 1st International reference preparation of HCG a subunit (75/569);
5) 1st International reference preparation of HCG 3 subunit (75/551);
6) In addition purified HCG kindly supplied by Dr R Edwards, St 
Bartholomews Hospital, London EC1 and designated HCG(Barts) was tested. The 
hormone preparations were in it ia l ly  dissolved as outlined in table 4.1 a fte r  
which they were diluted 1:10 in ELISA diluent.
TABLE 4.1
Hormones tested for crossreactivity with monoclonal antibody to h-TSH, 
concentrations used.
Hormones
HCG(Barts) HCG
75/537
LH
68/40
FSH/LH
78/549
HCG a sub- 
Unit 75/569
HCG 3 sub- 
Unit 75/551
Assigned 
unitage in 
hormone 
preparation
3000.OIU 650.0IU=
70yg
77.0 IU 25IU LH 
10IU FSH
70.0 IU= 
• 70 yg
70.0IU=
70yg
Di ssolved 
in it ia l ly  in 
d is tille d  
water
3.0ml 6.5ml 10.0ml 10.0ml 7.0ml 7.0ml
In it ia l con­
centration
1000.0
IU
100.0IU= 
10.77yg
770.OmU 2500mU
LH
lOOOmU
FSH
10.0IU=
10yg
10.0IU=
10yg
c) Monoclonal antibody a ffin ity
A modification of the procedure for the rapid determination of binding 
constants with special reference to monoclonal antibodies described by 
Frankel and Gerhard (1979) was used. The major modification involved the use 
of the goat anti-mouse-HRPO conjugate I instead of a radiolabelled antimouse 
immunoglobulin as the observed bound signal.
The indirect ELISA method B was used to obtain the data for the 
determination of the a ffin ity  binding constants. The experiments were run in 
tr ip lic a te  and culture supernatant was used as the antibody preparation.
First each supernatant was titra ted  by serial dilution against 1 yg/ml 
solid phase TSH. A standard curve was derived from culture supernatant 1 for 
which the antihody content had been determined previously by radial immuno­
diffusion (Chapter 3).
Finally increasing antigen concentration 1, 2.5, 5, 10 and 20 yg/ml TSH 
was coated to a series of wells and one dilution of each supernatant 
(Table 4.2) was titra ted  against the series of increasing antigen coated 
wells.
TABLE 4.2
Supernatant dilutions used with increasing antigen coating concentrations 
in a ffin ity  constant determination. These were a rb itra rily  chosen to give 
high OD readings under the assay conditions.
SN1 SN2 SN3 SN4 SN5 SN6
Dilutions 1:200 1:200 1:180 1:120 1:60 1:120
d) Immunoglobulin class, subclass and light chain composition
The immunoglobulin class, subclass and lig h t chain composition secreted 
by the monoclonal antibody cell lines were determined by the Ouchterlony 
double immunodiffusion technique (Ouchterlony and Nilsson 1979).
The plates were subbed as described for single radial immunodiffusion in 
Chapter 3. 1.5% (w/v) Noble agar dissolved in phosphate buffered saline
containing 3.0% (v/v) PEG 6000 was poured hot onto the subbed plates on a
levelling table. The cooled plates were then stored in a humidified box.
Immediately before they were to be used the wells were cut and the agar plugs 
aspirated. The well sizes were such that they held 5 yl sample volume. The 
antimouse immunoglobulins antisera (supplied by Serotec Ltd, Bicester, Oxon), 
anti IgA, IgM, anti IgG, IgG2a, IgG2b, IgG3; anti-K and anti-A , were placed 
in the central wells. They were used at three concentrations neat, diluted  
1:5 and 1:10. Neat supernatant (SNa) and ammonium sulphate precipitated 
supernatant antibody (SNb) and 1:50 dilution of ascitic flu id  (AF) were
placed in the individual wells arranged around the central well (see
figure 4 .1 ).
The plates were then incubated in a humidified box at 4°C for 48 hours, 
after which they were washed gently in phosphate buffered saline for about 
2 hours. They were then stained, destained and pressed dry by placing 
several layers of f i l t e r  paper on top of the gel and placing an even weight 
on top. They were le f t  overnight a fte r which the plates were examined for 
precipitation lines.
Staining and destaining
Staining solution consisted of 1.25 g Coomassic B rillia n t blue R250 
(BDH Chemicals Ltd, Enfield, Middlesex), dissolved .in a. .solution.of 21.3% 
(v/v) glacial acetic acid. After mixing and leaving overnight the solution 
was filte red  before using. The plates were immersed in staining solution for 
5 minutes after which they were differentiated in the acetic acid solution. 
The plates were washed until the background was clear.
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FIGURE 4.1
Pattern of wells cut in agar and the distribution of samples for 
Ouchterlony double immunodiffusion, (o) Plate identification mark. Well 
No.l contains antimouse antisera. Wells 2, 3 and 4 = one antibody prepara­
tion SNa, SNb and AF respectively. Similarly wells 5, 6 and 7 = another 
monoclonal antibody SNa, SNb and AF antibody preparation respectively.
2 Sodium Dod.yc.yle Sulphate Polyacrylamide Gel Electrophoretic Analysis Of
Monoclonal Antibody Preparations
The method of Laemmli (1970) was used to analyse reduced and unreduced 
preparations of internally labelled antibodies. One of the important 
advantages of monoclonal antibodies is the fa c ility  for easy radiolabelling . 
by biosynthetic incorporation of ^ C , or ^S  into the immunoglobulin 
molecules.
This is usually accomplished by substitution of a radiolabelled essential 
amino acid in the culture media. The method described by Galfre and Milstein  
(1981) was used to internally label the monoclonal antibodies.
Preparation of in ternally labelled antibodies
The incorporation media consisted of 9.0 ml (-lys) RPMI 1640: RMPI 1640
lysine free medium (supplied by Gibco Bio-cult Ltd, Washington Road,
Paisley). 1.0 ml of [ 1Z*C] lys: L-[U -^C] lysine monohydrochloride (Cat.No.
CFB.69) 50 yCi/ml (supplied by The Radiochemical Centre, Amersham,
International PLC, UK) and 1.0 ml foetal ca lf serum which has been dialysed 
against double d is tille d  water after which balanced salt solution. (Flow
laboratories) was added to l/9 th  the volume of the dialysed serum.
2 x 106 cells from each exponentially growing monoclonal culture with
cell v ia b ilitie s  of between 90.8 and 94.5% were pelletted on a bench MSE
centrifuge for 5 minutes. The cells were washed with 10 ml lysine free
RPMI 1640. After pelletting the cells of each culture were resuspended in
1.0 ml incorporation media and plated into 24 well Costar tissue culture
plates. These were then incubated for 37°C in 5.0% CO2  in a ir humidified'
environment.
After 8 hours incubation a further 2 x 10^ ce lls , washed and resuspended 
in 1.0 ml lysine free medium were added to each radioactive culture.
Following a further 15 hours incubation the supernatants were collected and 
stored at -20°C.
In tracellu lar labelling of myeloma k chain
The method described by Cotton et al (1973) was used for the intra
cellu lar incorporation of radiolabel into the immunoglobulin kappa lig h t
chain synthesized by the myeloma cells (Kohler and Milstein 1975). The cells
were lysed and the immunoglobulin chain preparation obtained according to the 
method of Awdeh et al 1970. I t  was necessary to release the labelled
immunoglobulin L-chains because they are synthesized but not secreted by NSI 
myeloma cel Is .
5 x 10  ^ log phase growth NSI cells were washed in 10 ml RPMI 1640 
lysine free medium and then pelletted and resuspended in 10 ml fresh 
RPMI 1640 lysine free medium in which they were incubated for 15 minutes at 
37°C.
The cells were then recovered by centrifugation on the MSE bench
centrifuge. Following this they were resuspended and incubated for 
15 minutes in 0.8 ml RPMI 1640 lysine free medium containing 10% (v/v) 
dialysed foetal calf serum and supplemented with sodium pyruvate and 
penicillin/streptomycin as described in Chapter 3. To this was added 200 yl = 
10 yCi L-[U -^C] lysine monohydrochloride (Amersham Int UK). The cells  
were then pelleted. The supernatants were col1ected and stored. These
represented the extra-cellu lar flu id .
Cell lysis
The in tracellu lar soluble proteins were extracted by resuspension of the 
cells in 0.8 ml of solution E consisting of 0.01 M Tris (hydromethyl) amino 
methane pH7.5, 0.01M potassium chloride (KC1) and 0.001M Magnesium chloride 
(MgCl2).
Cell lysis was accomplished by the addition of 0.2 ml of 5% (w/v) sodium 
deoxychlolate.
The lysed cell material was layered on to sucrose gradient consisting of
1.0 ml 4% (w/v) sucrose in solution E, 1.0 ml 10% (w/v) sucrose and 8.0 ml
30% (w/v). sucrose. The material centrifuged for 1 hour in a Beckman 60 Ti
Rotor at 39,000 RPM. The top 3 ml wa's then removed and stored at -20°C until 
required.
Preparation of Gel 
Stock solutions
Gel Stock: 30% (w/v) acrylamide containing 0.8% (w/v) N^-methylenebis- 
acrylamide in d is tille d  water.
Buffers A: consisted of 1.5 M Tris-HCl pH8.0 containing 0.4% (w/v) SDS.
B: 500mM Tris-HCl pH6.8 containing 0.4% (w/v) SDS.
C: 25mM Tris-HCl pH8.3 containing 192 mM glycine and 0.1% (w/v) SDS. 
D: 62.5mM Tris-HCl pH6.8 containing 2.3% (w/v) SDS, 15% (v/v) 
glycerol, 5% (v/v) 2-mercaptoethanol and 0.001% bromophenol blue.
The cuvettes were each made up of two glass plates 120 mm x 100 mm x 
1.5 mm; one of which had a 20 mm deep x 100 mm long notch cut out from one 
long edge. The two clean dry plates were placed together, with the notched 
top edge open and 5 mm wide plastic spacers between the plates along the two 
sides and bottom edge. The plates were then clamped securely together and 
the sides and bottom of the cuvette sealed with molten 1.5% (w/v) agar. The 
assembled cuvettes were secured in a vertical position. Great care was taken
to ensure that the cuvettes were water tig h t. The lower running gel
consisting of 10.0 ml of buffer A, 13.3 ml gel stock, 16.6 ml d is tille d  water 
was mixed immediately before required, and polymerization was in itia ted  by
the addition of 20 yl tetra methyl ethylene diamine (TEMED) and 240 yl of a
freshly prepared 10% (w/v) solution of ammonium persulphate. The mixture was 
then poured into the cuvettes to a height of 80 mm. A layer of d is tille d  
water was gently overlayered on top of the gel mixture. After polymerization 
was completed (about 30 minutes) the water layer was carefully aspirated. 
The stacking gel consisting of 2.5 ml buffer B, 1.0 ml gel stock, 6.5 ml 
d is tille d  water mixed with 60 yl of 10% (w/v) ammonium persulphate solution 
and 20 yl TEMED was poured into the cuvettes on top of the running gel.
Before polymerization, a perspex comb was introduced into the stacking 
gel to form sample wells. After polymerization the comb was carefully
removed so as not to distort the wells.
Buffer C was poured into the wells of the stacking gel to keep them 
patent. The bottom spacer was carefully removed from the cuvette which
was then placed into the electrophoresis tank, the upper and lower reservoirs 
of which were f i l le d  with buffer C. I t  was important to remove any trapped 
a ir bubbles from the bottom edge of the gel in the cuvette.
Sample preparations
Two types of radioactive samples were introduced into the wells. The 
f ir s t  were the reduced monoclonal antibody samples. These samples were 
diluted in buffer D in a ratio of 1:3 buffer: sample. The samples were
placed in a boiling water bath for 3 minutes. They were then cooled and 
30 yl were applied with an Eppendorf pipett c a re fu lly -to  wells in the 
stacking gel.
The second sample type was the unreduced samples. These were also 
diluted 1:3 buffer: sample. In buffer D used here 2-mercaptoethanol was
replaced by 4.0% (w/v) iodo-;acetamide (Hudson and Hay 1981) after which they 
were treated sim ilarly to the reduced samples.
Standard proteins
Standard proteins were also included in the sample wells. 1 mg of each 
standard was mixed together in 1 ml buffer D for reduced or unreduced samples 
and treated as described above. 15 yl of the standard samples were applied 
to the standard wells. The standard proteins included those in Table 4.3 
below.
TABLE 4.3
Standard proteins used at 1 mg/ml in S.DS-PAGE analysis of monoclonal 
antibodies and their molecular weights
Standard Proteins Molecular weight
Sheep IgG : 150,000
Albumin (BSA) 68,000
Albumin (Hen egg) 45,000
Aldolase 40,000
Chemotrypsinogen 25,000
Cytochrome C 12,500
Electrophoresis
The electrodes were fin a lly  connected to the power supply with the anode 
to the lower chamber and the cathode in the upper. A constant current of 
20 mA was applied until the bromophenol blue just entered the running gel at 
which stage the constant current was increased to 40 mA until the bromophenol 
blue marker is about 5 cm from the bottom end of the gel. The power was 
switched o ff. The cuvette was removed from the tank and the plates carefully  
separated. The stacking gel was cut o ff and the gels stained.
Staining
Staining solutions consisted of 0.25% (w/v) Coomassie B rillia n t Blue
dissolved in methanol .-acetic acid:water, 5:1:5. The gels were placed in th is  
solution for about 45 minutes after which they were destained in several 
changes, of destaining solution (methanol:acetic ac id :d istilled  water 5:1:5) 
until the background was clear.
Drying
The cleared gels were placed on to a clean piece of clear plastic and was 
overlaid with damp f i l t e r  paper. These were then transferred to drying 
equipment - the paper towards the porous plate. The gels were then dried by 
applying a vacuum. The gels were reduced to a thin film  attached to the 
f i l t e r  paper.
Autoradiography
The gels were stored under a weight to keep them f la t .  These were then 
placed f la t  onto a Kodak No .screen film  NS-2T (Kodak, USA) held firm ly  
between two glass plates. The gel and film  were kept in contact for 5 days 
after which the films were processed. All manipulations were done in a 
photographic dark room.
4.2.3 Radioiodination Of Monoclonal Antibodies
As indicated ea rlie r one advantage of monoclonal antibody is the fa c ility  
for biosynthetic labelling. However for some purposes eg, immunoradiometric 
assay (Miles and Hales 1968) gamma emitting label may be preferred.
Antibodies required for radioiodination or for other purposes for example 
as the solid phase capture antibody in the sandwich ELISA (see Chapter 5) 
need to be highly purified.
The antibody binding characteristics and d ifferentia l elution profile  of 
various antibody subclasses on protein A, together with its  sim plicity in 
application (E ye t al 1978 and reviewed by Goding 1978) dictates its  use for 
a ffin ity  chromatography in these circumstances.
Protein A purification
The procedure outlined in Hudson and Hay (1980) was used.
Buffers: (1) 0.15M Phosphate buffered saline pH 7.2 containing 0.01% (w/v)
thimerosal.
(2) 0.1M Phosphate buffer pH8.0.
(3) 0.1M Citrate-phosphate buffers pH6.0, 5.5, 4.5 and 3.5.
(4) 1.0M Tris-HCl buffers pH8.5 and 9.0.
1 .5g Protein A-Sepharose CL-4B (supplied by Pharmacia (GB) Ltd, Hounslow, 
Middlesex) was swollen in 10.0 ml phosphate buffered saline for 1 hour at
room temperature. The swollen gel was packed with phosphate buffered saline 
into a 5 ml syringe which contained a small scinter disc in the end. This,
column was stored and run at 4°C.
The column was equilibrated by running through 30 ml of 0.1M phosphate
buffer pH8.0. The ascitic flu id  or supernatant was centrifuged gently for 
5 minutes on the MSE bench centrifuge. 0.5-1.0 ml ascitic flu id  was diluted 
with an equal volume of 0.1M phosphate buffer pH8.0, and the pH of the
samples ascitic flu id  or supernatant adjusted to pH8.1 with 1.0M Tris-HCl
pH9.0.
The sample was then applied to the top of the column and wash through
with 0.1M phosphate buffer. pH8.0 until no protein was detectable in the 
eluate. The bound immunoglobulins were then eluted as follows:
IgGj was eluted with 30 ml 0.1M citra te  phosphate buffer pH6.0.
This was followed by 30 ml 0.1M c itra te  phosphate buffer pH5.5.
IgG2a and IgG2  ^ were eluted at very low pH, therefore 2.5 ml Tris HC1 
buffer pH8.5 was added to collecting tubes prior to collecting the fractions.
IgG2a was eluted with 30 ml of 0.1M citrate-phosphate buffer pH4.5.
Finally IgG2k was el uted with 30 ml of 0.1M c itra te  phosphate buffer 
pH3.5. The column was then re-equilibrated to pH8.0. The optical density of 
the fractions were checked at 280 nm. The fractions containing the mono­
clonal antibody were pooled and the 0D2qq determined and used to calculate 
the antibody content of the pooled fraction as described in Chapter 2.
Radioiodination procedure
The monoclonal antibodies were radioiodinated by the chloramin T method 
of Hunter and Greenwood (1962) and described in detail by Hunter (1979). The 
radioiodination was carried out in the Grade C laboratory, Biochemistry Dept, 
University of Surrey.
Reagents
IOC
Na ■Ld3i was supplied by The Radiochemical Centre, Amersham International 
PLC, UK).
0.5M sodium phosphate buffer pH7.5 (iodination buffer).
50 yg purified antibody protein in 50 y l .
Sodium metabisulphite 0.05% (w/v) in d is tille d  water.
0.15M phosphate buffered saline pH7.4 containing 0.1% (w/v) bovine serum 
albumin (BSA) (elution buffer).
Chloramin-T 2.6% (w/v) in phosphate buffered saline freshly prepared.
The iodination was carried out in small V-bottomed iodination vial on a 
magnetic s t irre r , a small teflon coated triangular magnetic flea  (Pierce and 
Warner (UK) Ltd, Chester, Cheshire) was used to s t ir  the iodination mixture, 
stop clock was also essential.
A chromatograph column 30 cm x 1.5 cm was packed with Sephadex 150 
(supplied by Pharmacia (GB) Ltd, Houslow, Middlesex) swollen overnight in 
0.15M phosphate buffered saline pH7.4 and equilibrated with 50 ml elution 
buffer.
Procedure
50 yl containing 50 yg monoclonal antibody protein was put into- the
iodination vial containing the magnetic flea .
10 yl of iodination buffer was added followed by 10 yl Na 
(10 y l = 1 mCi), with continual s tirring .
10 yl freshly prepared chloramin-T was added to the iodination vial and
its  contents. Precisely 30 seconds la te r  200 yl sodium metabisulphite was 
added.
The iodination mixture was then put onto the prepared gel f i l t ra t io n  
column. The iodination vial was carefully rinsed with 200 yl elution buffer 
and this was also applied to the top of the column which was eluted with the 
elution buffer. 10 yl samples of each fraction was counted.
.4 Distinction Of Epitope Specificity
Frequently i t  is important to determine whether two monoclonal antibodies 
are directed at precisely the same antigenic determinant. This is particu­
la r ly  relevant when they are required for use in , for example, two site
binding type assays (Hales and Woodhead 1980, Wisdom 1976) where the antigen 
is required to be bound by a solid phase antibody at the bottom of the 
sandwich and by another antibody at the top. I f  both antibodies used in such 
an assay was directed at the same epitope then one would be expected to 
considerably hinder the binding of the other especially where the epitope was 
a single non-repeating unit.
Epitope specificity may be distinguished by examining the competitive 
inhibition of binding of a labelled antibody to the solid phase antigen by 
the unlabelled competitor antibody.
Procedure
1 ug/ml h-TSH was coated to polyvinyl chloride wells as already
described. 100 yl of each unlabelled protein-A purified monoclonal antibody
at 4 yg/ml was added to a series of wells.
This was followed by the addition of 100 yl (about 100,000 CPM) of each
1 PR antibody in a checker board sequence such that each unlabelled mono­
clonal antibody is in combination with each labelled antibody. The positive 
control was the competition between the labelled and unlabelled preparations 
of the same antibody. Total binding was derived from binding in wells which 
contained labelled antibody but the unlabelled antibody was replaced by ELISA 
diluent buffer. The wells were incubated at room temperature for 2 hours 
after which the radioactive waste was aspirated and the wells washed three 
times with ELISA washing buffer. The wells were then a ir dried separated and 
counted. Four replicates were done for each antibody mix.
4.3 RESULTS
4.3.1 Characteristics Of Monoclonal Antibody Preparations
a) Antibody t i t r e
The dilution curves obtained by the indirect ELISA method B and solid 
phase RIA for the monoclonal antibodies ascitic flu id  preparations are 
presented in figures 4.2 and 4.3 respectively and for the supernatants in 
figure 4.4.
The monoclonal antibody titre s  determined by these methods and standard 
liquid phase RIA are tabulated in Table 4.4. The titre s  were defined as 
fol 1 ows:
ELISA titre s  were taken as the dilutions of the antibody preparations 
which gave optical densities 0D greater than the Highest negative observed 
for a series of negative samples examined. 0D values greater than 0.5 were 
therefore regarded as the t itre s . The RIA titre s  were taken as the dilutions  
which bound 50% of the maximum labelled hormone bound. The monoclonal 
antibodies have been demonstrated to be applicable in all three assay 
systems. The apparent t i t r e  by ELISA was higher than that observed by the 
solid phase by a factor of between 2 and 8, and sim ilarly the t itre s  were 
higher by the sol id phase method than by the standard liquid phase RIA by a 
factor of between 8 and 80. With the two assay methods developed specifica lly  
for detecting the monoclonal antibodies the antibody could be used at much 
greater d ilu tion.
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FIGURE 4.2 ELISA Titration curves for 6 Monoclonal Antibodies from TSH8. 
These cell lines were named SY/T8/1-6. AF1 • — •  ;
AF2 □ — □ ; AF3 O —  O ; AF4 ■ ; AF5 A — A  ;
AF6 a  —  a . The titre s  (ie  0D values >0^5 is regarded as
the positive t it re )  range between 3.3 x 10 and 1.4 x 10 .
A -------A is a pooled mouse Anti TSH anti serum positive;
a -------a  is a non-immune mouse serum (negative control).
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FIGURE 4.3 Solid phase RIA titra tio n  curves.
Ascetic fluids 1 •  —  •  ; 2 □ —  □ ; 3 O —  o  ;
4 ■ — ■  ; 5 a — a  ; 6 A — - a  .
RIGHT HAND ordinate a — -a  = positive control 
pool ed'mouse Anti TSH antiserum; —a = negative
mouse serum.
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TABLE 4.4
Antibody tit re s  observed by ELISA, Solid Phase RIA and standard liquid  
phase RIA for ascitic fluids (AF) and supernatants (SN). For the ascitic  
flu id , the ELISA t i t r e  was taken dilution with OD^ gg greater than the highest 
negative (ie , >0.5). For the SN the ELISA t i t r e  was taken as the dilution  
with OD^ gg = 1.0. The RIA t i t r e  was taken as the dilution which bound 50% of 
the maximum bound label. % inhibition is calculated from the displacement of 
dilution curves by TSH, see figures 4.5 - 4.7.
Samp!e 
SY/T8/-
ELISA t i t r e  
(AF)
Solid Phase 
t i t r e  (AF)
Standard RIA 
t i t r e  (AF)
ELISA t i t r e  
(SN)
% Inhibition  
with TSH in SN
1 1 1.8 x 105 1 6.4 x 104 1 1.6
COor-1X 1:290 76.0%
2 1 1.0 x 105 1 3.5 x 104 1 0.6 x 103 1:200 79.0%
3 1 1.2 x 105 . 1 4.8 x 104 1 0.6 x 103 1:230 65.0%
4 1 3.0 x 105 1 3.5 x 104 1 4.0 x 103 1:200 66.7%
5 1 1.9 x 105 1 5.6 x 104 1 2.5 x 103 1:100 65.0%
6 1 6.4 x 104 1 5.2 x 104 1 1.2 x 103 1:200 85.0%
Displacement curves
In addition to dilution curves displacement curves are usually set up. 
These give useful information about the a ffin ity  of the anti serum. The 
degree of displacement is an indirect measure of the a ffin ity  of the antibody 
preparation (Morris 1981, Hunter 1979) for the antigen.
The displacement curves obtained are presented in figures 4.5 -  4.7. No 
displacement was observed with the NIBSC TSH preparation and any of the 
monoclonal antibody preparations. A sim ilar result was obtained by 
Dr D Teale in the standard liquid RIA performed using ascitic flu id  antibody 
preparations.
Preincubation of the antibody and the NIBSC TSH for 2 hours at 37°C did 
not result in improved displacement. At the supernatant t it re s  in Table 4.4 
the percentage inhibition or displacement with TSH(Barts) was calculated 
thus:-
% Inhibition = (1 - x ELISA 0DAQn displacement wells )
(  — --------------   — -----   ) x 100
( x ELISA OD^ gg antibody dilution wells )
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The results are contained in Table. 4.4. The results suggests SN6 should
be the highest a ffin ity  antibody since i t  displayed the greatest displacement 
under these conditions.
b) Antibody cross reactivity
The results of these specificity studies are presented in figures 4.8 -
4.12. Antibody SY/T8/4 showed the most cross reactiv ity , evidenced by the
apparent inhibition of binding relative to that observed in the control wells 
which was taken as 100% binding. The inhibition was most marked with HCG 3 
subunit, HCG^ garts) preparation, and FSH at 100 mU/well. The inhibition of 
binding although apparent, occurred to a lesser extent with HCG a subunit.
The mouse anti-TSH anti serum, however, displayed the greatest inhibition
of binding in the presence of HCG a subunit (figure 4.12). Antibody No4 on 
the otherhand did not show any cross reactiv ity  with the NIBSC HCG 
(figure 4.10).
A particularly notable phenomenon was the overt enhancement of binding by 
antibody SY/T8/1 observed in the presence of HCG 3 subunit (figure 4 .9 ).  
TSH(Barts) inhibited the binding of the monoclonal antibodies to the solid 
phase antigen to the greatest extent as expected (figure 4 .8 ). The cross 
reactiv ity  results are summarized in Table 4.5.
TABLE 4.5
Summary of antibody hormone specific ity . Binding of the antibody to 
solid phase TSH was inhibited by various concentrations of hormones.
+ = cross reactivity -  = no cross reactivity
HORMONES
Antibody NIBSC
SY/T8/- ^ GBarts HCG LH FSH HCG a HCG 3
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FIGURE 4.8 Binding of monoclonal antibodies to 
solid phase TSH in the presence of 
TSH (Barts).
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FIGURE 4.12 Relative binding of mouse anti TSH to 
solid phase TSH in the presence of 
HCG •  — •  ; and subunit a — a  ; 
and 3 subunit o — o
c) Antibody a ffin ity
The antibody antigen binding is a reversible reaction which obeys the law 
of Mass action:
• k i
Ab + Ag   AbAg (1)
k2
Ab = antibody, Ag = antigen, k^  and k2  = forward and reverse reaction 
rates respectively.
At equilibrium therefore:- K = k^/k£ = [AbAg]/[Ab][Ag] (2)
The rationale of the experimental procedure was based on the Scatchard
(1949) transformation of the above relationship to give the following
equation. .
[Ab]bound/[Ab]free[Ag]total = sKi -  ([Ab]bound/[Ag]total) Kin (3)
where K = the equilibrium binding constant; while s and n are the valency 
of the antigen and antibody respectively.
The expression was rewritten:
[Ab]bound/[Ab]total -  [A]bound = (sKi[Ag]total)-([Ab]bound Kin) (4)
This expression formed the basis of the determination of the binding 
constant described by Frankel and Gerhard (1979). The equation requires that 
only antibody bound and antibody total quantities be known and providing the 
antigen concentration is kept constant which i t  is in the solid phase, then
the absolute concentration is not required to be known.
The amount of antibody bound ([Ab]bound) at each dilution was derived by 
extrapolation to the linear standard calibration curve of known antibody 
concentration. The antibody total ([Ab]total) was taken as the maximum 
antibody bound at maximum antigen concentration derived for one antibody 
dilution. At this increased antigen concentration in the assay wells 99% of 
antibodies with equilibrium constants greater than 4 x-10^M~  ^ and 95% with 
equilibrium constants greater than 9 x 10^M“* w ill be bound (Frankel and 
Gerhard 1979). The total antibody in the other dilutions was then calculated 
in relation to that antibody d ilution.
The results of the binding experiments are presented in figure 4.13 and 
4.14. These figures show that at between 300 and 500 ng antibody added per 
well, the antigenic sites were saturated under the experimental conditions.
A plot of [Ab]bound/[Ab]total-[Ab]bound vs [Ab]bound yield a slope of -2K 
for a bivalent antibody. Figure 4.15 is the Scatchard plot of the data,
linear regression analysis of which yields the equilibrium constant values 
out!ined in Table 4.6.
TABLE 4.6
Linear regression analysis of Scatchard plots data allows determination 
of slopes— -2K and hence equilibrum binding constants K.
Hybridoma Antibody 
Supernatant
Equilibrum 
Constant K(M )
SY/T8/1 7.31 ± 0.23 x 1010
SY/T8/2 2.37 ± 0.29 x 1011
SY/T8/3 8.15 ± 0.31 x 1010
SY/T8/4 5.25 ± 0.13 x 1010
SY/T8/5 5.04 ± 0.19 x 1010
SY/T8/6 1.13 ± 0.41 x 1011
d) Antibody classes
Precipitation lines were observed with a ll of the ascitic flu id
preparations and the neat anti-IgG 2 a and anti k anti sera.
Precipitation reactions were also found with the ammonium sulphate 
precipitated and concentrated supernatant and the neat IgG2 a and k anti sera. 
The results are presented in Table 4.7.
The antibody class IgG was confirmed in a newly published procedure (Kohn 
1984).
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ELISA of supernatant from monoclonal antibody cultures. 
200 yl of each supernatant dilution was added to a 
series of wells coated with 1 yg/ml TSH. SN1 ( • - • ) ;
SN2 (□-□); SN3 (o-o).
The antibody total was obtained in relation to that 
bound at maximum antigen concentration.
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14 ELISA of supernatant from monoclonal antibody cultures. 
200 yl of each supernatant dilution was added to a 
series of wells coated with 1 yg/ml TSH. SN4 (■-■);
SN5 (a - a ); SN6 (a - a ) .
The antibody total was obtained in relation to that 
bound at maximum antigen concentration.
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FIGURE 4.15 ELISA binding data from monoclonal antibody supernatants 
1-6. Data from figure 4.15 and 4.16 replotted in the 
modified Scatchard form. Linear regression analysis of 
the data yields slopes “ 2k.
SN1 ( • - • ) ;  SN2 (□-□); SN3 (o-o); SN4 (■-■); SN5> - * ) ;  
SN6 (a - a ) .
TABLE 4.7
Ouchterlony immunodiffusion analysis of the monoclonal antibodies 
SY/T8/1-6. + =  precipitation lines; -  = no precipitation lines formed
Monoclonal
antibody
Antimouse immunoglobulin
y k X G1 G2a G2b G3 A
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.2 Electrophoretic Analysis Of Monoclonal Antibody Protein
o
Figure 4.16 and 4.17 are photographic records of (Jpmassie Blue stained 
SDS-PAGE electrophoresed reduced and unreduced supernatant samples; and auto­
radiographic development of the biosynthetically radiolabelled antibodies 
respectively.
No heavy chain was observed to be secreted by NSI in Figure 4.17 as no 
radiolabelled protein tracks were observed in the extracellular flu id . The 
internally labelled protein solution however showed several bands one of 
which coincided with the L-chain band in the reduced sample of the purified  
sheep IgG sample track, figures 4.16 and 4.17. This also identified the L 
and H chain bands of the monoclonal antibodies reduced sample. The specific 
antibody /binding activ ity  may therefore be assigned to the occurence of new 
H and L chains. These band positions were also confirmed by the mobility of 
the samples in relation to the standards (see figure 4.16).
No myeloma H chains were expected or observed so a ll H chains must be of 
spleen cell origin the only contaminant chain expected was the NSI synthe­
sized k chain which was shown to be minimal. A lengthy incubation period was 
required for these bands to show up by autoradiography.
NSI extra ce llu la r  
f l  uid
NSI intra ce llu la r  
protein solution
STANDARD
origin
NSI extra ce llu la r  f lu id
NSI in tra  ce llu la r  
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Purified sheep IgG 
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FIGURE 4.16
10% SDS-Page analysis of reduced and unreduced supernatant samples. 
Gel stained withcoomassie blue and vacuum dried onto f i l t e r  paper.
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FIGURE 4.17
Autoradiography of polyacrylamide gel after electrophoresis. 
Biosynthetically labelled monoclonal antibody and NSI in tra -c e llu la r  and 
extra-cellu lar flu ids.
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3 Antigenic Determinant Specificity
In order to radioiodinate the monoclonal antibodies the various
preparations were purified by Protein A chromatography. The elution profiles
obtained are presented in figures 4.18 - 4.20 and the elution of the peak
protein in each case at pH4.5 is consistent with the antibody classes being
^ a -
There was some additional protein eluted at pH5.5 from ascitic flu id  1-4 
this was probably contaminant mouse immunoglobulin against the hybridoma 
ce lls . This was however not confirmed. The specific antibody was confirmed 
by the indirect ELISA to reside in the pH4.5 eluted peaks.
The monoclonal antibodies so purified were each radioiodinated.
Radioiodination of the antibodies did not appear to interfere with' th e ir  
binding to the antigen.
The mean of the wells containing labelled antibody in which the 
unlabelled antibody was replaced by assay diluent buffer was taken as the 
100% total binding. The other test ac tiv ities  were then expressed re lative
to these thus:-
Relative % Inhibition in the presence of unlabelled antibody =
(1 - x CPM bound in test wells ) 100
x CPM in total binding wells )
The results presented in table 4.8 suggest that there is some in te rfe r­
in g  interaction between all the labelled antibody binding the solid phase 
antigen and the unlabelled antibodies. The main inference may be that they 
a ll may bind the same antigenic determinant resulting in the reciprocal 
inhibition observed although the degree of inhibition is variable. This 
however is by no means entire ly  substantiated and the results may have any of 
several other interpretations.
For instance the binding of any of the unlabelled antibody may cause the 
alteration of the configuration of other antigenic; determinants thereby 
resulting in reduced binding by the labelled antibody. On the other hand the 
binding of the unlabelled antibody may cause steric hinderance to the binding 
of the labelled antibody because the antigenic determinants are not identical 
but very close. One distinct feature of these competitive binding results is  
that the labelled SY/T8/4 is inhibited to a lesser extent by the other 
unlabelled antibodies. Unlabelled SY/T8/2 however inhibited SY/T8/6 by 93.3% 
much greater than the inhibition of labelled SY/T8/2 by the unlabelled
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SY/T8/2. This would suggest either that 6  bound the same antigenic 
determinant as 2  but with a greater a ffin ity  or the labelling procedure has 
altered the binding site  of 6  su ffic ien tly  to decrease binding efficiency to 
the antigenic determinant. The nonspecific binding in all cases was very low 
<3.0%.
TABLE 4.8
Epitope binding specific ities determined by competition of labelled and 
unlabelled monoclonal antibodies. The results were expressed as percentage 
(%) inhibition compared to the binding in wells in which the unlabelled 
antibodies were replaced with assay diluent. These were taken as 100% total 
binding.
Unlabelled
monoclonal
antibodies
SY/T8 / -
• ^ 1 -monoclonal antibodies SY/T8 / -
1 2 3 4 5 6
Relative % inhibition
1 6 6 . 0 63.4 63.7 20.5 44.9 64.8
2 57.3 63.2 60.4 21.4 55.6 74.2
3 66.7 75.9 74.75 35.2 62.2 27.0
4 23.9 32.4 39.8 62.3 49.6 29.4
5 54.2 62.8 61.0 51.4 66.9 32.1
6 62.4 93.3 21.4 23.4 35.4 74.2
DISCUSSION AND CONCLUSIONS
All the monoclonal antibody producing hybridomas gave high t i t r e  antibody 
preparations as measured by ELISA solid phase RIA and standard liquid  
phases RIA.
The antibodies were shown to be highly specific for binding with 
TSH(Barts) ant1*9en» No crossreactivity was observed with SY/T8/1, 2, 3 or 6 . 
Antibody SY/T8/1 however did show an unexplained enhancement of binding to 
the antigen in the presence of HCG 3  subunit (figure 4 .8 ). SY/T8/4 showed
the greatest inhibition of binding to the solid phase antigen in the presence 
of a ll the hormones tested except the NIBSC HCG preparation where no cross- 
reactivity was observed.
One major observation was that none of the monoclonal antibodies could be 
displaced by the NIBSC TSH 68/38 standard (see figures 4.5 - 4.7) even when 
very large amounts were used. This situation was also observed in the liquid  
phase RIA kindly performed by Dr Teale, Clinical Biochemistry, St Lukes 
Hospital, Guildford, Surrey. He reported no displacement of the radio- 
labelled TSH by unlabelled TSH 68/38 standard in assays set up using diluted  
ascitic flu id .
Because this characteristic was observed in both the ELISA and RIA using 
cell supernatants and ascitic flu id  as the antibody preparations respect­
ive ly, i t  was concluded that the results could not be due to the assay 
conditions which prevented the antibodies binding TSH 68/38. - I t  was 
concluded therefore that the antigenic determinants to which the antibodies 
were specifically directed could not be present at least in suffic ient 
numbers in TSH 68/38 standard to be detected above the background.
TSH 68/38 could not therefore be used to set up an assay using these 
monoclonal antibodies. The TSH(Barts) an ti9 en which was used to prepare the 
spleen c e ll, calibrated against TSH 68/38 in a liquid phase RIA (see 
Chapter 2) was therefore used as standard in the ELISA (Chapter 5 ).
A ll’ the monoclonal antibodies were found to be IgG£a with very high 
a ffin itie s  of between 5 x 10^  and 2.37 x lO **. The high a f f in it ie s  meant 
they _ could possibly be useful in immunocytochemical procedures where high 
a ffin ity  specific antibodies are required.
High a ffin ity  antibodies are not so c ritic a l in immunometric type assay 
as was proposed. The antibody in such assays are usually added in excess 
thereby ensuring complex formation. Conditions influencing the equilibrium  
of reaction therefore have very limited effects in such assay systems 
(Ekins 1981).
There was no evidence of antibody contamination by the myeloma k ligh t 
chain. But the case of internal labelling of the monoclonal antibodies was 
demonstrated. On the other hand they could also be radiolabelled with
relative ease and s t i l l  retained antigen binding capacity.
Although the antibody protein in supernatants was contaminated by only 
a minimal amount of foetal calf immunoglobulin and was therefore very pure, 
the preparation nevertheless contained serum proteins. For some purpose such 
as radioiodination the antibody needed to be purified. The ease and 
efficiency of protein A purification was demonstrated, and the antibody 
binding capacity did not appear to be diminished by the treatment.
The antibodies a ll appeared to bind the same epitope with the possible
exception of SY/T8/4 (table 4 .8 ). I f  this epitope is absent or diminished-on
the TSH 68/38, this then would explain the lack of binding of any of the 
antibodies with that TSH preparation.
From the results of characterization SY/T8/2 with the highest a ff in ity  
was chosen to set up the ELISA; and all the monoclonal antibodies were
demonstrated in the immunocytochemistry procedure.
CHAPTER 5
Applications of Monoclonal 
anti-human-TSH Antibodies
INTRODUCTION
Antibodies specific to h-TSH have been derived and used in two main areas 
of TSH investigations. They have been used to describe by immunocytochemical 
procedures the localization of the particular hormone secreting cells in the 
pitu itary gland (Phifer and Spicer 1973, Nakane 1970, Tangard et al 1980). 
All six monoclonal antibodies which have been characterized have been used in 
an indirect immunoperoxidase technique to demonstrate the occurrence of the 
antibody specific determinants in various p itu itary and other tissue 
sections. The second important application has been th e ir use in specific 
quantitation of h-TSH in body.fluids (Odell and Utiger 1973, Hall et al 1971, 
Miyai et al 1976, John and Woodhead 1982). One monoclonal antibody was 
therefore selected and used to develop an enzyme linked immunosorbent assay 
for h-TSH.
Immunocytochemical Demonstration Of Thyrotropic Cells
The hypophysis is located at the base of the brain. I t  is a small gland 
weighing about 0.5g. I t  is linked in a feedback system of actions with the 
endocrine organs i t  controls, and the neurosecretions by which i t  is 
controlled (Labrie et al 1979).
The unequivocal identification of the individual hormone secreting cell 
types is the primary objective of p itu itary immunochemistry. The c la r if ic a ­
tion of the functional classification and nomenclature of the various cell 
types have only been achieved with immunocytochemical techniques. The 
correlation of the tincto ria l cell types (Bloom and Fawcett 1975) with 
immunocytochemical identification is well documented (Halmi and Morianty 
1977, Nakane 1970 and 1975, Kovacs et al 1981).
The thyrotropic cells
Histologically these cells were described as basophils which were 
preferentially distinguished from acidophils by th e ir pink staining with the 
periodic acid-schiff (PAS) reaction. Thyrotropes however have been 
distinguished from the other basophils: the gonadotropes, by the selective
staining of their granules with aldehyde fuchsin (Bloom and Fawcett 1975).
Immunocytochemical identification of thyrotropes have to the present time 
been performed exclusively with polyclonal anti sera to thyroid stimulating 
hormone (Phifer and Spicer 1973). These antisera have of course carried the 
inherent disadvantages of cross reactivity to the gonadotrophic glycoproteins 
described in Chapter 1. Much of the d iffic u lty  was however eliminated with 
the use of antisera to the 3 -subunit of the hormone (Tougard et al 1980, 
Baker and Yu 1971). These procedures together with electron microscopic 
studies (Nakane 1975) have confirmed the polygonal or stella te shape of 
thyrotropes arranged in clusters in the center of the cord. Their glandular 
distribution is depicted in figure 5.1. Although most descriptions of these 
cells have been derived primarily from studies on rat p itu itaries (Nakane 
1970, 1975, Baker 1974) they are similar to those of other species. Human
thyrotropes have however been described (Phifer and Spicer 1973, P e lle tie r et 
al 1978, Mori arty and Tobin 1976).
A comprehensive description of p itu itary immunocytochemistry is given by 
(Petrusz and Ordronneau 1983) and immunocytochemistry generally by 
Sternberger (1979), Polak and Van Noorden (1983).
A well characterized monoclonal antibody in terms of specific ity  and 
a ffin ity  provides the means of overcoming the persistent cross reactiv ity  
problems of a polyclonal anti sera. Low a ffin ity  monoclonal antibodies may 
however lim it th e ir application here. Since only a single species of 
antibody is contained in the antibody preparation i t  may be easily eluted 
during the procedure and so specific binding may be lost. This is unlike the 
situation occurring in a heterogeneous polyclonal antibody preparation where 
accidental elution of low a ffin ity  antibodies would not affect the specific 
binding of the remaining high a ffin ity  antibodies. High a ffin ity  monoclonal 
antibodies are therefore a p rio rity  for this purpose.
The importance of p itu itary immunocytochemistry is by no means lim ited to 
characterizations in the normal gland, but are of c ritic a l importance in 
identifying p itu itary  tumors (Heitz 1983) and in the localization of 
pitu itary hormones as non pituitary tumor markers(Heyderman 1983).
Pars
Nervosa
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FIGURE 5.1
Distribution of human thyrotropic cells in mid horizontal cross section 
of the pitu itary gland. Dense dots along the anterior edge of the gland 
represents the most intense concentration of the ce lls . They occur in 
variable amounts within the anteromedial portion (Adopted from Phifer and 
Spicer 1973).
-5.1.2 ELISA
Several modifications of ELISA procedures have been described for the 
detection and measurement of antigens (Voller 1979). These include as for 
RIA procedure, the competitive type’ of assay (Avrameas and Guilbert 1971, 
Engvall and Perlmann 1971, Van Weeman and Schuurs 1971 and 1972) and the non­
competitive binding assays (Engvall and Perlmann 1972, Maiolini and Masseyeff 
1975, Guesdon and Avrameas 1977).
Avrameas (1981) suggested that for the measurement of multivalent 
antigens they found the non-competitive assays more sensitive. The 
additional advantages of such assays were that they were more robust, less 
expensive in terms of precious antigen and as such were more suitable for 
routine work. This type of assay also requires labelled antibodies which 
were universal reagents described in Chapter 2, instead of the labelled 
antigen of the competitive system.
Consequently we attempted to set up double antibody sandwich non­
competitive ELISA for measuring h-TSH. This was described diagramatically in 
figure 5.2.
FIGURE 5.2
Double antibody sandwich ELISA for measuring antigens
STEP 1
Wash x 3
PBS Tween + 0.1% BSA
STEP 2
T S H
2  hour incubation
Antibody A adsorbed 
to polyvinyl chloride 
plates(monoclonal Ab),
Test antigen sample 
added.
Incubated overnight
Wash x 3
STEP 3
Wash x 3
Add specific 
antibody B. 
Incubate 2 hours
STEP 4
Wash x 3
STEP 5
Add enzyme labelled  
anti-B antibody. 
Incubate 2 hours
Add enzyme substrate 
OPD.
Incubate 30 mins.
adopted from Voller et al 1979.
5.2 MATERIALS AND METHODS
5.2.1 Tissue Preparation
Four human pitu itary autopsy specimen preparations, and other tissue 
preparations including human kidney, placenta and gut were all kindly 
supplied by Professor Gibbs, Pathology Dept., Royal Surrey County Hospital, 
Guildford. The tissue preparations were,all supplied as formalin fixed, 
paraffin embedded blocks and some mounted sections.
The baboon pituitary sections were kindly supplied by Dr J Drake, 
University of Surrey, Guildford; as Bouins fixed mounted sections. They were 
derived from young females.
The dog p itu itary sections were kindly supplied by Dr J Hooson, Wyeth 
Laboratories, Burnham, Bucks; as formalin fixed, paraffin embedded mounted 
sections.
The rat and ferret p itu itary preparations were kindly supplied by Miss 
J Howarth, Pathology Lab., University of Surrey, Guildford; as formalin fixed 
paraffin embedded sections. These sections were cut and mounted as described 
below.
Cutting sections
Additional human pitu itary and other tissue sections were cut from the 
blocks at a thickness of 6  y using an American Optical Spencer 820 rotary 
microtome. The sections were floated on d is tille d  water kept at 50°C until 
the creases disappeared. The sections were then mounted by dipping the clean 
slide into the water. By withdrawing i t  the thin section was drawn onto the 
slide. The slides were then dried on a hot plate after which they were 
stored overnight in 37°C incubator. The slides were then packed and stored 
at room temperature until required. The mounted sections supplied by 
Professor Gibbs Dept were cut and mounted as described above (Verbal 
communication: Mr P Jenkins, Pathology Dept. Royal Surrey County Hospital,
Guildford).
Histological staining
Periodic Acid Schiff (PAS) stained sections of the 4 human p itu itary  
preparations and haematoxylin eosin stained sections were kindly supplied 
(Mr P Jenkins, Royal Surrey County Hospital, Guildford). In addition PAS 
sections and haematoxylin eosin stained sections of the rat and ferret p itu i-  
taries were prepared by Miss J Howarth, Pathology Lab, University of Surrey).
.2 Immunocytochemical Procedure
Since neither the monoclonal antibodies nor the enzyme-linked second 
antibodies had previously been used in this procedure, then a range of 
dilutions of the two antibody preparations had to be investigated to find the 
most effective combinations. A variety of techniques have been described
(Van Noorden and Polak 1983, Sternberger 1979). The technique used in this 
study is the indirect method. This is regarded as more sensitive than the 
direct method and the second enzyme-labelled antibody can be used to locate a 
variety of antigens provided the primary antibodies are obtained from the 
same species.
Reagents
1) Buffers: 0.025M Tris saline buffer pH7.6
9.1g Tris (hydroxymethyl) ami noethane (Sigma London Chemical Co Ltd, 
Poole, Dorset) was dissolved in 750 ml d is tille d  water;
25.5g Sodium Chloride was added and mixed thoroughly.
The tr is  saline solution was titra ted  to pH7.5 with I.OM HC1. Then the 
volume was made up to 3.0 litre s  with d is tille d  water. Finally the pH 
was adjusted to pH7.6. (Buffer may be kept for up to one month stored 
at 4°C.)
2) C itrate Acetate buffer pH5.0
5.3g c itr ic  acid (BDH Chemicals Ltd, Enfield) was dissolved in 500 ml 
d is tille d  water
12.Og Ammonium acetate (BDH Chemicals Ltd, Enfield) was dissolved in 
3 litre s  d is tille d  water. The c it r ic  acid solution was added to the
ammonium acetate solution until the pH was 5.0. (This buffer was also 
kept at 4°C for one month.)
Peroxidase blocking solution
This was made up of 120 ml hydrogen peroxide (H2 O2 ) (30% w/v) (BDH 
Chemicals Ltd, Enfield), and 200 ml methanol (BDH Chemical Ltd, Enfield).
This peroxide blocking solution was made up fresh every two days. I t  was
used to block endogenous peroxidase ac tiv ity  in the tissue sections which 
could cause non specific staining effects.
Chromogen
The chromogen solution consisted of 340 ml c itra te  acetate buffer pH5.0 
in which was dissolved 125 mg 3 .3-diaminobenzidine tetrahydrochloride (DAB) 
(supplied by BDH Chemical Ltd, Enfield), and fin a lly  200 yl hydrogen peroxide 
was added. (Note: DAB is said to have possible carcinogenic properties
therefore extra care was taken in handling the material.)
Sera
1) 1% (v/v) normal goat serum (Guildhay) in Tris-saline.
2) 1% (v/v) normal donkey serum (Guildhay) in Tris-saline.
3) Monoclonal antibodies as ascitic flu id  preparations were diltued 1:50 
up to 1:500,000 in Tris saline buffer containing 1.0% normal goat or donkey 
serum. (Normal goat or normal donkey serum was used with the corresponding 
goat or donkey HRP0 conjugate.)
4) Goat anti-mouse HRP0 conjugate I was diluted 1:20 to 1:100 in tr is  
saline buffer.
5) Donkey anti-mouse HRP0 conjugate I I  and I I I  were diluted 1:4 up to 
1:64.
Protocol
The preliminary experiments were set out after the protocol outlined 
below in Table 5.1.
TABLE 5.1
Human pitu itary sections were incubated with the monoclonal antibodies 
and conjugate dilutions cross matched (af) etc.
Goat anti- Monoclonal antibody dilutions
mouse HRP0 
Conjugate I a
1:50
b
1:250
c
1:500
d
1 : 1 0 0 0
e
Buffer control
f .  1 : 2 0 af bf cf df ef
g. 1 : 1 0 0 ag bg eg dg eg
The sections were dewaxed by soaking for 10 minutes in xylene followed by 
progressive rinsing in alcohol 100%, 75% and 50% (v/v) in d is tille d  water for 
1 minute each, and fin a lly  to d is tille d  water for 1 minute.
The dewaxed sections were then soaked for 10 minutes in gently running 
tap water, followed by soaking for 1 0  minutes in the peroxidase blocking 
reagent.
The sections were washed for a further 10 minutes in gently running tap 
water. Care must be taken not to dislodge the sections from the slides.
The excess water was removed by tapping the slides on clean tissue paper. 
Then 200 yl of 1.0% normal goat serum or normal donkey serum was spread 
carefully over the tissue sections with a bent Pasteur pipette. These were 
incubated at room temperature for. 30 minutes.
The excess liquid was then removed by tapping the slides on edge. 200 yl 
of the appropriate monoclonal antibody dilution was then spread evenly over 
the sections which were incubated overnight in a humidifed slide box in the 
cold room at approximately 4°C.
The slides were then washed twice by squirting tr is  saline buffer onto 
them and leaving for 1 0  minutes between each wash.
- The tissue free areas of the slides were dried and 200 yl of the 
appropriate dilution of the second antibody, goat or donkey anti-mouse HRP0 
conjugate was evenly spread over the sections. These were incubated at room 
temperature for 2  hours in the humidified slide box.
Following 2 x 10 minutes washes with tr is  saline buffer the slides were 
immersed in the chromogen solution for exactly 3 minutes at room temperature.
They were washed for 10 minutes in gently running tap water, followed by 
counter staining with haematoxylin. At each successive stage, care was taken 
to ensure that the tissue sections did not dry out since this would increase 
the background.
Haematoxylin staining and mounting
The sections were placed in Ehrlich's acid haematoxylin (supplied by
R A Lamb Ltd) for 15 minutes. They were then gently washed in running tap 
water for 5 minutes, followed by d ifferentiation in acid alcohol (consisting 
of 1% (v /v ), hydrochloric acid in 70% (v/v) alcohol) with gentle agitation
for about 5 seconds.
The sections were again rinsed in running tap water for 2 minutes and
examined by low power microscopy to ensure sufficient d ifferen tiation .
The sections were rinsed fin a lly  for 15 minutes in tap water and
progressively dehydrated by passing through 70% (v/v) alcohol followed by 
100% alcohol twice for 30 seconds each time. They were then cleared in two 
changes of xylene for 30 seconds. The sections were mounted by placing one 
drop of DPX (BDH Chemicals Ltd, Enfield) mountant onto a clean coverslip and
inverting a slide taken d irectly  from the xylene on to the coverslip and 
pressing down so that the mountant spread evenly over the coverslip and 
tissue section and excluded all a ir  bubbles.
The slides were then ready for microscopic examination. In a l1 succeed  ^
ing batches a human pituitary section processed with 1 : 1 0 0 0  dilution of the 
monoclonal antibody and 1:20 dilution of-the goat anti-mouse conjugate I or 
1:8 dilution of conjugate I I I  was included as positive re lia b ility  control of 
the method. In addition, the negative control sections were prepared in
which normal nonimmune mouse serum was used at the same dilution as the
positive sera or positive sera was replaced with buffer solution, and binding
indicated with 1 : 2 0  dilution or 1 : 8  dilution of the appropriate conjugate.
Adsorption controls
Two adsorption procedures were tried .
1) Liquid phase adsorption was attempted by diluting the monoclonal 
antibody 1:32000 and incubating with 10 yg TSH at 4°C for 24 hours the 
solution was then used in the indirect immunochemical staining procedure
(Van Noorden and Polak 1983, Waiilstrom et al 1981).
2) Solid Phase adsorption. This was kindly done by Dr R Edwards, NETRIA
St Bartholomew's Hospital, London. They prepared the purified h-TSH used in 
the course of the work; and have available a TSH immunoadsorbent column. The 
ascitic flu id  preparations were returned as freeze dried samples derived from
10 ml eluate in 0.05M phosphate buffer. This was a 1:20 dilution of the
original sample. These immunoadsorbed preparations were used for staining 
controls (Van Noorden and Polak 1983).
3 Two Site ELISA I
For this ELISA procedure i t  was proposed to use a sheep anti-h-TSH
antisera as one side of the sandwich and the selected specific monoclonal 
antibody on the other. The high specific ity  of the sheep anti sera was not 
c ritic a l since the specificity of the assay system was expected to be 
provided by the monoclonal antibody. An enzyme-linked immunosorbent assay 
has been described by Wada et al 1982 in which anti-a-subunit monoclonal 
antibodies were used as solid phase capture antibody for three of the 
glycoprotein hormones TSH, LH and HCG. The enzyme conjugated monoclonal 
a n ti-3 -subunit antibody specific to each hormone provided the required 
specific ity for the assay.
Sheep anti-h-TSH
Sheep anti-h-TSH batches (HP/S/1001-18.11.81) and (HP/S/1001-11.12.81) 
were kindly supplied by Guildhay, University of Surrey. The anti sera had 
been stored at 4°C with 1.0% sodium azide added as preservative.
Purification of sheep anti-h-TSH ?
Both antisera preparations were purified by diethyl ami noethyl (DEAE) 
cellulose ion exchange chromatography after ammonium sulphate fractionation. 
Buffers:-
1) 0.3M Phosphate buffer pH7.3 made up as follows:
160g - di Sodium hydrogen phosphate (^HPO^);
51g - Potassium di-hydrogen phosphate (KH2 PO4 ) and 
18.6g - Ethylenediaminotetra-acetic Acid di-sodium salt (Na2 EDTA.2 H2 0 ) were 
dissolved in 5 lit re s  of d is tilled  water..
2) 0.03M Phosphate buffer pH7.3 consisted of a 1:10 dilution of 0.3M 
Phosphate buffer.
a) Ammonium sulphate purification
1 0 0  ml of each antisera was precipitated with 60 ml saturated ammonium 
sulphate as described previously section 2.2 .1 . Each precipitate was 
redissolved to a volume of 40 ml in 0.03M Phosphate buffer pH7.3 followed by 
extensive dialysis against several changes of 0.03M Phosphate buffer. 
Finally the preparations were spun down on the bench MSE centrifuge for 
5 minutes, and the supernatant collected and stored at 4°C until required.
b) DEAE cellulose ion-exchange chromatography
A column 25 cm x 2.5 cm packed with DEAE cellulose was available by the
kind courtesy of Guildhay, University of Surrey, Guildford.
The column was extensively eluted with several volumes of 0.3M phosphate 
buffer pH7.3. The pH of the eluate was checked and the column was equli- 
brated until the eluate pH was equal to the loading buffer.
Two volumes of 0.03M Phosphate buffer was then washed through the column. 
The ammonium sulphate prepared fraction was loaded carefully on top of the
column, which was then eluted with 0.03M phosphate buffer pH7.3. The eluate
was collected in 8  ml fractions.
Regeneration of the column was achieved by elution with 0.3M phosphate 
buffer pH7.3 followed by two volumes of 0.1M sodium hydroxide to remove any 
bound lipoproteins. Finally the column was again eluted with 0.3M phosphate 
buffer to return to the starting pH of 7.3.
The protein content of the fractions was monitored on the Cecil CE292 
spectrophotometer at 280 nm. The protein peak fractions were pooled, 
dialysed against 0.15M phosphate buffered saline (PBS) pH7.4. The volume was
made up to that of the original serum. An aliquote was taken to assess the
immunoreactivity. The protein content was determined by the Lowry et al 1951 
method (Chapter 2) and then diluted to give 10 mg/ml. This was stored at 4°C 
with 0 . 0 1 % (w/v) thimerosol as preservative.
Assessment of immunoreactivity of sera
A liquid phase RIA was use to determine the immunoreactivity of the DEAE 
purified antibody preparation compared to the neat unpurified anti sera. This
was set up according to the following protocol (Table 5 .1 ). (Dr S Hampton,
Guildhay, University of Surrey, personal communication).
TABLE 5.2
Dilutions of the sera used in the assessment by RIA of DEAE -  purified  
sheep anti-h-TSH antibody compared to the neat antiserum
1st Antibody Sheep 
anti-h-TSH
In it ia l normal sheep 
serum dilution
In it ia l 2nd antibody 
Donkey anti-sheep
1 : 1 k 1 : 1 2 0 0 1 : 8  ( 1 0 0  y l )
1 :2 k ( 1 0 0  y l ) 1:16 "
1:4k ( 1 0 0  y l )  . 1:32 "
1 :8 k ( 1 0 0  y l ) 1:64 "
1:16k ( 1 0 0  y l ) 1:128 "
1:32k ( 1 0 0  y l ) 1:256 "
1:64k ( 1 0 0  y l ) 1:512 "
1:128k ( 1 0 0  y l ) 1:1024 "
Each f ir s t  (1st) antibody preparations were assayed in duplicate at each
dilution. -^I-TSH (kindly supplied by Dr D Teale, Biochemistry Lab, St
Lukes Hospital, Guildford) was diluted 1:40 in d is tille d  water and 100 yl of 
this containing approximately 110 pg was added to each LP3 assay tube. The 
specific ac tiv ity  of the preparation was 80 yCi/yg. The normal sheep serum 
and precipitating donkey anti-sheep antisera were both kindly supplied by 
Guildhay, University of Surrey, Guildford. Two non specific binding tubes 
containing 100 yl RIA assay diluent and hormone label were set up and the 1:8 
dilution of the second antibody was used in the nonspecific binding tubes.
This procedure was used as a speedy assessmentof the binding of the
purified antibody preparations as compared to the unpurified antisera.
Assessment of solid phase adsorption of sheep anti-h-TSH
The solid phase adsorption of purified sheep anti-h-TSH to polyvinyl 
chloride microtitre plates (Dynatech Ltd) was assessed.
Sheep anti-h-TSH preparations DEAE-cellulose purified (batch HP/S/1001- 
11.12.81) and diluted in 0.15M PBS pH7.4 to 10 mg/ml protein stock solution.
This solution was seria lly  diluted 0,2.5,5,10,20,40 and 80 yg/ml with
ELISA coating buffer, and 200 yl of each dilution was added to four wells. 
The ‘O' wells contained 200 yl coating buffer alone. These were incubated 
for 2 hours at 37°C a fter which the wells were washed three times with ELISA 
washing buffer and 100 yl -^ I-TSH consisting of about 100 pg TSH with 
specific ac tiv ity  of 80 yCi/yg was added to each well and incubated for
2 hours at 37°C. The wells were then alternately aspirated and washed 
carefully three times. The wells were then a ir dried.
Negative binding wells were set up with normal sheep serum diluted as for
the sheep anti-TSH anti sera.
The optimum adsorption time was determined by incubating 200 yl/ml 
purified sheep anti-h-TSH or normal sheep sera for various time intervals  
between 2 and 24 hours. The wells were then washed three times as described 
and 100 yl of the ^ 5 I-TSH was added and incubated for 2 hours at 37°C. 
Finally the radioactive contents were aspirated from the wells which were 
washed carefully three times.
The wells were then a ir dried and separated using a plate cutter designed 
in the University workshop. The cut out wells were placed in LP4 tubes 
(Luckham Ltd, Burgess H i l l ,  Sussex) and counted for 100 seconds on 1260 LKB 
multi Gamma I I .
Titration  of sheep anti-TSH and monoclonal antibody
Polyvinyl chloride micro-ELISA wells were coated with 0,2 .5 ,5 ,10 ,20 and 
40 pg/ml DEAE-cellulose purified sheep anti-TSH as described, above. After a 
2 hour incubation at 37°C the wells were washed three times. 150 pi of 
125;mU/l TSH(garts ) was added to each well and incubated overnight at 4°C. 
After washing, 200 pi of ascitic flu id  SY/T8/2 or normal mouse sera diluted 
between 1:200 to 1:51200 was added to appropriate wells in a cross t it ra t io n  
pattern (see table 5 .3 ). Each dilution was assayed in quadruplicate. These 
were incubated for 2 hours at 37°C after which 200 pi of 1:1600 dilution of 
donkey anti-mouse horseradish peroxidase conjugate I I  was added and incubated 
.fo r 2 hours at 37°C. After careful washing three times the chromogen 
solution was added as in Chapter 2. This was incubated for 30 minutes after 
which the enzyme-activity was stopped and the optical density read.
TABLE 5.3
Cross t itra tio n  of sheep anti-TSH and the monoclonal antibody 
NSB = nonspecific binding, these contained normal sheep serum
Sheep anti-TSH 
antibody pg/ml
Monoclonal antibody ascitic f lu id /  
normal mouse serum (NMS) dilution
0 1:200 1:400 1:800 1:1600 etc.
0
NSB 0 150 pi of 125mU/l TSHjBartsj in each well
2.5 
NSB 2.5
5.0 
NSB 5.0
200 pi Donkey anti-mouse HRP0 conjugate in 
each well
1 0
NSB 10 
etc.
Titration of monoclonal antibody and enzyme conjugate
200 pi of 40 pg/ml sheep anti-TSH in coating buffer was incubated in a ll
walls of polyvinyl chloride micro ELISA plates. After 2 hour incubation at 
37°C the wells were washed and 150 pi of 125mtl/l TSH(garts) was added to each 
well which were incubated overnight at 4°C followed by washing three times 
after which various dilutions 1:200 to 1:51200 of ascitic flu id  SY/T8/2 was 
added to the wells. These were incubated for 2 hours at 37°C followed by 
washing and 200 pi donkey anti-mouse HRP0 conjugate I I  was added to the wells 
as appropriate (see table 5 .4 ).
TABLE 5.4
Cross t itra tio n  of monoclonal antibody SY/T8/2 and donkey antimouse HRPO 
Conjugate I I .
Donkey anti-mouse HRPO 
Conjugate dilution
Monoclonal Antibody Ascitic Fluid 
0 1:200 1:400 1:800 1:1600 etc.
1:400
1:400
1:800 40 pg/ml sheep anti-TSH incubated in each well
1:800
1:1600 150 pi 125mU/l TSH -
1:1600 or "0" TSH was added to quadruplicate wells
1:3200
1:3200
A 1:200 dilution of normal mouse sera was incubated simultaneously with 
each conjugates dilution for non specific binding assessment.
The wells were fin a lly  developed with chromogen as previously described
and the optical density read.
Immunoradiometric investigation of monoclonal antibody binding
This method was a modification of Hales and Woodhead 1980.
40 pg/ml sheep anti-TSH was coated to polyvinyl chloride wells as
described above. 150 pi of various dilutions of TSH^gartsj (125 mU/1 to
0.48mU/l) was added to quadruplicate wells and incubated overnight at 4°C.
This was followed by washing and 200 pi ^^1 labelled monoclonal antibody 
(McAb) (see Chapter 4) was added according to the following:-
125I Me Ab =50 yg labelled
assuming 80% recovery = 40000ng in 2 ml
stored as 200 pi aliquots: = 4000 ng/aliquote
400 pi labelled antibody was diluted in 20 ml assay diluent
2 0 0  pi diluted label per well = 80.0 ng/well
11
= 3.0 x 10AA antibody molecules/well
The labelled antibody was added in excess of the amount of TSH added per
w e ll:-
12.5 ng/ml = 125mU TSH/litre  
200 pi per well = 2.5 ng/well
= 5.4 x 10^  TSH molecules/well
The amount of labelled antibody: the highest amount of TSH added per
well was therefore 5.6:1.
Additionally the TSH and labelled antibody were preincubated overnight 
before incubation in the wells containing the solid phased sheep anti-TSH
antibody to allow prior binding of monoclonal antibody.
4 Two Site ELISA I I
A suitable assay could not be derived with the sheep anti-TSH antibody as 
the solid phase antibody we therefore decided to reverse the antibody
sandwich for the reasons which are discussed in Section 5.4.
Assessment of solid phase adsorption of monoclonal antibody
Protein A purified monoclonal antibody (see Chapter 4) was double diluted 
1.25,2.5,5,10,20,40 and 80 yg/ml with ELISA coating buffer. The procedure
1 o r
was as described for sheep anti-TSH in the preceding section. ±^I-TSH  
added was approximately 110 pg/well with a specific ac tiv ity  of 100yCi/yg. 
Alternatively, to each well containing solid phase monoclonal antibody was 
added 200 yl of a 1:1600 dilution donkey anti-mouse HRP0 conjugate I I ,  and
the assay performed according to ELISA method A, Chapter 2.
ELISA I I
The enzyme conjugate was a donkey anti-sheep HRP0 conjugate kindly
supplied by Guildhay, University of Surrey, Guildford.
The sheep anti-TSH and the donkey anti-sheep HRP0 conjugate were cross 
titra te d  with 40 yg/ml protein A purified ascitic flu id  adsorbed to the wells 
and 125 mU/1 TSH(Bar t S) ac*ded t 0  eac  ^ well as described above. Sheep an ti- 
TSH was diluted between 1:1000 to 1:8000 and the donkey anti-sheep HRP0 was 
diluted between 1:250 to 1:32000. The procedure*was as described for the 
'Two-site' ELISA I above.
Time optimization studies
To investigate the influence of time on the binding of the various parts 
of the ELISA sandwich the following studies were undertaken:
1) Optimum time for monoclonal antibody adsorption on to m icrotitre plates.
2) Optimum time for antigen binding to solid phase antibodies.
3) Optimum time for sheep anti-TSH binding to the captured antigen.
4) Optimum time for donkey anti-sheep HRP0 binding.
Reagents
Protein A purified antibody SY/T8/2 at 40 yg/ml, 200 yl per well; 125mU/l 
TSH(Barts) was use(* at 150 yl per well; and sheep anti-TSH at 1:8000 dilution  
used at 200 yl per well; with donkey anti-sheep HRPO diluted 1:2000 and used 
at 2 0 0  yl/well for this series of experiments.
Procedure
1) The Monoclonal antibody solution was allowed to adsorb for
30 minutes, 1 hour, 2, 15.5, 17.5 and 19.5 hours on to m icrotitre wells. The
TSH antigen was then added and incubated for 2 hours followed by sheep an ti- 
TSH incubated for 2 hours and donkey anti-sheep incubated for 2 hours and 
f in a lly  the chromogen was incubated for 30 minutes. The ELISA 0 D4 gQ was 
then read.
2) The solid phase antibody was incubated for 2 hours followed by the
addition of h-TSH at various times allowing 30 minute, 1 hour, 2, 4, 15.5,
17.5 hours incubation. The remaining procedure was as described above (1 ).
3) The solid phase antibody was incubated fo r 2 hours followed by the
addition of TSH antigen and incubated overnight. The sheep anti-TSH was then 
added at various times to allow 30 minutes, 1 hour, 1.5, 2, 3 .5 , 5.5 hours 
incubation. The procedure was then completed as described above.
4) The solid phase antibody was incubated for 2 hours followed by
addition and incubation of h-TSH overnight, then sheep anti-TSH was incubated 
for 2 hours. Finally donkey anti-sheep HRPO was added at various times to 
give 30 minutes, 1 hour, 2, 3, 4 and 5.5 hours incubation times. Chromogen
was then added and incubated for 30 minutes.
I t  must be noted that careful washing procedure was always performed 
between each addition at each stage of the procedure (see figure 5 .2 ).
Standard curve
Standard curves were set up according to the following procedure:-
200 yl of a 40 yg/ml solution of protein A purified SY/T8/2 in ELISA 
coating buffer was incubated for 2 hours in each well. The wells were
emptied and washed carefully with ELISA washing buffer. Then various
dilutions between 0 and 250 mU/1 h-TSH^Bartsj was added at 150 y l/w e ll. 
These were incubated overnight at approximately 4°C. Three human TSH control 
samples were included in the assay:
Sample I low concentration = 1.9 - 2.5 mU/1
Sample I I  medium concentration = 7.1 - 9.1 mU/1
and Sample I I I  high concentration = 16.0 - 20.0 mU/1
The control samples were supplied by Dr D Teale, Biochem. Dept., St Lukes 
Hospital, Guildford. The samples were orig inally obtained from Environmental 
Chemical Specialists In c ., 3700 East Micaloma, Ca 92807.
The contents of each vial was reconstituted as recommended in 5 ml 
d is tille d  water.
After incubation .the wellswere emptied and washed, then 200 yl of a 
1:8000 dilution of sheep anti-TSH was added and incubated for 2 hours at 
37°C. The wells were again washed, 200 yl donkey anti-sheep HRPO was added 
diluted at 1:2000 and incubated for 2 hours at 37°C. Finally after washing 
the wells 200 yl of chromogen solution was added to each well and incubated 
for 30 minutes at 37°C following which the optical densities were read at 
490 nm.
A standard curve was also set up with this double antibody sandwich 
system using the standard TSH preparations and control TSH samples supplied 
as a part of the Dac-Cel TSH k it for TSH Radioimmunoassay (Wellcome 
Diagnostics, Wellcome Foundations Ltd, Dartford). The control sample TSH 
value was given as 14.5 ± 2.5 mU/1.
The standard curves were set up with the h-TSH standard diluted in ELISA 
diluent buffer and in Horse Serum 3 (HS38 supplied by Wellcome Reagents Ltd, 
Wellcome Foundation Ltd, Dartford). Horse Serum was recommended for use in 
place of TSH free human serum (Wood et al 1975) (personal communication 
Dr D Teale, Biochem. Dept, St Lukes Hospital, Guildford).
5.3 RESULTS
5.3.1 Immunoc.ytochemistr.y
Histological indications
The haematoxylin eosin stained sections were prepared for general
microscopic examination of the tissue. These showed typically  blue staining 
nuclei and bright pink staining cytoplasm. The integrity of the tissue 
preparations was demonstrated. The human p itu itary sections showed some post 
mortem deterioration exhibiting typical pycnotic nuclei. This was not
apparent in the rat or ferret preparations since they were fixed as fresh 
preparations. PAS positive cells were however clearly evident in the 
human preparations demonstrating the presence of basophilic cell types. 
These were demonstrated in figure 5.3. PAS and Haematoxylin eosin stained 
preparations of both the rat and ferret p itu itaries were prepared and results
for the rat are presented in figure 5.4.
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FIGURE 5.3 
Human Anterior P itu itary  Sections
a) Haematoxylin eosin stained
b) Periodic Acid Schiff stained
at xSOG magnification
a)
b)
FIGURE 5,4 
Rat P itu itary  Sections
a) Haematoxylin eosin stained
b) Periodic Acid Schiff stained
a t x 79 m ag n ifica tio n
In d ire c t immunoperoxidase sta in ing
All six ascitic flu id  monoclonal antibody preparations (SY/T8/1-6) gave 
strong staining reactions with the human p itu ita ries , at all dilutions up to 
1:500,000 with conjugate I diluted 1:20. The conjugate I was too dilute at 
1:100, and gave very l i t t l e  specific staining at any dilution of the primary 
monoclonal antibody. At 1:500,000 dilution the apparent intensity began to 
diminish s lightly , primarily for SY/T8/2.
A striking observation was that as the primary antibodies were diluted 
out so the intensity of staining appeared to increase. No non-specific
background staining was observed with any of the monoclonals and conjugate I 
(except when the preparations were allowed for whatever reason to dry out; 
care must be taken therefore to prevent this occurring during the procedure).
Conjugate I I  was diluted up to 1:64 but excessive background was observed 
at each primary antibody dilution although strong positive staining was also 
observed.
Conjugate I I I  on the other hand was found to give good positive staining 
at 1:8 dilution with all concentrations of the primary antibodies with no
background staining.
The human pitu itary preparation No.4 was found to give the most abundant 
TSH positive reactive cells. I t  was also the best preserved preparation. 
The distribution of the positive staining observed in this preparation is 
shown in figure 5.5a at x79 magnification. Figure 5.5b demonstrates the 
distribution of the positive staining obtained in the baboon p itu itary also 
at x79 magnification. I t  was noted that the specific staining was more
intense in the baboon sections with a ll the monoclonal antibodies. This is 
clearly demonstrated by a comparison of 5.5a and 5.5b. There also appeared 
to be a higher number of positive cells in the baboon section. I t  was 
thought this was not the result of overt differences in the areas from which 
the sections were derived, although this was not controlled^ but was probably 
due to differences in the ages of the specimens. The cell density in the
baboon section was very much greater than that in the human sections.
Figures 5.6 and 5.7 shows the human and baboon positive sections at 
magnifications of x313 and x800 respectively.
These demonstrate the individual ce llu lar staining of the preparations. 
The staining is therefore not a background a rtifa c t but confined within 
discrete cellu lar boundaries.
All the sections photographed were processed with SY/T8/1 ascitic flu id  
diluted at 1:32000 and the conjugate I diluted 1:20.
FIGURE 5.5 
Positive Anterior P itu itary  Sections
a) Distribution of TSH positive cells - Human
b) Distribution of TSH positive cells  -  Baboon
(both at x79 magnification). Sections were processed with 1:32000 monoclonal 
antibody and 1:20 enzyme labelled anti-immunoglobulin.
FIGURE 5.6
Positive Anterior P itu ita ry  Sections
a) Human section
b) Baboon section
at x313 magnification showing the ce llu la r  nature of staining. Sections were 
processed with 1:32000 monoclonal antibody and 1:20 enzyme labelled an ti-  
immunogl obul in.
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FIGURE 5.7 
Positive Anterior P itu itary  Sections
a) Human section
b) Baboon section
at x800 magnification showing the ce llu la r  staining. Sections were processed 
with 1:32000 monoclonal antibody and 1:20 enzyme labelled anti-immunoglobulin.
The negative control human pituitary sections (figure 5 .8 ); the ra t,
fe rre t and dog p itu itary sections (figures 5.9 and 5.10a) showed no posi­
tiv e ly  stained cells . Additionally all other tissues, ie , human placenta 
(figure 5.10b), human gut and kidney (figure 5.11) showed no positively  
stained cells.
Adsorbed controls
The liquid phase adsorption was found to be inappropriate. Under the 
conditions of the procedures the entire section was stained. There was very
l i t t l e  apparent difference between previously positive cells and the
.background.
However the solid phase adsorption remove^the positive staining property 
in four of the ascitic fluids except SY/T8/3-4 where the intensity was 
greatly reduced but not completely extinguished. There was also residual 
binding of radiolabelled h-TSH in these two which although greatly reduced 
was not completely removed. (Verbal communication Dr Ray Edwards NETRIA, 
St Bartholomews Hospital, London.)
Summary
The immunocytochemical results are summarized below.
TABLE 5.5
Immunocytochemical staining using monoclonal antibodies to human-TSH
POSITIVE NEGATIVE
Human anterior p itu itary sections 
Baboon anterior p itu itary sections
Dog rat and fe tte t anterior 
p itu itary  sections
Human kidney gut and placenta 
sections
FIGURE 5.8
Human anterior p itu ita ry  negative control section processed with 1:32000 
normal non immune mouse sera and 1:20 enzyme labelled anti-immunoglobulin 
(x79 magnification).
a)
b)
FIGURE 5.9 
Negative P itu itary  Sections
a) Rat p itu itary
b) Ferret p itu itary
Section processed with 1:32000 dilu tion of monoclonal antibody and 1:20 
dilution enzyme labelled anti-immunoglobulin (x79 magnificaton).
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FIGURE 5.10 
Negatively stained tissue sections
a) Dog p itu itary
b) Placenta section
Sections were processed with 1:32000 diluted monoclonal antibody and 1:20 
enzyme labelled anti-immunoglobulin (x79 magnificaton).
a)
b)
FIGURE 5.11 
Negatively stained tissue sections
a) Human gut
b) Human kidney
Sections were processed with 1:32000 diluted monoclonal antibody and 1:20 
enzyme labelled anti-immunoglobulin (x79 magnificaton).
.2 Double Antibody ELISA I
Investigation of sheep anti-TSH antibody as solid phase antibody
The immunoreactivity of the purified sheep anti-TSH was nearly identical 
to that observed in the unpurified antiserum as demonstrated in figure 5.12. 
The greatest difference was apparent at the highest dilutions of the two 
preparations. The majority of the protein eluted from the DEAE-column was in 
the f irs t  peak eluted and by the observed immunoreactivity we may assume that 
the majority of sheep immunoglobulins was the protein in this peak. No 
binding of -^I-TSH Was observed in the fractions with low protein content or 
in the second small peak eluted. Table 5.6 summarizes the results.
TABLE 5.6
Protein determination by Lowry et al 1951 method of DEAE-cellulose eluted 
pooled fractions.
0D720nm
yg/ml Protein 
at 1:250 dilution
Undiluted 
Protein content
Diluted to 
10 mg/ml (ml)
0.135 64 yg/ml 16 mg/ml 160 ml
The purification procedures did not greatly diminish the antigen binding 
capacity of the purified sheep anti-TSH preparation (figure 5.12), while 
removing a great deal of irrelevant serum protein, and sodium azide which 
inhibits peroxidase ac tiv ity .
Solid phased adsorbed antibodies
. Both the purified sheep anti-TSH (figure 5.13) and the protein A purified
monoclonal anti-TSH (figures 5.16 and 5.17) adsorbed maximally onto 
polyvinyl chloride plates at a coating concentration of 40 yg/ml. A higher 
^ 5I-TSH background binding was observed with the normal mouse sera used as 
negative control. But this was perhaps to be expected because this control 
sera was not purified and the label was nearing the end of its  shelf l i f e .
Two hour coating of the sheep anti-TSH was found to be sufficient to give
maximum adsorption on to the wells (figure 5.14).
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FIGURE 5.12 Anti serum (A/S) dilution binding of I-TSH before 
purification (a - a ); after DEAE-cell ulose purification  
the pooled fractions (a - a ). (A/S batch 1001-11.12.81)
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FIGURE 5.13 The binding of 125I-TSH by solid phase sheep anti-TSH 
(a - a ) and normal sheep sera (a - a ) adsorbed onto 
polyvinyl chloride plates. Error bar represents the 
standard error on the mean (SEM for n = 4)..
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FIGURE 5.14 Sheep anti-TSH ( • - • )  diluted at 40 yg/ml adsorbed on to 
polyvinyl chloride plates for various times. Negative 
control normal sheep sera (o-o). (SEM for n = 4 ).
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FIGURE 5.15 Immunoradiometric standard curve with 40 yg/ml solid 
phase sheep anti-TSH and 125I-monoclonal anti-TSH. 
(The NSB was 104 CPM and total count was 227561 CPM.) 
(SEM for n = 4 )
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FIGURE 5.16 Binding of I-TSH by solid phase protein A pur.ified -
ascitic flu id  (■-■) and normal mouse serum (□-□) onto 
polyvinyl chloride plates. Solid phase adsorption and 
antigen incubation times 2 hours each. (SEM for n = 4)
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FIGURE 5.17 Ascitic flu id  monoclonal antibody adsorbed by 
polyvinyl chloride plates indicated by Donkey 
antimouse HRPO conjugate I I  and ELISA substrate. 
(SEM for n = 4)
ELISA I
125mU/l TSH was used as the top standard. None of the combinations of 
sheep anti-TSH, monoclonal antibody and donkey anti-mouse HRPO conjugate 
resulted in a suffic iently  wide difference between the positive and negative 
control sera (table 5.7) or between wells containing TSH and those not 
containing TSH (table 5.8) to be useful in an ELISA assay.
TABLE 5.7
Titration  of solid phase sheep anti-TSH and monoclonal anti-TSH second 
layer antibody optical density measured at OD^ gg nm
+ve,= positive monoclonal antibody containing 
- v e =  negative normal mouse serum containing
Sheep anti-TSH 
yg/ml
Monoclonal antibody d ilu tion / 
normal mouse serum negative control
1:200 1:400 1:800 1:1600 1:3200 1:6400 0
0 +ve 0.35 0.36 0.20 0.21 0.13 0.06
0 1 < fD 0.26 0.16 0.07 0.07 0.02 0.04 -
2.5 0.42 0.34 0.31 0.26 0.19 0.21 0.23
2.5 0.36 0.34 0.30 0.24 0.20 0.19 0.15
5.0 0.44 0.42 0.39 0.37 0.33 0.30 0.20
5.0 0.41 0.40 0.34 0.31 0.29 0.25 0.17
10.0 0.44 0.37 0.33 0.31 0.26 0.24 0.24
10.0 0.43 0.37 0.36 0.29 0.29 0.22 0.15
20.0 0.52 0.32 0.36 0.35 0.29 0.29 0.21
20.0 0.49 0.30 ' 0.33 0.31 0.27 0.25 0.20
40.0 0.57 0.38 0.37 0.34 0.30 0.25 0.26
40.0 0.50 0.40 0.40 0.31 0.21 0.20 0.19
TABLE 5.8
T itration of monoclonal antibody and donkey anti-mouse HRPO. The OD was 
measured at 490 nm. (NMS = normal mouse sera)
Donkey 
antimouse 
dilutions
TSH per 
well mU/1
Monoclonal antibody dilutions
NMS
1:2001:200 1:400 1:800 1:1600 1:3200 1:6400
1:400 125 0.52 0.49 0.44 0.40 0.33 0.24 0.25
1:400 0 0.26 0.22 0.25 0.21 0.24 0.21 0.25
1:800 125 0.51 0.45 0.40 0.37 0.26 0.21 0.21
1:800 0 0.21 0.25 0.26 0.21 0.21 0.20 0.26
1:1600 125 0.54 0.41 0.37 0.34 0.23 0.22 0.26
1:1600 0 0.23 0.23 0.21 0.21 0.20 0.20 0.23 :
1:3200 125 0.52 0.36 0.31 0.29 0.22 0.22 0.24
1:3200 0 0.24 0.21 0.25 0.19 0.21 0.21 0.21
■^I-Monoclonal antibody binding
The amount of labelled monoclonal antibody bound by the captured TSH was 
very low. This was demonstrated in figure 5.15 although the total count 
added was very high and the amount of antibody added was in excess. 
Preincubation of the label antibodies and TSH before addition to the sheep 
anti-TSH coated wells did not improve the observed amount of bound label.
This low binding was not the result of fa ilu re  of the sheep anti-TSH to 
adsorb on to the wells or a fa ilu re  of the,adsorbed antibody to bind TSH 
since both these parameters were shown to give good resolution (figure 5.13). 
I t  was also not the result of fa ilu re  of the monoclonal antibody to bind TSH, 
since i t  bound sufficient TSH in the solid phase (see Chapter 3 ); and also 
when the monoclonal antibody was its e lf  solid phase adsorbed (figure 5 .15).
5.3.3 Double Antibody ELISA I I
The monoclonal antibodies was adsorbed maximally on to the polyvinyl- 
chloride plates when coated at a concentration of 40 yg/ml (figure 5.16). 
This was confirmed in the indirect ELISA (figure 5.17).
Cross t i t r a t io n  o f Sheep anti-TSH and Donkey anti-sheep HRPO
Very good resolution was obtained between the TSH (125 mU/1) containing 
wells for example, OD^ gg = 1.651, and the corresponding 'O' TSH wells 
OD49o = 0.123 (see table 5.9) this was in contrast to the results in 
table 5.6. The conjugate titra tio n  curve is given in figure 5.18.
TABLE 5.9
Titration of sheep anti-TSH and Donkey anti-sheep HRPO conjugate. The 0D 
was measured at 490 nm.
Sheep
anti-TSH
dilutions
TSH per 
well 
mU/1
Donkey anti- sheep HRPO,Dilutions
1:250 1:500 :L:1000 1:2000 1:4000 1:8000
1:1000 125 >2.0 >2.0 >2.0 >2.00 1.459 0.862
1:1000 0 0.27 0.22 0.20 0.165 0.196 0.182
1:2000 125 >2.0 >2.0 >2.0 >2.00 1.460 0.762
1:2000 0 0.26 0.23 0.19 0.140 0.125 0.124
1:4000 125 >2.0 >2.0 >2.0 1.840 1.198 0.594
1:4000 0 0.26 0.24 0.19 0.120 0.122 0.129
1:8000 125 >2.0 >2.0 >2.0 1.650 0.933 0.481
1:8000 0 0.25 0.20 0.19 0.123 0.116 0.116
A 1:8000 dilution of sheep anti-TSH and 1:2000 dilution of donkey an ti­
sheep HRPO was selected to be used with 40 yg/ml monoclonal antibody as the 
solid phase support in.the ELISA sandwich. The observed background binding 
was very low at these concentrations.
Optimization studies
The influence of incubation times on the adsorption and binding of the 
various items in the ELISA sandwich was investigated.
The following optimum incubation times were found. Two hour coating of 
solid phase monoclonal antibody and 4 hour incubation for the second layer 
TSH gave maximal optical density readings (figures 5.19 and 5.20) respect­
ively. Above 4 hour incubation and the amount of solid phase antibody
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FIGURE 5.18 Donkey anti-sheep HRPO. Enzyme conjugate titra ted
against sheep anti-TSH diluted 1:8000 and TSH 128 mU/1 
(■-■) and 0 mU/1 (□-□).
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so lid  phase antibody
FIGURE 5;19 Monoclonal anti-TSH (protein A purified) coated at
40 yg/ml and allowed to adsorb onto polyvinyl chloride 
plates for various times. Wells then incubated with 
125 mU/1 TSH for 2 hours; followed by sheep anti-TSH 
incubated for 2 hours and then Donkey anti-sheep HRPO 
incubated for 2 hours. Substrated incubated for 
30 minutes. (SEM for n = 4)
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FIGURE 5.20 Solid phase monoclonal antibody coated at 40 yg/ml and 
incubated for 2 hours followed by addition of TSH at
various times. Sheep anti-TSH diluted 1:8000 and
donkey anti-sheep HRP0 diluted 1:2000 were each
incubated for 2 hours followed by 30 minute substrate
incubation. (SEM for n = 4)
Incubation time (hrs) fo r
sheep anti-TSH binding
FIGURE 5.21 40 yg/ml monoclonal antibody coating on polyvinyl
chloride plate fo r‘2 hours followed by 125 mU/I TSH 
incubation overnight. Finally sheep anti-TSH added at 
various times. Donkey anti-sheep HRPO was incubated 
for 2 hours followed by 30 minute substrate incubation. 
(SEM for n = 4)
adsorbed rapidly declined, possible due to de-adsorption or steric hinderance 
of the antibody molecules. The binding of the sheep anti-TSH in the sandwich 
had not reached maximum in the period investigated (figure 5.21). However 
over the period the recorded optical density was suffic iently  high to give a 
good assay, and total assay time is an important consideration. Two hour 
incubation was therefore considered to be long enough to provide enough 
binding for a suitable assay. .
A 2 hour incubation of the HRPO conjugate was demonstrated (figure 5.22) 
to be optimum. For practical purposes however 2 hour incubation of solid 
phase antibody was employed followed by overnight incubation of TSH samples, 
2 hour incubation of the sheep anti-TSH and HRPO conjugate with a final 
30 minute chromogen incubation.
.4 Assessment Of The ELISA I I  Assay
The standard curve obtained with TSH^Bartsj was shown in figure 5.23. 
Dissolving the TSH standard in horse serum depressed the observed binding, 
but to a greater extent at the higher concentrations of TSH.
Figure 5.24 demonstrates the standard curve obtained in this sandwich 
ELISA system using Wellcome TSH standard preparations.
Assay sensitivity
The sensitivity may be described as the a b ility  of an analytical method 
to detect small quantities of the measured component (International
Federation of Clinical Chemistry 1975).
This in turn suggest the practical detection lim it of the assay system is 
the smallest amount of substance which is distinguishable with confidence 
from Zero concentration.
The definition of sensitivity used here was that suggested by Borth 1959, 
and denotes the 95% confidence lim it from zero. I t  was therefore given as
the mean (S) of several zeros plus twice the standard deviation (SD).
The Detection L im it = J  + 2.SD.
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FIGURE 5.22 Solid phase monoclonal antibody coated at 40 yg/ml for 
2 hours followed by TSH overnight and sheep anti-TSH 
for 2 hours. HRPO conjugate was added at various 
times, followed by substrate incubated for 30 minutes. 
(SEM for n = 4)
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FIGURE 5.24 Standard curve with Wellcome Foundation standard TSH 
preparations, (n = 6)
Standard preparations were taken from The Dac-Cel 
TSH k it RD48.
Table 5.10 tabulates the sensitiv ities observed.
TABLE 5.10
Detection lim it of the assays were defined as I  + 2SD
Assay standard 
curve
Number of 
Zero
samples (n)
Mean x 0D/ 
hour of 
Zero sample
SD
Sensitivity • 
mU/1 
TSH
TSH in assay diluent 12 0.2824 0.0302 1.8
TSH in serum 32 0.2652 0.0304 4.0
Wellcome TSH 25 0.2540 0.0220 5.0
Assay precision
The within batch precision was calculated from determinations of the
three control sera and the Wellcome control sera which were assayed 10 times, 
and 6 times respectively.
The between assay precision demonstrating the reproduceability of the 
assay was also calculated from the values obtained for the three control sera 
assayed on 8 d ifferent occasions.
The standard deviation was calculated from 8 pairs of estimations using 
the formula:
SD = Z ( X 2 -  X j )2
N 2n
where SD = standard deviation
h  = observation 2 ) of each pair
= observation 1 )■
n = number of pairs
The precision estimates obtained are shown in Table 5.11 below. All the 
TSH values observed for the three controls were well above that expected.
TABLE 5.11
Precision estimates within and between assays
TSH samples
Mean TSH 
mU/1 SD
Within
Assay
C.V.%
Mean TSH 
mU/1 SD
Between
Assay
C.V.%
Sample I (low) 5.8 0.8 13.8 6.6 1.6 24.2
Sample I I  (medium) 15.5 1.5 9.7 15.5 2.5 16.1
Sample I I I  (high) 23.5 2.0 8.5 23.5 3.5 14.9
Wellcome control 14.0 1.0 7.04 - -
Figure 5.25 gives the intra and interassay precision profiles obtained 
from the serum based standard curves assayed 10 and 8 times respectively. 
The intra assay precision was fa ir ly  good with the interassay precision, 
rising dramatically at the lower end of the TSH dose.
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5.4 DISCUSSION AND CONCLUSIONS
5.4.1 Immunoc.ytochemi stry
The major consideration in immunocytochemistry is the positive id en tific ­
ation of immunoreactive substances within the tissue or cell preparations.
Many peptides have sequence homologies; and those of the p itu itary glyco­
proteins have already been described in Chapter 1. Since each antibody 
within a polyclonal antiserum population may be regarded as a site specific 
rather than an antigen specific reagent (Larsson 1981), this results in the 
many cross reactions observed with polyclonal anti Sera.
Monoclonal antibodies on the other hand are also site specific, but the. 
preparations contain antibodies specific to only one s ite . Any observed' 
cross reactivity cannot be removed by diluting i t  out as may be possible with 
polyclonal anti sera where the cross reacting antibodies may represent only a 
small part of the antibody population. Dilution therefore seriously 
diminishes its  proportion in the antibody preparation and therefore its  
prominence. Observed cross reactions with monoclonal antibodies indicate 
truely homologous shared structures.
Almost a ll immunocytochemical localizations up to the present time have 
been performed with polyclonal antisera (De May 1983). But the c ritic a l 
c rite ria  is that the specificity of the anti sera whether poly or monoclonal 
be firmly established. Swaab (1982) has suggested that the usual RIA 
specificity characterization is not adequate since by RIA there may be no 
cross reactivity which may la te r become apparent in immunocytochemistry 
possibly as a result of the high dilutions at which the antibody preparations 
are used in RIA. However RIA is usually the most convenient available assay 
procedure. For this work the specificity in an ELISA system which in v itro  
mimics immunocytochemistry procedure was established using highly purified  
. h-TSH and the other glycoprotein preparations (see Chapter 4 ). This in 
combination with the adsorption studies suggests that the specific staining 
was indeed human TSH, with similar antigenic determinants occurring in the 
baboon TSH. However the determinants were absent in the dog rat and fe rre t 
preparations.
Although the disappearance of staining after adsorption of a polyclonal 
antibody merely suggests that the antigen bound the antibodies, i t  does not 
exclude staining due to contaminating antibodies induced by an impurity in 
the antigen (Swaab 1982). In the case of monoclonal antibody disappearance 
of staining does not preclude the possibility that the selected antibody was 
directed against an antigen contaminant also present in the immunoadsorbent.
However a successful adsorption is usually suggested as a primary 
indication of specificity (Van Noorden and Polak 1983). In the liquid phase 
adsorption attempted in this work we concluded that nonspecific adsorption of 
the antigen-antibody complex onto the entire surface of the tissue section 
was responsible for the widespread staining observed in these sections, since 
the control sections gave the expected reactions.
The antigenic- determinants bound by these monoclonal antibodies were' 
absent in the other tissues - gut, kidney and particularly the placenta. The 
placenta results were especially significant since they confirm the 
antibodies specificity in terms of HCG cross reactiv ity . The placenta is a 
rich source of HCG demonstrated with a monoclonal immunoperoxidase technique 
(Wahlstrom et al 1981). No placenta staining was observed, although SY/T8/4 
was found to cross react minimally with' HCG, a and 3-subunits. In addition, 
human placentas have been found to produce a material with thyrotropic 
activ ity  (Hershman and Starnes 1969), which did not react in the immuno­
chemical procedure used, possibly indicating the absence of the particular 
pituitary TSH antigenic determinant in the placental material.
The antibodies have therefore been demonstrated to be highly specific in 
terms of th e ir binding to h-TSH secreting cells with negligible background 
nonspecific binding. Remarkable primate and tissue specific ity was also 
clearly demonstrated. These antibodies with the exception of 3 and 4, which 
require further adsorption studies, were found to be eminently suitable for 
use in immunocytochemical investigations. The universality of the antimouse 
HRPO conjugate was also demonstrated where i t  was used in this and the ELISA 
procedures.
5.4.2 ELISA
Monoclonal antibodies are specific to only one antigenic determinant. 
Only one molecule of antibody therefore w ill bind an antigen unless of course 
the antigenic determinant is a repeating unit on the antigen. We therefore 
decided to use an available polyclonal sheep anti-TSH anti serum as the solid 
phase capture antibody. This anti sera was purified because the majority of
irrelevant serum protein would have taken up adsorption sites which were
• . /
required for the anti-TSH antibodies. Very l i t t l e  immunoreactivity was lost 
in the purification procedure as demonstrated in figure 5.12. The sensit­
iv ity  of sandwich ELISA for TSH has been shown to be improved dramatically 
using purified adsorbed antibodies (Tshikawa et al 1982).
The purified sheep anti-TSH was adsorbed onto the well of the micro ELISA 
plates and bound TSH maximally at 40 yg/ml. However no satisfactory resolu­
tion of top TSH standard and 'O' TSH could be obtained using ^ I - la b e l le d  
monoclonal antibody (figure 5.15), or in the ELISA system (tables 5.7 and 
5.8 ). Even though the ELISA system carried the potential for appreciable 
signal amplification, unsatisfactory signal detection in terms of magnitude 
was found. I t  was reasoned that the low observed signal was probably due to 
the singular specificity of the monoclonal antibody binding possibly only one 
or a very few antigenic determinant units per antigen molecule. Only a very 
limited number of bound monoclonal antibodies would therefore be available 
for binding by the enzyme labelled anti-immunoglobulins. Hence the limited 
signal intensity observed.
I f  this was the case then turning the assay upside down i t  was reasoned 
should provide a better signal amplification. The monoclonal antibody 
captured a precise amount of antigen. All other antigenic determinants would 
be available for binding by the polyclonal antisera, containing as i t  does 
antibodies to several antigenic determinants. By this procedure many more 
antibody molecules should be available for binding by the enzyme labelled 
anti-immunoglobulin, resulting in an increased signal.
This was convincingly demonstrated to b^  the case and a standard curve 
(figure 5.23) was derived. Indeed Ehrlich and Moyle (1983) have shown that 
mixtures of monoclonal antibodies act in a cooperative way to yield sensitive 
immunoassays not derived using the same antibodies singly. Ehrlich et. al
(1982) and Moyle et al (1983) have also reported increased antibody 
a ffin itie s  when more than one monoclonal antibodies were mixed in the assay 
of HCG.
The specificity of the assay relies on that endowed by the monoclonal 
antibody in the sandwich, although the crossreactivity of HCG with the sheep 
anti-TSH was given to be <0.1% (Guildhay, University of Surrey), and as such 
the assay should not suffer from crossreactivity interference as experienced 
by Wada et al (1982).
The sensitivity of the assay of 4 mU/1 in the serum response curve was 
not as good as that observe by Wada et al (1982) or in RIA (Hall et al 1971) 
or more recently the highly sensitive chemiluminescent assay reported by 
Jones et al (1984). However the possibility exists to provide a more 
sensitive assay probably of the chemiluminesence type reported by Weeks et al
(1983) for measuring a foetaprotein or of course that for measuring TSH 
reported by Jones et al (1984) since our assay system already incorporates 
the peroxidase enzyme then an assay based on luminol mechanism is feasible 
(Olsson and Thore 1981). Alternatively the assay sensitivity may be improved
using a combination of monoclonal antibodies as described by Ehrlich and 
Moyle (1983), or even using monoclonal antibody Fab fragments to increase 
antigen binding potential of the adsorbed antibody (Tshikawa et al 1982).
The theoretical sensitivity of this type of immunometric assay is 
probably as l i t t l e  as one molecule of analyte (Ekins 1981). However in 
practice the detection lim it is determined to a great extent by the 
background noise levels against which the minimum signal must be perceived.
Consequently such very high sensitivities can only be achieved in situa­
tion where a low background is combined with an amplified positive signal. 
The background in this assay is very low but the signal at low analyte 
concentrations is also small hence the low sensitivity. A signal detection 
system including those already suggested capable of resolving and amplifying 
such small signal differences would be more practical. Wada et al 1982 
pointed out that the sensitivity of the assay could be improved by increasing 
the amount of enzyme conjugate added. But i t  must also be noted that the 
background also increases with increasing conjugate concentration 
(figure 5.18).
This does not therefore remedy the sensitivity problem i f  the increased 
signal at low hormone concentration is obscured by the increased background. 
Tshikawa et al (1982) therefore recommended the use of the lowest conjugate 
concentration to give a good calibration curve.
The within assay precision of between 8.5 and 13.8 and the between assay 
precision of 14.9 and 24.2 for the three control samples was good although 
the observed TSH values were all high. The precision may however have been 
improved with glutaraldehyde pretreatment of wells (see Chapter 2 ) , but this  
was not attempted. Between assay precision up to 20.0 per cent were reported 
as common in TSH RIA (Tunbridge and Hall 1976). The precision profile shows 
good assay precision over the entire range therefore.
The Wellcome TSH was substituted in pur assay to demonstrate the binding 
of the monoclonal antibody to purified TSH other than our specific antigen. 
This was because of the d iffic u ltie s  observed with the binding to the NIBSC 
TSH preparation. Figure 5.24 was the standard curve obtained.
The total assay time was approximately 26 hours and could be as l i t t l e  as 
10.5 hours i f  the antigen was incubated with solid phase antibody for 2 hours 
rather than overnight which is done for convenience. However this may also 
be reduced by storing the antibody precoated plates until required (Voller et 
al 1979). However monoclonal antibodies, especially in the purified state are 
sometimes unstable. Therefore storage conditions would need to be 
investigated.
The monoclonal antibody investigated was therefore shown to be suitable 
for use in this ELISA assay. However the results demonstrated some of the 
d iffic u ltie s  which may be encountered using monoclonal antibodies. The f ir s t  
assay ELISA I indicated that a suitable assay was not feasable under the 
conditions used. Had we used a solid phase monoclonal antibody with a top 
monoclonal antibody in the assay, th e . system may have been abandoned 
altogether. I t  demonstrates once again that all aspects of monoclonal
antibodies must be investigated to define their appropriate terms of uses, 
and i t  must be emphasized that their behaviour is not equivalent in many 
respects to polyclonal antibodies.
Presented here is the basis of an assay which shows tremendous potential 
for a sensitive re liab le and speedy assay for TSH and which carries great 
promise for clin ical application in possibly neonatal hypothyroid screening.
CHAPTER 6
Discussion and Conclusions
MONOCLONAL VS POLYCLONAL ANTIBODIES
Conventional antisera unlike monoclonal antibody suffers from the 
considerable disadvantages listed below in Table 6.1. In addition,™ general 
greater than 90% of antibodies in a hyperimmune sera are irrelevant immuno­
globulins which do not bind the antigen (Klinman and Press 1975, Kreth and 
Williamson 1973, Kohler 1976), and the specific antibodies in a conventional 
antisera, bind most of the antigenic determinants present on the immunogen. 
As a consequence conventional anti sera display negative properties such as 
cross reactions, and batch variations.
Monoclonal antibodies on the other hand circumvent these major lim ita­
tions of conventional anti sera. Table 6.2 summarises the many advantages of 
monoclonal antibody preparations.
TABLE 6.1
Properties and disadvantages of conventional antisera
1) Heterogeneous mixture of antibodies.
2) A pure immunogen is necessary and/or
3) Purification of antisera for specificity.
4) Cross reactions may not be genuine.
5) Antisera is not exactly reproduceable in terms of specificity or binding 
characteristics.
6 ) Physical properties, such as avidity, are an average.
TABLE 6.2
The advantages of monoclonal antibodies summarized
1) Antibody product is pure - only one molecular species.
2) Impure immunogen may be used.
3) Specificity for one antigenic determinant.
4) Cross reactions usually mean a shared antigenic determinant.
5) High t i t r e  antibody samples may be obtained.
6 ) High or low a ffin ity  antibodies may be selected depending on the proposed
application.
7) Antibody quality is reproduceable in terms of specificity and binding 
characteristics.
8 ) Large animals/farms are not required.
9) Unlimited amounts of specific antibody are produced in vivo and in v itro .
10) Immortal cell lines for continuous production.
11) Carries the potential to provide world wide standard reagents.
HYBRIDOMA DEVELOPMENT
Monoclonal antibody production although possessing all these advantages 
is by no means a simple technique. In addition to the fact that the
technique is expensive and time consuming, the many inherent problems of the 
technology such as the control of contamination, the ra rity  of the fusion 
event, hybrid in s tab ility  and storage and recovery d iffic u ltie s  all combine 
to complicate the procedure.
We suggest here however, that even with these major d iff ic u ltie s  the 
technique is well worth while when viewed in conjunction with the many 
advantages and its  wide applications. Perhaps the most immediately strik ing  
feature of this technology for immunochemists is that a meaningful measure of 
specific antibody quantity is possible. As a result antibody techniques can 
now incorporate precise quantitative methodologies which allow defin itive  
comparisons in routine immunochemistry.
The immunization of mice with highly purified human thyroid stimulating 
hormone permitted the successful generation of the high a ff in ity , highly 
specific monoclonal antibodies. Their su itab ility  in two specific areas of 
application have been successfully and clearly demonstrated.
Immunoassay screening
The successful conclusion of the technique - the rescue of the specific 
antibody secreting function, as suggested earlie r was largely dependent upon 
the integrity of the screening assay. A liquid phase radioimmunoassay (Hall 
et al 1971) was used for detecting the monoclonal antibodies in the f i r s t  
6  fusions.
This assay was demonstrated (Chapter 3) to be eminently suitable for 
monitoring the antibody responses of the TSH immunized spleen cell donor mice 
and as a result was considered to ’ be adequate to detect the mouse anti-TSH 
monoclonal antibodies in culture supernatant. After 6  fusions however with 
528 primary cultures screened and 46 possible positives from fusions 1-3 
rescreened, together with 8  primary cultures cloned from fusion number 3 
consisting of 768 wells, with no stable positive culture derived, i t  was 
concluded that the screening assay was probably deficient. The possible 
positives carried forward to the next stage in fusion 1-3 were only 
marginally positive by the crite ria  set up for describing positive cultures.
At the earliest stages when the f irs t  assays were performed only minute 
quantities of specific antibody was expected to be present to bind the 1 abel. 
Therefore only a small amount of bound label would be available for
detection. In addition to th is , the double antibody separation system 
depends on the precise balance of the various reagents to allow sufficient 
complex formation incorporating the f ir s t  antibody and labelled antigen in 
quantities which permit the precipitation of perceptable labelled material. 
The amount of such precipitate even in normal RIA procedures is usually very 
small and significant loss of material arises during supernatant aspiration. 
Practically, normal carrier sera from the same species as that in which the 
f ir s t  antibody was produced is added to increase the bulk of the precipitate 
and therefore to allow a more complete precipitation (Hunter 1979, Morris
1981), with concomitant proportionally less loss of material. But even with 
this modification, because of the small quantities involved in the f ir s t  
instance in monoclonal antibody screening then the detection level must be 
low. Additionally the effect of prozone which is the resolubilization of the 
complex in (in this case) second antibody excess may also be a prominant 
factor in the fa ilu re  of this screening procedure.
However the use of PEG as the precipitating agent (Desbuquois and Aurbach
1971) did not improve the results for positive cultures. This would suggest 
therefore that the d iffic u lty  arose with the minute amount of specific
antibody available in i t ia l ly  in the cultures. I t  must be noted that the 
monoclonal antibodies, once they were established, performed satisfactorily  
in the liquid phase RIA procedures, and was used to derive the t itre s  of the 
ascitic flu id  monoclonal antibody preparations (see table 4 .4 ). There was 
therefore no intrinsic hindrance to the use of monoclonal antibodies in the 
RIA procedure.
On the above considerations therefore i t  was decided to develop the 
indirect ELISA and solid phase RIA screening procedures described in
Chapter 2. In the indirect ELISA system the solid phase absorbed antigen
acted as an immunoadsorbent surface effectively extracting, concentrating and 
purifying the specific antibody from the culture supernatants. The binding 
of the enzyme labelled anti-mouse immunoglobulins also carrying the in trins ic  
fa c ility  of signal amplification suggested a more sensitive assay system for 
screening purposes. This was indeed.the case and the developed assay was 
used to good effect in the next fusion No.7, and a gradation in the intensity 
of positive cultures was observed with this assay by which 7 stable cultures 
were derived and fin a lly  stored.
On the same premise i t  was thought that the cellulose bound solid phase 
second antibody would immuno-extract any f ir s t  antibody present in the 
supernatant, those binding labelled antigen and those not binding antigen. 
This method circumvented the need for carrier protein and micelle formation 
accelerators.
This system however suffered from one major d iffic u lty  demonstrated in 
figure 4.3. Where there was excess f ir s t  antibody then the hook effect 
phenonenon (Miles and Hales 1968) was apparent. This was possible due to the 
fact that the second antibody bound the f ir s t  antibody labelled and unlabel­
led antibody species in the proportion in which they occurred in the assay 
mixture. Therefore where there was a larger excess of f irs t  antibody then a 
lower quantity of labelled antibody w ill be evident. This consideration was 
however not expected to present d iffic u ltie s  in screening as enough f ir s t  
antibody was not expected to be present to cause this effect.
The precision of the ELISA method B was however not very good. This was 
possibly due to the d ifferentia l adsorption of protein to the plastic wells 
(Denmark and Chessum 1976, Voller A, personal communication). Pretreatment 
of the wells with 0.1% (v/v) glutaraldehyde (Stafford and K ilgall an 1980) 
improved the within assay precision. There have been various verbal reports 
that prewashing with d is tille d  water, ELISA diluent without the nonspecific 
protein, or even decon improves the precision of the assay. For control of 
the between assay precision the results were corrected in terms of the 
reference positive wells to account for day to day minor variations in assay 
conditions.
No such d iffic u lty  was observed for the solid phase RIA. Both screening 
assays developed during the course of this work specifically for the 
screening of hybridoma cultures have been shown to be particularly suitable 
for this type of work, and has been used to good effect. The assays are 
particularly relevant because theoretically they may be adapted for use in 
the detection of any monoclonal antibodies of murine origin. The v e rs a tility  
of the solid phase RIA for example was demonstrated in the methotrexate assay 
(figure 2 .4 ).
Both the enzyme labelled anti-immunoglobulins and the cellulose bound 
anti-immunoglobulins were re la tive ly  cheap to produce and were stable for 
long periods >1.75 years and 1 year respectively with no apparent 
deterioration.
Both assays were very suitable for screening at all stages of hybridoma 
production and were particularly appropriate because of the capacity to 
process a large number of samples simultaneously. The ELISA method was semi­
automated while the solid phase RIA required less pipetting of material and 
so the whole procedure was simplified. Where there is an objection to the 
use of radiolabelled material or visual distinction of positive from negative 
alone is required and a quick assay is indicated then the ELISA method is 
preferable. However on the basis of precision, the solid phase RIA was 
preferred. The importance of the correct choice of screening assay has been 
clearly demonstrated. Perhaps one small drawback ( i f  i t  may be so termed) to
the ELISA assay is that i t  is lik e ly  to result in the selection of only high 
a ffin ity  antibodies (Catty et al 1981) ie , those that can withstand the 
washing stages. This, of course, is a major objective of this work, and the 
proposed application in immunocytochemistry in particular demands the use of 
high a ffin ity  antibodies (Sternberger 1979).
The back up screening with the solid phase RIA allowed for the selection 
of those antibodies which may have been of lower a ffin ity .
2 Contamination Control
The cell culture environment provides an ideal situation for the growth 
of not only the intended culture ce lls , but also for many microorganisms. 
All the essential nutrients are present in addition to favourable temperature 
and gaseous concentrations. As a consequence exceptional aseptic culture 
practices are essential for routine long term culture. Bacterial contamin­
ation was usually controlled with a penicillin/streptomycin preparation. 
Fungal and yeast contamination which in-lo"ng term cultures may prove more of 
a problem than bacterial contamination may be inhibited by fungistatic agents 
such as fungizone or nystatin (Perlman et al 1961, Paul 1980). However where 
widespread contamination persists, i t  is more feasible to discard the 
contamination cultures than to try  to save them. Fungal spores are airborne 
and as such spread rapidly i f  not sw iftly eliminated (Paul 1980).
One other major and persistant contaminant of tissue culture cells  
consists of the pleuropneumonia-like organisms (PPLO) or mycoplasma (Carski 
and Shepard 1961, Macpherson 1966, Paul 1980). These organisms live  
in tracellu larly  and lead to the slow but eventual death of the culture.
Again i t  is sometimes necessary to attempt the rescue of valuable 
cultures. Kanamyan (Kannasyn) has been suggested as the most effective  
treatment (Paul 1980). However the cells may be laundered so to speak by 
passaging them interperitoneally in syngeneic mice as for ascites production 
(Hudson and Hay 1980) and the ce lls , free from contamination, recovered from 
the ascites tumor (Edwards 1981, Marcus et al 1980 and Schimmelpfeng et al 
1980). Antimycoplasma monoclonal antibodies have now been derived (Buck et 
al 1982) which should speed up the identification of contaminated cultures 
before they are damaged irretrievably.
With the control of mould and fungal outbreaks in mind the effects of 
econazole using NSI cells as the cell model system were investigated. 
Unfortunately econazole was found to exert dramatic cytotoxic effects on the 
cells (see Chapter 3). I t  was therefore demonstrated to be unsuitable for 
use in this hybridoma production work. Rather than using fungizone with
similar reported adverse effects (Dolberg and Bissell 1974, Hackett et al
1972) a s tric t .aseptic routine was followed very successfully to the control 
of such contamination.
.3 Fusion Promotion and Hybrid S tab ility
All the fusion solutions used gave good hybrid production with the 
majority of wells bearing actively growing cells in most cases. However 
because of the possible toxic effects of low molecular weight PEG on the 
cells (Fazekas de de St Groth and Scheidegger 1980), and the risk of 
contamination with the more complicated fusion procedure (Sikora et al 1982) 
with no obvious beneficial effects in terms of greater hybrid numbers 
obtained, these fusion systems were abandoned in favour of fusion solution 
no.3 described in Chapter 3. In addition i t  is thought PEG effects membrane 
changes; of a variety of possible^origins(Poste and Nicolson 1978), therefore 
the fusion system causing as l i t t l e  perturbation to the hybrids as possible 
was used while effecting fusion.
Hybrid in s tab ility  leading to the loss of antibody activ ity  is one of the 
main causes of loss of valuable cultures. This may be manifest by the 
unexplained death of the entire culture or of course as the loss of specific 
antigen binding ac tiv ity , while neither of these manifestations are d irectly  
under the control of the experimenter nevertheless unnecesary manipulations 
are avoided since these may exacerbate the situation (Pontecorvo et al 1977). 
For example immediately a fter fusion too rapid dilution of the cells may 
result in extensive cell lysis (Fazekas de St Groth and Scheidegger 1980). 
Culture-stable antigen positive hybrids were successfully derived with fusion 
protocol 3 while none were derived7with protocols 1 and 2 (see Chapter 3 ). 
This was not to say the fusion protocols were necessarily faulty as the 
screening assay was probably not effective.
4 Hybrid instab ility  -  freezing and recovery-
For several reasons the preservation and storage of liv ing cells are 
necessary in the long term. As soon as positive cultures become established 
aliquots must be frozen to ensure against contamination losses.
Cell hybrids tend also to lose chromosomes (Ringertz and Savage 1976), i t  
is therefore prudent to store positive cultures at each stage of the 
procedure so that i f  losses occur at any stage, the cell line is not lost but 
may be resurrected at the previous stage. Positive cell lines are also lost 
due to overgrowth by unimportant faster growing hybrids, or even due to 
dilution effects (Yelton et al 1981). In addition cells kept for extended
periods during expansion or cloning in a rapid state of proliferation tend to 
change characteristics (genetic d r if t )  leading to the production of variants 
(Cotton et al 1973, G a lfrl, Milstein 1981) and such change may lead to a 
changed product or loss of production all together (Goding 1980).
Positive cells were therefore frozen at each stage of the procedure and 
thawed rapidly when required.
This recovery sometimes presents a problem as was discovered for the cell 
lines frozen in fusion 7. The cultures could not be thawed satis factorily . 
On some occasions there was no growth at all on thawing of the cultures. On 
other occasions the cells grew slowly at f ir s t  then eventually died. I t  is  
possible the freezing procedure used resulted in ice crystal formation which 
resulted in the death of some cultures. But all cell lines were not frozen 
down in the same batch, and the same procedure was used for the cell lines of 
fusion 8  with no d iffic u lty  experienced upon recovery of these cells . The 
conclusion was that the hybrid in stab ility  due to the freezing and/or thawing 
process was one unexplained d iffic u lty  of the technique. Other workers have 
verbally reported similar hybrid recovery problems. This problem was 
specifically linked to the hybrid cells as no d iffic u lty  was experienced upon 
recovery of the NSI ce lls . The use of feeder layer cells did not improve the 
recovery of the affected cultures. This was therefore not a dilution cell 
density effect.
CELL LINES AND MONOCLONAL ANTIBODIES
I t  has been clearly demonstrated that the hybrid cells growth lik e  the 
parent NSI ce lls , was density dependent. This is an important relationship  
to identify and is c ritic a l to the continued good health of the cultures. 
These findings indicate that for good culture management they should be 
allowed to grow to no greater density than the maximum empirically derived 
(see table 3 .6 ).
In general however the cultures may be routinely sp lit every two to three 
days. With experience microscopic examination of the cultures was su ffic ien t 
to indicate that the maximum density had been reached. The f ir s t  indications 
of overgrowth was the budding up of the cell membranes from being smoothly 
rounded. In addition the fresh culture media which contained a pH indicator 
was salmon pink but the spent media was pale yellow. These observations 
indicated the cultures required immediate attention. With the appearance of 
these indicators the cultures die o ff very rapidly i f  ignored. In figure 3.4  
the culture death was somewhat inhibited by the fact that the nutrient was 
not lim iting. But routinely the death of the culture would be more rapid 
because in addition to the density effect the nutrients were being rapidly  
depleted.
Spent culture supernatant was used as a source of the antibody. In such 
cases a separate smaller culture was usually maintained to continue the 
culture without the need to perhaps resuscitate the overgrown ce lls . The 
second source of monoclonal antibody was from induced ascites (Wright 1980).
The monoclonal cell lines were selected visually from cloning wells, and 
only wells with a single small culture was selected. However cellulose 
acetate electrophoretic analysis of the ascites antibody preparation in t^wo 
cases, SY/T8/2 and 5, showed a double immunoglobulin band. The less intense 
band could possibly be mouse immunoglobulins secreted in response to the 
introduced cell line . This phenomenon has been suggested (verbal discussion 
with other workers) to be sometimes responsible for the diminished quality  
and content of ascites - produced monoclonal antibody. The injected mouse 
produces antibodies not only . against the'injected cells but also against 
th e ir products - the monoclonal antibodies. This reaction is not always 
manifest and is a response of the individual mouse. Because of this 
contamination by other such mouse antibodies some workers prefer to use the 
supernatant antibodies which contain only minimal foetal immunoglobulins.
Protein A purification of the antibody preparations (figures 4.18 -  4.20) 
however yielded a very pure antibody preparation since the subclasses are 
d iffe ren tia lly  eluted (Ey et al 1978, Kohler et al 1978, Goding 1978). Such 
a ffin ity  purified antibodies were suitable for purposes where a pure 
preparation free from contaminating serum proteins was required.
Purified antibody preparations are a primary requirement, for enzyme or 
radiolabelling or where they are required for use in solid phase systems, a ll 
of which were required in this work.
MONOCLONAL ANTIBODY PRODUCTS
A dominant facet of monoclonal antibody technology is the considerable 
potential for the production of'unlimited amounts of antibody with constant 
properties.
In this work the monoclonal antibodies were produced in v itro  in culture 
supernatant or in vivo in cell primed mice. A large-scale cytostat method 
(Fazekas et St Groth 1983) for in v itro  production and immediate purification  
has recently been reported. I t  serves to demonstrate the ease with which the 
monoclonal antibody may be harvested once the stable hybridoma cell line has 
been established.
All the monoclonal antibodies characterized were found to be IgG2a, 
k-ligh t chain and this was confirmed by the protein A elution profiles of the 
antibodies. Both chain type composition and antigen binding character was
stable in the six cell lines examined, persisting even after continuous 
culture for six months. During this period both properties were examined
frequently. The contamination of the monoclonal antibody product by the 
k-light chain synthesized by the NSI cells was not demonstrated. Only 
minimal k -ligh t chain was shown to be synthesized by the NSI cells as 
demonstrated by SDS PAGE electrophoresis of the in tracellu lar NSI protein. 
A NSI k-light chain band was not observed in the reduced monoclonal antibody 
product.
Because NSI synthesize k-light chain but do not secrete i t  (Cowan et al 
1974) in tracellu lar heavy and light chain complementation was nevertheless 
expected to result in three types of immunoglobulin molecules (M ilstein and 
Kohler 1977) see figure 6.1. I t  is possible that such complementation did
occur but that the NSI k -lig h t chain was present in only very small amounts.
The k-chain in the NSI is degraded as fast as i t  is synthesized, and the rate 
of the antibody secretion is equal to that of synthesis in the secreting 
partner (Cowan et al 1974). There is no evidence to suggest that in the 
hybrid the two rates of synthesis -  that of the NSI partner and the spleen 
cell partner becomes synchronized. I f  therefore the rate of synthesis/ 
secretion of the spleen cell derived immunoglobulin is faster than the rate
of synthesis of NSI k-chain then the amount of NSI k -ligh t chain
contamination observed should be minimal.
MONOCLONAL ANTIBODY PROPERTIES
The a ffin ity  of all six monoclonal antibodies was found to be very high. 
This therefore, i t  may be argued, ju s tified  the rationale behind the immuniz­
ation procedure used to prepare the spleen cell donors. This was that the 
a ffin ity  and specific ity of the antibodies increases with time (Odell et al 
1969). However Wada et al (1982) reported a n ti-3 -TSH monoclonal antibody 
with a ffin ity  of 3.5 x 10^M"* while Soos and Siddle (1982) reported 
monoclonal antibody a ffin itie s  of between 2 x 10® and 5 x 10^M"* with two 
immunizations. Moderately high a ffin ity  antibodies may therefore be derived 
with less intense immunization schedules. We maintain however that consis­
tently high a ffin itie s  were the result of the more intense antigen challenge 
employed in this work. The immunization regime was undertaken with two 
primary objectives therefore. The f ir s t  was the production of high respond­
ing spleen cell donors, the antibody t i t r e  of which was indicative of the 
numbers of antigen positive cells available for fusion (Soos and Siddle
1982). The response was monitored by TSH radioimmunoassay of serum (figures 
3.1 - 3 .3). The second objective was to make available for fusion, cells  
with high a ffin ity  antigen receptors, corresponding to the antibody quality  
(Mitchison 1967).
NSI myeloma cells Spleen cells
X - Antigen specific Ig
k-chain synthesized HLHL
Hybrid cells 
Ig molecules expected 
HLHL - antigen specific 
HKHL - antigen binding 
HKHK - no antigen binding
FIGURE 6.1
Immunoglobulin molecules expected to be secreted by hybrids formed from 
P3 -NSI-1/Ag4-1 myeloma cells and antigen primed spleen ce lls .
The six monoclonal antibodies investigated were demonstrated to be highly 
specific to the h-TSH antigen.
No appreciable cross reactivity was demonstrated to human FSH, LH, HCG or 
the a and $ subunits of HCG.
HCG preparations from two sources were investigated ie , the MRC standard 
75/537 and purified HCG(Barts) preparation (see Chapter 4 ).
Additionally and perhaps more convincingly were the concordant results 
obtained by the two independent procedures used to investigate HCG cross­
reactiv ity . The f irs t  was as indicated above, the indirect ELISA competitive 
assay, in which HCG competed with solid phase TSH for the 1imited number of 
monoclonal antibodies, while in the second procedure the monoclonal antibody 
was used in an indirect immunocytochemical procedure (Chapter 5) to demon­
strate the localization of specific antigenic determinants in the placenta. 
The placenta in addition to being a rich source of HCG (Wahlstrom et al 1981)
also contain a thyrotrophic material (Hershman and Starnes 1969). No specific
staining was observed (figure 5.10b). Contrast this with the positive 
staining of the human pitu itary section (figure 5.5a).
There was no cross reactiv ity  with HCG in the placental tissue but also 
any thyrotropic material contained did not possess the TSH antigenic 
determinants to which the monoclonal antibodies were directed.
A major d iffic u lty  however arose from this study. None of the monoclonal 
antibodies bound the MRC TSH standard 68/38 in the displacement experiments 
figures 4.5 - 4.7. This presented d iffic u ltie s  for establishing an assay 
where TSH 68/38 was to be used as the standard. The assay was however estab­
lished using TSH(Barts) as the standard and was calibrated against TSH 68/38.
Two major differences are known to exist between TSH 68/38 and
(Barts) •
1) TSH 68/38 was a standard preparation established in 1974, while
TSH(Bartsj was prepared fresh on a fortnightly basis (McLean et al 1981).
2) TSH 68/38 was prepared by harsh procedures which used acetone-dried
pitu itaries or p ituitary powders as the starting material (Condiiffe 1973), 
while TSH(Barts) preparations were extracted into solution from deep frozen 
glands with buffers of near normal pH (McLean et al 1981).
I t  is the contention that the age of the TSH 68/38 and/or the harsh
treatment of the starting material together with the extraction procedures 
(Pierce et al 1971) resulted in the loss or gross deterioration of the
antigenic determinants on this TSH preparation so they were not recognised by 
the monoclonal antibodies. This view was supported by McLean et al (1981) in 
discussing growth hormone derived from acetone dried glands as opposed to
deep fro-zen glands (growth hormone is the f ir s t  anterior p itu itary hormone 
extracted from such glands and from the remaining product the gonadotrophins 
and TSH are then d iffe re n tia lly  extracted). They described many disadvantages 
of the acetone prepared material in clin ical application. For example the 
immunogenicity was altered from that found in the frozen gland preparations, 
and the harsh procedure caused major denaturation including aggregation of 
the extracted material. Children whose growth after long term treatment with 
the acetone prepared material went into a refractory phase upon further 
treatment with this material became responsive again when treated with the 
frozen gland prepared material. This would suggest that the method of 
preparation of the material not only governs its  immunogenicity and 
structural in tegrity but also its biological ac tiv ity . As a result of this  
d iffic u lty , TSH standard from another source was used in the two site ELISA 
with the monoclonal antibody to confirm its  specificity for TSH. A standard 
curve was derived (figure 5.24) with the Wellcome TSH standards.
The specificity of the monoclonal antibodies for TSH was however also 
confirmed overwhelmingly in the immunocytochemical procedure, the positive 
cells were located as expected for thyrotropes. In addition to the clustered 
distribution a few were to be found scattered throughout the section. In 
addition when compared to the periodic acid schiff (PAS) stained sections i t  
is clear that not all the PAS positive cells were positive by the specific 
immunoperoxidase procedure. The numbers, location, and distribution of TSH 
positive ce lls , described in Chapter 5, were found to be entirely consistent 
with that expected. Additionally, species specificity of the monoclonal 
antibodies for primate derived TSH was demonstrated. The monoclonal 
antibodies were demonstrated to be suitable for immunocytochemical work and 
the ascitic fluids could be used up to a dilution of 1:500,000 without loss 
of specific colour intensity. I t  must be noted that the Sephadex purified  
and selected conjugate I I I  fractions were found to be better in this  
procedure in terms of the low background observed as compared to the ammonium 
sulphate purified conjugate I I .  .
The d iffic u ltie s  observed with TSH 68/38 were by no means confined to the 
ELISA procedure but were also found in the RIA procedure (verbal communic­
ation Dr D Teale, Clinical Biochemistry Dept, St Lukes Hospital, Guildford, 
Surrey). No displacement of - ^ 1 -TSH was observed when unlabelled TSH 68/38 
was added in competition.
The results obtained for antigenic determinant specificity were 
consistent with a ll but one of the monoclonal antibodies binding, the same 
determinant. They were all mutually inhibitory but to varying degrees. This 
was unlike the clear cut situation observed by Soos and Siddle (1982) where
some were reciprocally inhibitory while the binding of other to the antigen 
was unaffected. However this is not the sole explanation of the results and 
perhaps as lik e ly  an explanation is that the binding of one monoclonal 
antibody prevented the binding of the second not because they both bind the 
same determinant, but because the binding of one caused conformational 
changes in the molecule and hence the other antigenic s ite , then binding is 
inhibited. Steric hindrance of the second antibody binding by the f ir s t  may 
also arise i f  the two antigenic sites are juxtaposed or even overlapping. I t  
is to be remembered that in Chapter 5 i t  was concluded that only one or a 
very few SY/T8/2 monoclonal antibody specific epitopes were expressed per TSH 
molecule and therefore only minimal inhibition would be required to give a 
large effect. The same could be true for the other monoclonal antibodies. 
However having said that, i t  is not unreasonable that all the monoclonal 
antibodies could be directed to the same determinant which may have been an 
immunogenically dominant structure.
Antibody preparations which bind distinct epitopes are essential for the 
derivation of two site immunoassays (Hale and Woodhead 1980). Where only one 
antigenic determinant is present on the antigen or the available antibody 
preparations bind only one determinant then this type of assay is not 
feasible. This information therefore establishes the lim its to the appli­
cation of the monoclonal antibodies and suggests modifications which may be 
required for the successful use of the antibody preparations.
MONOCLONAL ANTIBODIES IN ASSAY
Ekins (1981) observed that the primary obstacle to the widespread use of 
the theoretically more sensitive labelled antibody technique over the 
labelled antigen procedures in immunoassays has been the limited av a ila b ility  
of large amounts of pure antibody. Indeed up to recent times such labelled 
antibody techniques have only been instituted with a ff in ity  purified  
conventional anti sera (John and Woodhead 1982, Sutherland et al 1982).
The advent of monoclonal antibody technology (Kohler and Milstein 1975, 
1976) has however provided the solution to the av a ilab ility  problem. In this  
work monoclonal antibodies have been derived in large quantities in v itro  and 
in vivo. The antibody preparations in culture supernatant are re la tive ly  
free from contaminating immunoglobulins, containing only minimal amounts of 
foetal calf immunoglobulin and other serum proteins.
The ascitic flu id  on the other hand contains extraneous mouse immuno­
globulins in significant quantities. These preparations of antibody however 
have been shown to be easily purified (figures 4.18 -  4.20) and to be very
versatile in their labelling capacity. Not only have they been successfully 
radioiodinated but they have been shown to be easily radio!abelled by the 
biosynthetic incorporation of radioactively labelled essential amino acids. 
There have been reports that some monoclonal antibodies are unstable follow­
ing radioiodination (Mason and Williams 1980). Where such d iffic u ltie s  arise 
then biosynthetically labelled monoclonal antibodies may. be a practicable 
alternative.
The monoclonal antibody used in the development of the two site ELISA 
method in this work was never enzyme labelled directly but its  binding was 
indicated by an enzyme labelled anti-mouse horse radish peroxidase conjugate. 
Nevertheless monoclonal antibodies have been used directly labelled as has 
been demonstrated (Wada et al 1982, Weeks et al 1983, John et al 1984).
The additional layer of labelled anti-immunoglobulin was used in the 
ELISA developed here for two main reasons. First and most importantly this  
additional layer provided more scope for the signal amplification. Not only 
can each enzyme molecule catalyse the conversion of many molecules of 
substrate but since the antigen bound antibody molecules presented many more 
binding sites for the second antibody to bind to, then more enzyme would be 
made available (see figure 6 .2 ). The second reason was that the enzyme 
conjugates were available and were known to be immunologically and enzymat­
ica lly  active. One of the c ritic a l factors of enzyme labelling is to effect 
the joining of antibody and enzyme whilst retaining antigen binding and 
substrate cleaving ac tiv ity .
The two site ELISA developed for the measurement of human TSH was derived 
using a monoclonal antibody and a polyclonal antibody. From the results of 
the determinant binding data i t  became obvious that using two of the 
monoclonal antibodies may not provide a satisfactory assay i f  they both bound 
the same antigenic determinant and especially i f  only a very few of such 
determinants were present on the antigen. I t  was concluded therefore that 
the use of a monoclonal antibody which bound to specific determinants in a 
two site sandwich assay leaving the remaining determinants free to be bound" 
by the polyclonal antibodies would constitute a suitable assay system.
The ELISA assay as described in this work shows good sensitiv ity  with a 
detection lim it of 4 mU/1 and shows good in tra- and inter-assay precision 
over the working range (see figure 5.23). The sensitivity was however not as 
good as has been reported for immunoradiometric assays (IRMA) using 
polyclonal antisera. Sutherland et al (1982) reported IRMA sensitiv ity  of 
<2 mU/1 while John and Woodhead (1982) reported 3 . 4 mU/1, while Jones et al 
(1984) reported for a chemiluminometric assay incorporating a monoclonal 
antibody a,sensitiv ity of 0.015 mU/1.
Enzyme labelled 
anti-antigen antibody
Antigen
(b)
Anti-antigen antibody
Enzyme labelled 
antiimmunoglobulin
Antigen
FIGURE 6.2 Signal amplification.
(a) Enzyme labelled antibodies directed against the antigen.
(b) Antiimmunoglobulin enzyme labelled.
In system (b) more binding sites are available for enzyme labelled 
antibody^ resulting in extensive signal amplification.
The theoretical sensitivity of these labelled antibody type of assays 
according to Ekins (1981) is one molecule of analyte which is  realised as the 
antibody quantity is increased towards in fin ity . Under such conditions of 
antibody excess the analyte-antibody complex formation is k inetically  
favoured. The antibody a ffin ity  therefore has l i t t l e  effect in these 
systems.
Of greater importance to the sensitivity of the assay in these 
circumstances according to Ekins (1981) is the signal detection, and this is 
dictated by the a b ility  to d ifferentiate a minimum positive signal from any 
inherent background noise. This of course is dependent upon the specific 
activ ity  of the label which is a measure of the amount of enzyme bound per 
antibody molecule in the conjugate preparation. This on the other hand is 
indicated by the number of substrate molecules transformed per unit time per 
molecule of antibody. The OD4 Q3  nm/C^gg nm describing the ratio  of horse­
radish peroxidase to immunoglobulin molecules in the conjugate was suggested 
as optimal between 0.3 to 0.6, representing an average of 1 to 2 horseradish 
peroxidase molecules bound per antibody molecule (Wilson and Nakane 1978). 
Ratios greater than this represented antibody molecules which were over 
conjugated and lead to diminished antibody activ ity  in addition to high 
background. This suggests that there is a lim it to the number of enzyme 
molecules per antibody molecule giving the required assay characteristics. 
Additionally where the enzyme antibody conjugate was increased the background 
sim ilarly increased (figure 5.18). Above a certain level of enzyme content 
therefore the results are self-defeating because as background increases so 
the detection at lower antigen levels decreases. In practice therefore even 
with the inbuilt signal amplification the sensitivity obtainable with the 
enzyme conjugate is limited by this factor. Other factors which affect the 
sensitivity and precision of the ELISA system were described in Chapter 2. 
This is a complex assay system incorporating many variables all of which must 
be controlled to yield a serviceable assay system.
The assay achieved by comparison to RIA (Hall et al 1971) is. re lia b le , 
time saving, the enzyme conjugate is cheap and stable for very long periods 
(>1.75 years) compared with radiolabelled material (radiolabelled material 
is usable for up to 1 month at the most. The half l i f e  of * ^ I  is only 
57 days). These together with the many advantages of the monoclonal antibody 
already stated constitutes a highly suitable assay for TSH measurement. The 
constraint of polyclonal antisera s t i l l  exists for the second antibody used 
in the system however, but because this is a two site assay the monoclonal 
antibody provides the precise specificity for the assay and any anti-TSH 
antisera providing only attachment points for the enzyme labelled antibodies.
The testing of such anti sera therefore need not be as rigorous as would be 
required otherwise. The automated m icrotitre plate procedure fa c ilita te s  a 
high sample handling capacity and is therefore suitable for large scale 
screening purposes.
The successful generation and application of these anti-TSH monoclonal 
antibodies establishes them as very useful reagents in both immunocyto- 
chemistry and the ELISA procedures. The use of the alternative enzyme label 
not only avoids the hazzards associated with the use of the most frequently 
used radiolabel, but in some countries where the law severely restric ts  the 
application and use of radioisotopic procedures then the enzyme-labelled 
procedures come into their own. The use of radiolabelled procedures require 
expensive counting equipment and special disposal fa c ilit ie s  which are not 
always available in small laboratories or again in some countries. In these 
circumstances the ELISA procedures may be substituted (Voller 1979). The 
automated ELISA equipment is re la tive ly  inexpensive and requires no special 
fa c ilit ie s  except those available in even the most basic laboratories.
As the procedures develop, and the sensitiv ities and re lia b ility  of the 
enzyme and other non-isotopic labelling procedures approach or surpass those 
obtainable in the established assay systems they w ill no doubt gain greater
acceptance in the wider clinical setting.
SUGGESTED FUTURE WORK
Additional work is required to further evaluate the ELISA developed for 
measuring TSH. This includes the correlation of observed serum assay values 
as measured by the two site ELISA method and the established RIA method. 
This describes the new assays performance in relation to the established 
method. The two site ELISA therefore requires further validation prior to
its  application in a clin ical environment.
During the course of the work several issues arose which merited further
investigation but time and finance did not permit further elaboration of 
these points. Some of these were of c r itic a l importance to the hybridoma 
production scene. For example, there is s t i l l  the urgent need to find a 
suitable antifungal agent which is compatible with normal cell growth in 
culture. A great deal of work now involves long term cell and tissue 
cultures which are affected by contamination. A safe universal antifungal 
agent would greatly assist in this type of work.
The investigation of hybridoma s tab ility  under various freezing and 
recovery regimes may suggest ways of avoiding the disasterous affects 
encountered in fusion 7 where the cells could not be resuscitated following 
freezing.
Another important issue was the identification of the particular an ti­
genic difference between the TSH 68/38 and the TSH(Barts) which gave rise to 
the d ifferentia l binding observed with the two preparations. The antigenic 
difference may be as small as a charge difference which may be investigated 
by the binding of the antibody at different pH, or as large as the disruption 
of a unit structure in which case they may have to be identified from protein 
fragment analysis for example. Such investigations would be useful for 
providing specific information about the immunogenic/antigenic structures of 
TSH.
The Characterization of the remaining monoclonal antibodies is required 
and i t  may be that the ir combination with others from different sources may 
improve the performance in application.
With these final points remaining to be settled, the anti-h-TSH 
monoclonal antibodies have been shown to be highly suitable for immunocyto­
chemical work and their potential to establish a highly specific and 
sensitive assay has been demonstrated.
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